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THE ANALYSIS OF Burkholderia pseudomallei VIRULENCE AND EFFICACY OF 
POTENTIAL THERAPUTICS 
 
Burkholderia pseudomallei is the causative agent of the disease melioidosis and 
is classified as a category B Select Agent.  There are currently many challenges 
associated with both the study of this pathogen and its treatment in the clinical setting.  
Prior to these studies, there was no attenuated B. pseudomallei strain available that was 
exempt of Select Agent regulations and approved for study outside of biosafety level 3 
(BSL-3) containment, and consequently basic research on this pathogen was largely 
hindered.  The first purpose of these studies was to extensively characterize the 
attenuation of two B. pseudomallei mutant strains using melioidosis animal models.  The 
two mutants constructed were Bp82 and Bp190, purM derivatives deficient in adenine 
and thiamine biosynthesis.  These mutants were found to be fully attenuated in immune 
competent and immune deficient mouse and hamster melioidosis models.  Bp82 is 
currently exempt of all Select Agent regulations and can be safely handled in the BSL-2 
setting, greatly accelerating research on this priority pathogen. 
Since basic research on B. pseudomallei was not common in the Western world 
until its Select Agent classification, much is still unknown regarding the bacterial factors 
contributing to its virulence.  A second purpose of this research was to determine 
whether resistance-nodulation-cell division (RND) efflux systems and iron acquisition 
siderophores impact the virulence of B. pseudomallei in a pneumonic murine melioidosis 
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model.  This was examined using a clinical isolate naturally devoid of a characterized 
efflux system and the gene cluster for malleobactin siderophore synthesis, and by the 
construction of isogenetic mutants.  The two characterized B. pseudomallei efflux 
pumps, AmrAB-OprA and BpeAB-OprB, were both found to be completely dispensable 
during in vivo murine infection.  The removal of one or both of these systems did not 
reduce lethality of the mutant strains.  Unlike that observed with similar bacterial 
pathogens, the lethality of B. pseudomallei was also not reduced upon the removal of 
either the malleobactin or pyochelin siderophores.  This finding indicates B. 
pseudomallei is likely capable of utilizing alternative systems for iron acquisition within 
the host. 
 In addition to the challenges associated with the study of this pathogen, there are 
also many clinical challenges associated with melioidosis, providing a basis for the final 
two purposes of this research.  One particular challenge is the high frequency of patient 
relapse, even after appropriate prolonged antibiotic therapy.  A third purpose of this 
research was to determine whether traditional antibiotic therapy could be augmented by 
the co-administration of immunotherapy.  Cationic liposome-DNA complexes (CLDC), 
which are potent activators of the innate immune system, were found to synergistically 
reduce intracellular B. pseudomallei concentrations in macrophages in vitro when 
combined with the antibiotic ceftazidime.  In addition, this combination therapy also 
significantly increased mouse survival during both acute and chronic melioidosis.  A 
similar enhancement to ceftazidime therapy was observed with recombinant IFN-, 
illustrating the potential of immunotherapy to improve clinical outcome and decrease 
patient relapse.   
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The lack of an effective approved vaccine for human use is another substantial 
clinical challenge associated with melioidosis and its prevention.  The final purpose of 
these studies was to develop an effective mucosal vaccine, offering both short-term 
protection from acute pneumonic disease and long-term protection from disseminated 
chronic melioidosis.  CLDC was identified as a highly effective mucosal adjuvant within 
complexed to heat-killed B. pseudomallei, and this adjuvant offered moderate protection 
from acute disease when combined with Burkholderia protein subunits.  The longest-
term protection from lethal challenge in our murine model, lasting beyond 100 days, was 
elicited by the fully attenuated live Bp82 strain.  Since this strain is both fully attenuated 
and exempt of Select Agent regulations, it has great potential clinically for high-risk 
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REVIEW OF LITERATURE 
Burkholderia pseudomallei AND MELIOIDOSIS 
 
1.1  Pathogen of focus - Burkholderia pseudomallei 
The Burkholderia genus is comprised of more than 30 species that occupy a 
variety of ecological niches.  The majority of species within this genus are non-
pathogenic soil-dwelling bacteria, but a few species are highly pathogenic to humans 
and can result in severe disease [1].  One clinically relevant Burkholderia species is B. 
cepacia, an opportunistic pathogen that commonly causes respiratory tract infections in 
cystic fibrosis patients.  Two of the most pathogenic species within the Burkholderia 
genus are B. mallei and B. pseudomallei.  B. mallei causes the disease glanders in 
horses, mules, and donkeys [1].  Humans too can acquire glanders following exposure 
to B. mallei, and this pathogen was used by Germany in World War I as a biological 
weapon [2].  B. mallei is not able to persist in the environment outside of the equine host 
[3], whereas B. pseudomallei can survive a variety of harsh environmental conditions for 
extended periods of time [4].   Another closely related species is B. thailandensis, which 
is far less pathogenic than both B. mallei and B. pseudomallei.  B. thailandensis contains 
a functional arabinose synthesis operon that is largely absent in B. pseudomallei [5-6]. 
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B. pseudomallei is highly pathogenic to humans and causes the disease 
melioidosis [7].  It is an oxidase positive Gram-negative bacillus that produces varying 
colony morphologies ranging from smooth in appearance to dry and wrinkled when 
grown on agar media [8].   Burkholderia pseudomallei is an environmental bacterium that 
is found in rice paddies, stagnant waters, and moist soils within endemic regions of the 
world [3, 9].  This is a hardy pathogen that can persist in low-nutrient environments for 
prolonged periods of time, and has remained culturable in distilled water for 10 years 
after initial inoculation [10]. This bacterium persists best in soils containing a water 
content of 15% [11], and is believed to obtain its required nutrients from organic rotting 
matter.   Within the environment, B. pseudomallei is capable of infecting the free-living 
protozoa Acanthamoeba astronyxis [12].  B. pseudomallei is endemic to southeast Asia, 
northern Australia [4], and other tropical regions of the world located between 20N and 
20S lines of latitude [13].  This pathogen was first described in 1911 among morphine 
addicts in Rangoon, Burma by Alfred Whitmore and C.S. Krishnaswami [14].  Since its 
discovery, it has been described using variety of names, including Bacillus pseudomallei, 
Bacillus whitmori, Pseudomonas pseudomallei, and has been known as Burkholderia 
pseudomallei since 1992 [15].   
   
     1.1(1) B. pseudomallei Genomics 
B. pseudomallei strain K96243 has been fully sequenced and its genome is over 
7Mbp contained within two chromosomes, which is one of the largest bacterial genomes 
characterized to date [3, 16].  Chromosome 1 is composed of genes primarily involved 
with housekeeping functions including metabolism, motility, and cell wall and protein 
biosynthesis, whereas chromosome 2 specific genes are thought to be involved with 
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bacterial adaptation within the environment and host [16].  B. pseudomallei contains a 
variety of horizontally acquired genomic islands that are not present within the closely 
related pathogen B. mallei.  
B. pseudomallei is an organism with a genome of great plasticity.  It is thought 
that horizontal gene transfer, recombination, and mutation all take place within this 
organism and greatly influence strain to strain variation [16-17].  There have been recent 
reports of genetic divergence even among isolates within the same melioidosis patient, 
indicative of within-host adaptation by B. pseudomallei [18].  In addition, phenotypic 
changes in colony morphology within a single strain have also been reported and 
observed in B. pseudomallei isolated from various tissue sites in melioidosis patients [8, 
19-20]. 
  
     1.1(2) Select Agent Listing 
 B. pseudomallei has gained increased attention in the Western Hemisphere in 
recent years due to its potential for use as a biological weapon [21-22].  Because of this 
pathogen’s biodefense implications, B. pseudomallei is currently classified as a category 
B Select Agent by the Centers for Disease Control and Prevention (CDC).  Agents within 
this category are those that are moderately easy to disseminate, result in moderate 
morbidity and low mortality rates, and require enhanced disease surveillance 
(http://www.bt.cdc.gov/agent/agentlist-category.asp).  The Select Agent listing of this 
pathogen subjects all research using B. pseudomallei to strict Federal guidelines that 
govern its acquisition, possession and use [23].  Due to such guidelines, research 
utilizing B. pseudomallei in the United States can only be conducted by cleared 
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personnel.  In addition, all research with this pathogen is required to take place within 
CDC inspected biosafety level 3 (BSL-3) containment facilities, greatly hindering 
research on B. pseudomallei by those research institutions lacking such containment 
laboratories.   
For many bacteria on the Select Agent list, including Bacillus anthracis, 
Francisella tularensis and Yersinia pestis, there are already attenuated strains available 
that are excluded from Select Agent regulations (www.selectagents.gov/exclusions.html).  
Excluded strains are those that do not pose a severe threat to public health and safety, 
animal health, or animal products, and are thus removed from the list of select biological 
agents.  This exclusion allows the attenuated strains to be handled in BSL-2 laboratories 
and greatly facilitates studies on these pathogens by institutions lacking approved BSL-3 
containment.    Prior to the avirulent B. pseudomallei characterized as part of this 
research [24], there was no attenuated B. pseudomallei strain exempt of Select Agent 
regulations.  A variety of B. pseudomallei attenuated mutant strains have been 
constructed and tested in vivo to date (outlined in Table 1.1 below).  Most have these 
strains have been investigated in terms of protective efficacy rather than intensive 
demonstration of attenuation with the purpose of Select Agent exemption [25].  In 
addition, many were created using select agent non-compliant methods, therefore 
diminishing the likelihood of Select Agent exemption. 






Table 1.1.  Live attenuated B. pseudomallei strains.  This table was adapted from 
[25]. 











>106 CFU i.p. [26] 




>103 CFU i.n. [27] 
ilvI Branched chain 
amino acid 
auxotroph 
106 CFU i.p. [28] 
aroB Aromatic amino 
acid auxotroph 
>106 CFU i.n. [27] 





serC Serine auxotroph 106 CFU i.p. [30] 
purN 
purM                      
Purine auxotroph 
Purine auxotroph 
<107 CFU i.p 
>107 CFU i.p. 
[31] 
lipB Lipoate protein 
lipase B 
auxotroph 
<103 CFU i.n. [31] 
pabB P-aminobenzoate 
auxotroph 
>107 CFU i.p. [31] 
bipD Type III secretion 
mutant 




     1.1(3) Epidemiology of Melioidosis and Risk Factors 
 The primary endemic foci for B. pseudomallei infection are southeast Asia and 
northern Australia, approximately between 20N and 20S lines of latitude [4, 13].  B. 
pseudomallei was first identified in northern Australia in 1949 during an outbreak 
occurring in sheep in Queensland [33], and the first human case of melioidosis was 
reported in a diabetic patient in Townsville in 1950 [34].  The first cases occurred in the 
Northern Territory of Australia in the early 1960s [35].  The annual incidence of 
melioidosis disease in the Top End of the Northern Territory between 1989 and 1999 
was estimated at 16.5 cases per 100,000, but rates as high as 41.7 per 100,000 were 
reported in 1998 during severe weather events [36-37].  During 1995 to 2000, the annual 
incidence in the Torres Straight Islands that lie between northern Queensland and 
Papua New Guinea was reported as 42.7 cases per 100,000, one of the higher 
incidences reported to date [38].  This is thought to be related to the high prevalence of 
diabetes and high seasonal rainfall within this region [38].  B. pseudomallei has been 
isolated by environmental sampling from soil, mud, and pooled surface water in northern 
Australia [4], and two outbreaks have been linked to contaminated drinking water [39-
41]. 
   Compared to Australia, the annual incidence of melioidosis is lower in Asia [4].  
In northeast Thailand, the incidence was estimated at 4.4 melioidosis cases per 100,000 
between 1987 and 1991 [42].  However, it is likely that many B. pseudomallei infections 
are often undiagnosed in these areas due to the lack of culture facilities in many 
endemic tropical locations [4, 43].  There are higher rates of seropositivity in Thailand 
compared to those reported in Australia, as approximately 80% are seropositive in 
Thailand as measured by indirect hemagglutination compared to 5-13% seropositivity in 
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Australia [44-46].  One possible rationale for this observation is the presence of other 
less-virulent Burkholderia species found within the soil, such as B. thailandensis that is 
commonly found in Thailand but not Australia [4].  However, it was recently reported that 
antibodies from melioidosis patients are incapable of recognizing B. thailandensis 
antigens [47], causing this to be an unlikely explanation for the discrepancy in 
seroprevalence.  Similar to Australia, B. pseudomallei has been isolated from the soil 
and pooled surface water in Asia, and is commonly found within rice paddy fields in 
Thailand [4].  There were melioidosis cases in Thailand and among visiting tourists, and 
a cluster of cases in Indonesia that were linked to the 2004 Asian tsunami [48-51].  
Melioidosis cases have also been reported in Laos, Vietnam, Malaysia, Indonesia, 
China, and Taiwan [43, 52-56].    
 There have been cases of melioidosis in the Americas.  In the United States, 
there are reports of the disease in servicemen returning from duty in southeast Asia [57-
58], and two cases were thought to have been acquired from Honduras [13].  There 
have also been sporadic melioidosis cases occurring in the Caribbean, and Central and 
South America [4, 43].  A cluster of melioidosis cases was reported in northeast Brazil in 
2003 [59], and there was also a report of B. pseudomallei infection in a diabetic patient 
in Puerto Rico, likely infected by flooding during the rainy season [60].  One of the most 
controversial cases occurred in 1973 in the United States involving the “Oklahoma 
isolate” that was obtained from a soil-contaminated wound after a farming accident [61].  
At the time, this isolate was thought to be B. pseudomallei, but later confirmed as a new 
species, known as B. oklahomensis [62]. 
 Certain lifestyles in endemic regions have been shown to be risk factors for 
melioidosis, including rice paddy farming in Thailand and Aboriginal ethnicity in Australia.  
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Additional risk factors include diabetes mellitus, thalassemia, male gender, excessive 
alcohol consumption, renal disease, and chronic pulmonary disease [4, 63].  One 
commonality among many of these comorbidities proposed to increase susceptibility to 
B. pseudomallei infection is impaired neutrophil function [4, 46, 64-66].  It was recently 
demonstrated that neutrophils from diabetic patients have decreased phagocytosis of B. 
pseudomallei and reduced migration compared to non-diabetic subjects [67]. 
 
     1.1(4) Transmission of B. pseudomallei  
 Following exposure, B. pseudomallei causes the disease melioidosis, and there 
are several thousand natural cases occurring in endemic regions of the world per year 
[7, 11, 20, 68].  Patients with immunocompromising conditions have an increased 
incidence of melioidosis [4, 36].  B. pseudomallei can be acquired by inhalation, 
ingestion, or through breaks in the skin, and person to person transmission of this 
pathogen is rare [3, 68].   
Inhalation was initially regarded as the primary route for B. pseudomallei 
acquisition based on the finding that helicopter crews within endemic regions had 
increased incidence of disease, likely due to aerosolization of the bacteria from the soil 
[4, 69].  Increases in not only melioidosis cases, but also a shift to the pneumonic 
presentation of disease during seasons of heavy rainfall in endemic regions have also 
indicated inhalation as a means of natural exposure [70].  Currently, the subcutaneous 
inoculation route is hypothesized to be the primary means of B. pseudomallei acquisition 
within endemic areas [4].  This is based on the high incidence of melioidosis in rice 
paddy workers and the common report of injury prior to symptom onset in patients [36].  
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Such injuries and minor breaks in the skin are especially common to the feet of workers 
that have direct contact with the soil.   
Ingestion is also regarded as a means of B. pseudomallei transmission based on 
pathological findings of gastrohepatic node infection in both pigs and humans [36, 71].  
In addition, potable water contamination by B. pseudomallei has been linked to two 
separate melioidosis outbreaks in Australia [39-40].  Whether these outbreaks were 
actually due to ingestion of the contaminated water, or perhaps inhalation or 
subcutaneous inoculation, remains controversial.  Sexual transmission of B. 
pseudomallei has been suggested, but has yet to be confirmed in the literature [72].  
There is one documented case of B. pseudomallei transmission through breast milk and 
another single case of vertical transmission [73-74], but these routes are considered 
uncommon. 
 
1.2  Clinical Manifestations of Melioidosis 
The clinical presentation of melioidosis is dependent upon the infecting strain 
type, the route of exposure, and the host immune response [4].  There is a vast array of 
clinical manifestations associated with melioidosis, including pneumonia, septicemia, 
osteomyelitis, hepatic and splenic abscesses, skin infections, and neurological disease 
[4, 68].  Symptoms of melioidosis onset are dependent most heavily on the route of 
exposure, and the most common symptom at time of presentation is septicemia, usually 
involving bacterial dissemination to distant organs [20].  The lung is the most commonly 
affected organ in adult cases, and pneumonia is present in approximately 50% of 
melioidosis patients [75].  The lung can be infected directly by direct inhalation or 
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septicemic spread.  The time from exposure to onset of symptoms can range greatly, as 
symptoms can present within just a single day, or in some cases, evidence of disease 
may not present for decades [49, 57].   Without prompt, appropriate antibiotic therapy, 
infection with B. pseudomallei is often fatal, as illustrated by the high mortality rates 
among untreated cases [20].  The overall mortality rate in adults is approximately 50% in 
Thailand and 20% in Australia [46, 75].  The reduced mortality in Australia is likely due to 
the availability of intensive care treatment. 
The type of clinical presentation can vary largely based on geographic location.  
There is a high incidence of genitourinary infection with prostatic abscesses in Australia, 
occurring in approximately 18% of male melioidosis patients, whereas this presentation 
is uncommon in Thailand [75].  Suppurative parotitis is a common clinical finding in Thai 
children with melioidosis, characterized by fever and swelling of the parotid gland, but 
this observation is uncommon in Australia [76].  Brainstem encephalitis accompanied by 
flaccid paralysis is evident in approximately 4% of cases in northern Australia [75, 77], 
and similar neurological manifestations have been described in only a small number of 
child melioidosis cases in southeast Asia [78].   
 
     1.2(1) Acute and Chronic Stages of Melioidosis 
The various forms of melioidosis can be classified into three overall categories, 
including acute, sub-acute, and chronic [9, 69].   Acute melioidosis involves either an 
acute pulmonary or acute septicemic presentation of disease.  The acute pulmonary 
form, often preceding inhalation of B. pseudomallei, is characterized by respiratory 
distress, fever, and death within a few days if left untreated [9].  The acute septicemic 
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form is characterized by septic shock, meningitis, cellulitis, or skin lesions, and this form 
is also highly fatal within a short time period [9, 68].  Sub-acute disease is less severe 
and is characterized by prolonged fevers, and death can occur within weeks to months 
without appropriate antibiotic therapy.  The chronic stage of melioidosis is the most 
common form, and involves symptoms lasting longer than 2 months [57].  This form 
often involves bacterial spread to disseminated sites, such as the spleen, liver, or brain.  
Chronic melioidosis can also be sub-clinical (or latent) in nature and without apparent 
symptoms, and this form is often undiagnosed until disease resurgence.  Treatment of 
melioidosis is complicated because B. pseudomallei displays high levels of intrinsic 
resistance to many antibiotics.  Prolonged antibiotic therapy (months) is prescribed [23], 
and even with appropriate therapy, patient relapse is still common [7, 79-80]. 
The acute, sub-acute, and chronic melioidosis forms of disease do not always 
occur in a defined order.  The sub-clinical, latent form may be the initial stage presented 
and symptoms may not develop for years [81].  This latent form can also follow acute 
disease resolution, leading to eventual relapse.  Recurrence of disease is most likely 
following immunosuppression or trauma [81], and is common in patients with diabetes, 
chronic pulmonary or renal disease, and alcoholism [46].   
 
1.3  Melioidosis in Animals 
A variety of animals are susceptible to B. pseudomallei infection, including 
horses, cattle, deer, cats, dogs, goats, sheep, pigs, kangaroos, camels, koalas, and 
even marine animals [4, 71, 82-86], and there have been epizootic outbreaks among 
animals within endemic regions.  In 1957 there was B. pseudomallei infection among 
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pigs, sheep, and goats in Aruba, and there have been later outbreaks in the 1970s in 
France in zoos that contributed to both animal and human deaths [43, 87].   
To study this pathogen in vivo, a variety of melioidosis animal models have been 
established and they have typically utilized rodent species [88-91].  Currently, hamsters 
are a common model used to study acute stage melioidosis as this species is highly 
susceptible to B. pseudomallei, and the mouse model is often utilized for studies on both 
the acute and chronic stages of disease.  Mice have been extremely useful for the in 
vivo study of B. pseudomallei because different stages of the disease can be modeled 
based on manipulation of the challenge dose and route of inoculation, along with the 
strain of mouse utilized [3].      
 
     1.3(1) Murine Melioidosis Model 
  A variety of inoculation routes have been used in mouse melioidosis models 
including intraperitoneal, intravenous, and intranasal routes of infection [88, 90, 92-95].  
Since the inhalational route is considered one of the most lethal routes of exposure and 
the route most relevant in biodefense-related research [89, 96], many models have 
involved intranasal or aerosol challenge.  The BALB/c mouse is often used for 
melioidosis modeling and is considered more susceptible to B. pseudomallei than the 
C57/Bl6 mouse strain [90, 93, 97].  The human clinical melioidosis isolate B. 
pseudomallei 1026b is commonly used in murine models because it has been well 
characterized in the laboratory and is virulent to mice [98].  The intranasal LD50 for B. 
pseudomallei 1026b in BALB/c mice is approximately 900 CFU [99].   
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Similar to their human counterparts, both acute pneumonic and chronic 
disseminated melioidosis are observed in murine models [100], and the lungs, liver, and 
spleen are the primary targets of pathological involvement [75].  Delayed emergence of 
infection is consistently observed in antibiotic treated mice, indicating the relevance of 
this melioidosis model in the study of disease relapse [101].  Following lethal intranasal 
challenge with B. pseudomallei, mice typically succumb to acute disease end-point 
marked by respiratory distress, hunched posture, and ruffling, within just three days 
post-infection [24, 99-100].  Mice challenged with a sub-lethal inoculum or treated with 
therapy that subsequently survive acute pneumonic disease may show no symptoms of 
disease for 1-2 months, and it is currently unknown where B. pseudomallei reside during 
this asymptomatic latent period.  However, the gastrointestinal tract is considered a likely 
location for colonization (Goodyear et al., article in preparation).  Mice in the sub-clinical 
phase of melioidosis often have bacterial counts in the blood, lungs, liver, spleen, lymph 
nodes, and brain below the limit of detection (20 CFU/organ) despite eventual bacterial 
resurgence and progression to chronic melioidosis symptoms (Propst and Goodyear, 
unpublished observations).  It is currently unknown where B. pseudomallei reside during 
the asymptomatic latent period, and published studies using animal models have failed 
to identify such reservoirs.  Chronic disseminated disease in murine melioidosis models 
is typically associated with splenic infection and the formation of visible lesions, wasting, 
or neurological involvement [99-100] which will eventually progress to end-point 






1.4  B. pseudomallei Pathogenesis 
Initial infection with B. pseudomallei occurs at the epithelial cell layer of abraded 
skin in cases of cutaneous inoculation or the mucosal surface during inhalation or 
ingestion of this pathogen [81].  In vitro studies have revealed B. pseudomallei is 
capable of adhering to and invading many different epithelial cell types, including 
alveolar, bronchial, laryngeal, oral, and conjunctival cells [68, 102].  This initial 
attachment to epithelial cells appears to be dependent on both the polysaccharide 
capsule and type IV pili [103-104].  Previous studies have shown that attachment is 
mediated by B. pseudomallei binding to the asialoganglioside GM1-GM2 receptor 
complex on human pharyngeal epithelial cells [105].  
Following attachment, B. pseudomallei can invade and multiply within both non-
phagocytic and phagocytic cells [81, 106].  This pathogen can replicate in neutrophils 
and macrophages following either phagocytosis or invasion [3, 68].   Invasion of host 
cells is made possible by the presence of a Burkholderia secretion apparatus (bsa) type 
III secretion system (T3SS) and its effector protein BopE [107-108].  Following host cell 
entry, B. pseudomallei first enters into a phagosome.  The T3SS effectors cause 
degradation of vacuolar membranes, allowing for efficient phagosomal escape by this 
pathogen and entry into the host cell cytoplasm [3, 32, 68].  The T3SS protein BopA 
enables B. pseudomallei to evade killing by host cell autophagy [109], an important 
defense mechanism against intracellular pathogens involving sequestering of bacteria in 
vacuoles and degradation by lysozyme fusion [110].   
The polarly located B. pseudomallei protein BimA enables polymerization of host 
cell actin, leading to the formation of actin-based membrane protrusions on the bacterial 
surface.   The presence of these actin tails contributes to bacterial motility and the 
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spreading to neighboring host cells [3, 111-112].  Actin polymerization is also thought to 
lead to the fusion of host cells and multinucleated giant cell (MNGC) formation, a 
common observation among both phagocytic and non-phagocytic cells infected with B. 
pseudomallei [113-114].  MNGC formation is thought to be induced by the T3SS effector 
protein BipB [115], and it is hypothesized that host cell fusion and subsequent MNGC 
formation contributes to B. pseudomallei cell-to-cell spread, evasion of host defenses, 
and persistence in vivo [3] .   
This pathogen can cause both localized and disseminated disease [81].  
Examples of localized disease include pneumonia or abscess formation, and the 
mechanism by which B. pseudomallei spreads from these initial localized locations to 
secondary organ sites within the host (the liver, spleen, blood, or brain) has not been 
fully elucidated.  However, travel through macrophages within the lymphatic system has 
been considered likely, as this pathogen can successfully invade and survive within 
these cells [81].  B. pseudomallei can disseminate throughout the body and is capable of 
causing infection within a variety of locations in the host including the skin, blood, lungs, 
liver, spleen, genitourinary tract, brain, and parotid gland [68].  
There has been some controversy, especially with neurological melioidosis, as to 
whether the pathogenesis during B. pseudomallei infection is the direct result of bacterial 
spread or due to the production of a toxin.  It was reported in 1992 that B. pseudomallei 
was cultured from only one out of 7 melioidosis patients with brainstem encephalitis, 
indicating a potential exotoxin-induced neurological syndrome without direct central 
nervous system (CNS) infection [116].  However, a more recent report indicated the 
direct presence of B. pseudomallei within the CNS during cases of neurological 
melioidosis, demonstrating that B. pseudomallei invasion of the CNS and subsequent 
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inflammation may also be responsible for the neurological symptoms observed in 
melioidosis patients [77].   
 
     1.4(1) Role of Host Immune Response:  Innate Immunity 
Based on the findings that patients with diabetes, thalassemia, renal impairment, 
and alcoholism are at increased risk for melioidosis, the innate immune system is 
thought to play a primary role in controlling B. pseudomallei infection [4, 46].  Early 
studies indicated that B. pseudomallei is largely resistant to both the bactericidal activity 
of serum [117] and lysis by the terminal complement membrane attack complex [118].  
B. pseudomallei can also survive and multiply within both macrophage/monocyte and 
neutrophil cell lines following phagocytosis [106].  This pathogen is capable of destroying 
the phagosome membrane within only 15 minutes of intracellular infection, escape 
phagosome-lysosome fusion, and avoid subsequent intracellular killing [119].     
Research has indicated that B. pseudomallei is largely resistant to intracellular 
killing by neutrophils [67], which may explain why granulocyte-colony stimulating factor 
(G-CSF) does not consistently improve clinical outcome during advanced disease [120].  
However, recent studies by Easton et al. have demonstrated a critical role for neutrophils 
independent of phagocytosis during pulmonary melioidosis.  When neutrophil 
recruitment to the lungs was prevented with an anti-Gr-1+ cell-depleting monoclonal 
antibody, pulmonary disease was severely exacerbated following intranasal B. 
pseudomallei challenge in mice, and pulmonary burdens were increased by 1000-fold 
[121].  Key pro-inflammatory cytokines, including interferon- (IFN-) and tumor necrosis 
factor- (TNF-) that are imperative for defense against B. pseudomallei (discussed in 
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next section) were reduced by 98% in neutrophil-depleted mice.  Such observations 
indicate that neutrophils likely play an important indirect role in the generation of early 
cytokines within the lungs during melioidosis [121].  
   Much research emphasis has been placed on macrophages for the study of 
intracellular B. pseudomallei infection [81].  Macrophages are imperative for the 
production of pro-inflammatory cytokines, including interleukin-12 (IL-12), that are 
important for host defense against this pathogen [122] (discussed in next section).  
Macrophages are a common site for intracellular B. pseudomallei infection, and many 
processes within these cells, including the production of reactive oxygen and nitrogen 
species, antimicrobial peptides, and lysosomal enzymes are imperative for intracellular 
bacterial killing.  However, despite these defense strategies, B. pseudomallei can 
efficiently invade and replicate within macrophages [123-124].  Cells of 
macrophage/monocyte lineage are also thought to play a potential role in harboring B. 
pseudomallei during latent infection, but the precise location during latency currently 
remains unclear [4]. 
 One potential mechanism proposed for the avoidance of macrophage killing by 
B. pseudomallei is related to their unique response to this particular pathogen.  
Macrophages exposed to B. pseudomallei were shown to produce lower levels of 
inducible nitric oxide synthase (iNOS) and tumor necrosis factor alpha (TNF-) 
compared to macrophages exposed to other bacterial pathogens [125-126].  These 
observations provide a possible mechanism for the evasion of macrophage killing by this 
bacterial pathogen. 
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     1.4(2) Role of Host Immune Response:  Proinflammatory Cytokines 
Interferon- (IFN-) is a proinflammatory cytokine produced primarily by T cells 
and natural killer cells [81], and this cytokine has been shown to be vital for defense 
against Burkholderia species.  Previous research has demonstrated that IFN--/- mice 
succumb to B. mallei infection within just 2-3 days following intraperitoneal challenge 
and have uncontrolled bacterial replication, whereas wild type mice receiving the same 
challenge dose survive beyond 40 days [127].  Santanirand et al. demonstrated there 
was greater than a 4000-fold increase in organ bacterial burdens of B. pseudomallei and 
a 5-log reduction in the median lethal intraperitoneal challenge dose when IFN- was 
neutralized in mice [94].  It has also been demonstrated that IFN- is crucial for control of 
B. pseudomallei replication within the lungs as  IFN- -/- mice were also highly 
susceptible the intranasal challenge route [121]. 
A study using a mouse melioidosis model has demonstrated that during the early 
stages of B. pseudomallei infection, the dominant source of IFN- production is natural 
killer (NK) cells, with additional production by T cells, NK T cells, and macrophages 
[128].  However, this same study demonstrated that depletion of both T and NK cells 
surprisingly did not reduce the control of B. pseudomallei, therefore demonstrating 
significant redundancy in the various cellular sources of this vital cytokine and minimum 
threshold of IFN- required for efficient bacterial clearance [128]. 
Studies have been conducted to determine the mechanism by which IFN- 
increases host defense against this pathogen.  Intracellular B. pseudomallei killing was 
shown to be increased in vitro when macrophages were pre-treated with IFN-.  This 
was due to the induction of the inducible nitric oxide synthase (iNOS) and production of 
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reactive oxygen and nitrogen intermediates (ROI, RNI) in response to IFN-activation 
[81, 129].  Additional studies using animal melioidosis models have revealed that ROI 
play the bigger role in B. pseudomallei intracellular killing than RNI [130].  To decrease 
killing by reactive intermediates in response to IFN- activation, B. pseudomallei has 
been shown to repress iNOS expression [131].  IFN- has also been shown to induce 
autophagy, an intracellular defense against pathogens involving sequestering of bacteria 
into a phagosome and subsequent degradation by fusion with lysozymes [110].  
Lysozyme fusion with intracellular phagosomes containing B. pseudomallei is detectable 
within infected macrophages, however the bacteria are able to efficiently evade killing by 
this mechanism and their replication quickly overwhelms the macrophage [132]. 
Interleukin-12 (IL-12) is a proinflammatory cytokine released by macrophages 
during early infection and is essential for inducing the production of IFN- by natural killer 
(NK) cells and T cells [122].  IL-12 has been shown to be imperative for defense against 
a wide variety of intracellular pathogens and is also thought to be important for 
protection from Burkholderia [127, 133-134].  IL-12-/- mice were found in a study by 
Haque et al. to succumb to intraperitoneal challenge with B. pseudomallei 26 days 
before wild type mice, illustrating the necessity of this cytokine for controlling early 
infection [128].  This same study also illustrated the importance of interleukin-18 (IL-18) 
during early infection, as neutralization of this cytokine also rendered mice more 
susceptible to infection.  In addition, in vivo production of IFN- within this study was 
found to be largely dependent on IL-12, and to lesser extent on IL-18 production [128]. 
Another proinflammatory cytokine primarily produced primarily by macrophages, 
and to lesser extent by B and T cells, is tumor necrosis factor- (TNF-), and this has 
also been proposed to be important for defense against B. pseudomallei [4].  
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Neutralization of TNF- increased susceptibility to infection in a murine melioidosis 
model, and TNF- -/- and TNF- receptor -/- mice are both highly susceptible to B. 
pseudomallei infection [135-136].  However, using an in vitro model of B. pseudomallei 
and cytokine neutralization assays, our laboratory has demonstrated that this cytokine 
plays a far lesser role than IFN- in macrophage defense against this pathogen [100].  
 
     1.4(3) Role of Host Immune Response:  Adaptive Immunity 
  Even though human immunodeficiency virus (HIV) infection is prevalent in 
Thailand, this does not appear to be a risk factor for melioidosis [137], indicating that 
cellular immunity may not play a significant role in B. pseudomallei infection.  However, a 
study by Barnes et al. demonstrated that T cells may directly affect clinical outcome 
during melioidosis.  T cells isolated from sub-clinical melioidosis patients were shown to 
have increased proliferation and IFN- production compared to T cells isolated from 
melioidosis patients with clinical disease, indicating that a strong cell mediated immune 
response is important for the control of infection [138].  Studies using a murine 
melioidosis model have demonstrated that while T cells appear to be dispensable during 
early stages of B. pseudomallei infection, CD4+ T cells specifically play a vital role during 
later stages of infection.  Mice depleted of CD4+ T cells were found to have the shortest 
median survival time following intraperitoneal B. pseudomallei challenge compared to 
CD8+ T cell-depleted or wild type mice [128]. 
Even though seropositivity is common within endemic regions, the antibody 
response resulting from natural environmental exposure to both B. pseudomallei and B. 
thailandensis does not appear to be sufficient for preventing either primary melioidosis or 
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disease relapse [4].  Melioidosis patients often have detectable antibody titers, with the 
dominating type being IgG, for years after infection [139].  In addition, B. pseudomallei-
specific CD4+ and CD8+ T cells are detectable in the blood of melioidosis survivors 
compared to control subjects [140]. 
 
1.5  B. pseudomallei Virulence Factors  
B. pseudomallei is capable of persisting in a variety of hostile environments in 
both nature and within the host.  This is a highly resilient pathogen that can survive 
nutrient deficiency, extreme temperatures, acidic and alkali pH, many antiseptic 
solutions, and exposure to a wide variety of antibiotics [4].  In addition, studies using 
melioidosis animal models and in vitro cell culture have revealed a variety of bacterial 
factors thought to contribute to survival, pathogenicity, and long-term persistence within 
the host.  Even though all virulence factors for this pathogen have yet to be completely 
elucidated, many bacterial factors have been identified to date.  The major known 
virulence factors and their putative functions are outlined in Table 1.2 below. 
The presence of a capsule has been shown to increase B. pseudomallei survival 
within the blood by conferring resistance to complement deposition and decreasing 
phagocytosis [81, 141].  In addition, both the capsule and type IV pili are thought to 
mediate initial attachment of B. pseudomallei to host epithelial cells [103-104].  Following 
attachment, the presence of the Burkholderia secretion apparatus (bsa) type III secretion 
system (T3SS) allows for invasion, intracellular survival, and replication within both non-
phagocytic and phagocytic cells [81, 106, 108, 142] (further discussed under section 
1.4).  Actin polymerization on the polar ends of B. pseudomallei induced by the BimA 
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protein facilitates efficient cell-to-cell spread within the host [112].  B. pseudomallei also 
contains a type VI secretion system (T6SS) which is thought to play a role in 
macrophage invasion and intracellular survival, but the complete role of this system is 
not yet fully understood [143].           
B. pseudomallei produces a vast array of secreted enzymes, including protease, 
lipase, catalase, peroxidase, superoxide dismutase, hemolysins, and other virulence 
factors such as siderophores [4, 81].  The type II general secretory pathway (Gsp) is 
responsible for the secretion of protease, lipase, and phospholipase.  However, studies 
using a variety of gsp and protease mutants have indicated these three enzymes do not 
play a major role in virulence [144-145].  This pathogen produces three different 
phospholipase C enzymes which are thought to play roles in nutrient acquisition and 
macrophage infection, and one of these enzymes (Plc-3) was required for full virulence 










Table 1.2.  Virulence factors identified for B. pseudomallei and their putative roles 
during infection. 
Virulence Factor Putative Role  Reference  
Capsule (Type 1-O-PS) 
       (wab operon)  
Type III, IV O-PS 
LPS O-antigen 
Quorum sensing (pmlIR, 
bpsIR) 
 
Flagellin (fli, flg) 
Type IV pili (pilA) 
 
Type III secretion system 
(bsa operon)  
                                  
 
Actin polymerization (bimA) 
Type VI secretion system 
(tss) 
Type II secretion system 
 Phospholipase C           
(plc-1, 2, 3) 
 
Siderophores (mbaJ, 
mbaF, mbaJ, mbaI, fmtA; 
BPSS05087, fptA) 
RND efflux (amrAB-oprA, 
bpeAB-oprB) 
Morphotype switching 
Epithelial attachment; complement resistance 
 
Required for full virulence in mice; precise roles unknown 
Complement and defensins resistance 
Stationary phase gene regulation (metalloprotease, 
siderophore); required for virulence 
 
Motility and host cell invasion 
Epithelial cell attachment      
 
Translocators for delivery of effectors to host cell (bipB, bipC, 
bipD); Host cell invasion (bipD, bopE); Vacuolar escape 
(bsaZ); Evasion of autophagy (bopA);  multinucleated giant 
cell formation/apoptosis (bipB); bacterial spread                                                                                     
 
Intracellular spread to neighboring host cells 
Intracellular life cycle in macrophages, actin polymerization 
                                                                                         
Secretion of protease, lipase, and phospholipase C 
Phospholipid cleavage; nutrient acquisition; mutant strains 
are attenuated in hamsters 
                                                                                                                                                                                                       
Iron acquisition 
 
Quorum sensing regulation (bpeAB-oprB); antibiotic efflux                                                                                               
                                                                                           
Alteration of surface determinants in vivo 
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1.5(1) Iron Acquisition in B. pseudomallei 
Many bacteria acquire iron by the secretion of siderophores.  Siderophores are 
iron-scavenging molecules that have a high affinity for Fe3+ ions [161].  B. pseudomallei 
contains the hydroxamate siderophore, malleobactin (MbaA), that is expressed during 
iron-deficient conditions [81, 157].  Malleobactin is homologous to the pyoverdine 
siderophore produced by Pseudomonas aeruginosa [162].  The open reading frames 
mbaA and mbaF are involved with malleobactin biosynthesis, and the fmtA open reading 
frame encodes the FmtA receptor involved with its transport.  The last two open reading 
frames involved in the same operon are mbaJ and mbaI [157].  Malleobactin is capable 
of releasing iron from transferrin, lactoferrin, and to a lesser extent from erythrocytes 
[163].  Malleobactin deficient B. pseudomallei mutants failed to grow under iron-limiting 
conditions in vitro [157], and homologous genes in the related species P. aeruginosa 
and B. cepacia are essential for full virulence in many experimental models [164-165].   
However, the impact of malleobactin on B. pseudomallei virulence is largely unknown to 
date.  
Based on homologous sequences to P. aeruginosa, B. pseudomallei is also 
thought to produce a second siderophore known as pyochelin [157, 166-167].  Pyochelin 
is encoded by the putative gene BPSS0587, and the putative pyochelin receptor protein, 
FptA, is encoded by the fptA open reading frame [157, 168].  In P. aeruginosa, a 
homologous receptor is used for iron delivery to the bacterial cell when complexed with 
the pyochelin siderophore [166].  An fptA deficient B. pseudomallei mutant (unable to 
utilize pyochelin) was shown to have no growth defects under iron-limiting conditions, 
suggesting that the malleobactin siderophore has an increased affinity for iron compared 
to pyochelin [157].  A mutant strain lacking both mbaA and fptA (deficient in both 
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malleobactin and pyochelin) showed the same level of in vitro growth in iron-deficient 
media as the single mbaA mutant [157]. 
 
     1.5(2) Efflux Systems and Antibiotic Resistance  
B. pseudomallei displays resistance to a diverse group of antibiotics including 
penicillins, third-generation cephalosporins, aminoglycosides, and rifamycins which 
greatly hinders therapeutic options clinically [4].  Antibiotic resistance is largely due to 
the presence of multi-drug efflux systems.  Bacteria contain drug efflux transporters that 
are classified into five different families.  These efflux systems are able to pump out a 
broad range of unrelated compounds including antibiotics [169].  The efflux pumps most 
prominent in Gram negative bacteria belong to the resistance-nodulation-cell division 
(RND) superfamily [169].  RND pumps are tripartite structures containing a transporter 
protein (located in the cytoplasmic membrane), a membrane fusion protein (spanning 
the cytoplasm), and an outer membrane protein (reaching the extracellular space).  
These systems are capable of effluxing a variety of compounds across the entire 
bacterial cell envelope.  Genome sequencing of B. pseudomallei strains indicates the 
presence of at least 10 different RND efflux pumps that contribute to the intrinsic 
antibiotic resistance of this pathogen [16, 170].  To date, three of these efflux systems 
have been characterized in B. pseudomallei, including AmrAB-OprA, BpeAB-OprB, and 
BpeEF-OprC [158, 160, 171]. 
AmrAB-OprA was the first efflux system to be characterized and confers 
resistance to a variety of aminoglycosides, including tobramycin, kanamycin, and 
gentamicin.  This system also confers resistance to the macrolides, erythromycin and 
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clarithromycin [160].  A second efflux system, BpeAB-OprB, was identified in 2004 [172] 
and is capable of effluxing the macrolides, fluoroquinolones, and tetracyclines [159].  
BpeAB-OprB has also been reported to excrete quorum sensing molecules in B. 
pseudomallei strain KHW [158, 173].  It has been proposed that quorum sensing is 
dependent on this RND pump, and that BpeAB-OprB is required for the production of 
virulence factors controlled by quorum sensing, including biofilm formation, siderophore, 
and phospholipase C production [158].  However, it was most recently reported that 
BpeAB-OprB is not involved with quorum sensing or virulence factor production in B. 
pseudomallei strain 1026b [159], indicating potential variation between B. pseudomallei 
strains.     
A third B. pseudomallei efflux system that has been identified is BpeEF-OprC 
and its substrates include trimethoprim and chloramphenicol [171].  The operon 
encoding this efflux pump also encodes the putative lipase, BPSS0291 [171], indicating 
that efflux pumps could potentially play additional roles other than just antibiotic 
resistance during in vivo melioidosis infection.  Since the true function for efflux pumps 
within bacteria is largely unknown [169], the impact these systems have on B. 
pseudomallei virulence during in vivo infection is also not understood. 
B. pseudomallei contains various beta-lactamases which also contribute to its 
intrinsic antibiotic resistance.  Genome sequencing has indicated the presence of 
Ambler class A, B, and D beta-lactamases [16].  The Bush-Jacoby-Medeiros class 2e 
beta-lactamase BPS-1 encoded by blaA, also known as penA, is known to confer 
resistance to the majority of cephalosporins [174].  Mutations in blaA result in resistance 
to beta-lactam/beta-lactamase inhibitor combinations and also to ceftazidime, a 
commonly used antibiotic to treat melioidosis [175].  Expression of the class D beta-
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lactamases, OXA-42 and OXA-43, are also thought to contribute to resistance to 
ceftazidime [176].  
 
1.6  Diagnosis of Melioidosis 
Culture has remained the “gold standard” for definitive diagnosis of B. 
pseudomallei infection [20, 177-178].  It is recommended that samples of blood, urine, 
respiratory secretions, and throat swabs be cultured from patients with symptoms of 
melioidosis, and that wounds and pus be cultured during cases of cutaneous 
involvement [20].  The time to diagnosis with culture is typically 3 to 4 days and this 
constitutes one of its biggest downfalls.  This is especially problematic in cases of B. 
pseudomallei septicemia, as patients often die within just 24 to 48 hours of hospital 
admission [177].  Culture also requires skilled laboratory personnel for interpretation of 
the results because normal flora can overgrow B. pseudomallei [177].  To help combat 
this problem with non-sterile specimens, Ashdown’s agar is a selective media specific for 
B. pseudomallei containing trypticase soy agar, glycerol, crystal violet, neutral red, and 
gentamicin that is used for melioidosis diagnosis [179].  B. pseudomallei produces large 
purple-colored colonies when grown on this selective media.  A modified Ashdown’s 
agar containing colistin is also commonly used [180].  However, Ashdown’s agar is not 
always readily available for use in all laboratories, especially within endemic regions of 
the world. 
To decrease the time to diagnosis, various immunological-based diagnostic 
techniques have been explored, however there is currently no commercially available 
diagnostic test.  Indirect hemagglutination antibody (IHA) tests for B. pseudomallei 
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specific antibodies have been developed, but have been considered poor for diagnostic 
purposes due to the common finding of seropositivity among healthy persons within 
endemic regions.  It is estimated that 60-70% of Thai children are seropositive [181-182].  
The detection of B. pseudomallei antigens is considered far more useful for diagnosing 
melioidosis because it indicates active disease [177].  Antigen tests have been 
developed for blood cultures and for directly testing patient specimens [4].  A test 
commonly used in Thailand is a latex agglutination test containing monoclonal 
antibodies specific for B. pseudomallei lipopolysaccharide and exopolysaccharide 
antigens.  This test is used for blood culture fluid and was demonstrated to be both 
sensitive and specific [183-184]. 
Molecular tests have also been used for diagnosis of melioidosis.  A polymerase 
chain reaction (PCR) test specific for the type three secretion system (T3SS) has been 
developed [185], but its effectiveness has had mixed results [186].  PCR-based 
diagnostic assays are most sensitive when conducted on direct specimens, and have 
had lower sensitivity when performed on blood cultures [185, 187].  The lower limit of 
detection for PCR identification typically falls below B. pseudomallei counts within the 
blood during melioidosis disease [20].  
        
1.7  Melioidosis Therapies and Prevention 
 The current recommended intensive phase therapy for melioidosis is 50 mg/kg 
ceftazidime every 6-8 hours or 25 mg/kg meropenem every 8 hours for 10-14 days [23].  
The duration of therapy is increased to 4-8 weeks for deep-seated infections.  In cases 
of neurological, bone, joint, or prostatic melioidosis, 8/40 mg/kg trimethoprim-
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sulfamethoxazole is also included in the intensive phase therapy.  This initial 
treatment is then followed by oral eradication therapy consisting of trimethoprim-
sulfamethoxazole for 3-6 months or longer, and doxycycline may also be included in the 
eradication therapy [23].  Whether or not doxycycline improves outcome is under current 
investigation in Australia [186].  In cases where trimethoprim-sulfamethoxazole cannot 
be used (pregnant women), amoxicillin-clavulanate is an alternative antibiotic, but has 
been shown to be associated with increased relapse rates [188].   
In clinical trials conducted in the 1980s, the use of ceftazidime for intensive 
phase of therapy was shown to halve mortality over the previous conventional 
melioidosis therapy consisting of chloramphenicol/doxycycline/ trimethoprim-
sulfamethoxazole [189-190].  No alternative antibiotics have definitively proven more 
effective than ceftazidime to date [186].  Since carbapenems are known to be highly 
active against B. pseudomallei in vitro [191], the efficacy of imipenem and meropenem 
have been compared to ceftazidime.  In a clinical trial including more than 200 patients 
in Thailand, there was no difference in survival among patients treated with imipenem 
compared to ceftazidime.  However, in patients surviving longer than 48 hours, 
imipenem had a lower rate of treatment failure, but these results remain controversial 
[186, 192].  In a trial comparing meropenem to ceftazidime therapy among melioidosis 
patients in Australia, outcomes were similar for patients in both groups.  However, it was 
noted the more seriously ill patients were deliberately chosen to receive meropenem, 
suggesting that this antibiotic may be actually superior [193].     
Even with appropriate antibiotics, the response to therapy is often poor, and 
fevers with melioidosis last approximately 9 days.  Fevers lasting longer than 2 weeks or 
bacteremia persisting longer than one week despite antibiotic treatment constitutes 
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treatment failure [4].  Even with antimicrobial therapy, patient relapse is still common.  
Relapse occurs in approximately 13-23% of patients within a median time of 6-8 months 
[194-195].  Relapse is most often the result of reactivation of the original infecting strain 
of B. pseudomallei [195-196].  Relapse was shown to be increased in cases of severe 
disease, when doxycycline, quinolone, or ciprofloxacin-azithromycin were used during 
the oral eradication phase of treatment, or when eradication therapy was shorter than 8 
weeks duration [4, 197-199].  This relapse is indicative of incomplete clearance of B. 
pseudomallei and stable colonization by this pathogen even after appropriate 
antimicrobial therapy and apparent recovery. 
      
1.7(1) Immunotherapy for Treatment of Melioidosis 
 The use of immunomodulators for treatment of B. pseudomallei infection has not 
been thoroughly evaluated to date.  However, since mortality from melioidosis is highest 
in cases of sepsis, treatments explored for improving the outcome of septic patients are 
considered relevant [186].  Recombinant human activated protein C (rhAPC) is known to 
reduce apoptosis in monocytes and decrease inflammation, and has been shown to 
improve clinical outcome from sepsis [200-201].  A melioidosis patient from a 2005 
typhoon-related outbreak in Taiwan with acute pneumonic B. pseudomallei infection, 
septic shock, and multiple organ failure was treated with rhAPC and meropenem.  This 
combination therapy consisting of an antibiotic and immunomodulator was shown to be 
successful, and was one of the first reports of rhAPC improving the outcome of 
melioidosis sepsis [202].   
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Hydrocortisone administration has not been shown to reduce mortality from 
septic shock in recent studies, even though this treatment hastens the reversal of shock 
itself [203].  Therefore, hydrocortisone therapy is not expected to improve survival in 
cases of melioidosis sepsis.  Since diabetic patients have increased risk of melioidosis, it 
has been proposed that glycemic control could improve outcome from B. pseudomallei 
infection [4, 186].  However, insulin therapy was not found to improve outcome from 
sepsis in a clinical trial, and was actually shown to causes an increase in hypoglycemia-
related adverse events [204].   
Granulocyte-colony stimulating factor (G-CSF) is known to accelerate neutrophil 
recovery, and its impact on melioidosis outcome has been controversial.  A 1998 study 
conducted in Australia analyzing survival from melioidosis sepsis following the 
administration of G-CSF indicated that G-CSF administration markedly reduced mortality 
[205].  However in a small trial conducted in Thailand, G-CSF increased survival time 
from sepsis caused by suspected melioidosis, but did not improve mortality [120].  These 
differing results could be largely dependent on the differing medical resources available 
in the trial locations [186]. 
 Nonspecific activation of the innate immunity has been shown to improve 
outcome from B. pseudomallei infection in various melioidosis animal models.  
Unmethylated CpG oligodeoxynucleotides are potent stimulators of innate immunity and 
have been previously shown to elicit protection in mice from various intracellular bacteria 
[206].  It was reported by Wongratanacheewin et al. that intramuscular injection of CpG 
oligodeoxynucleotides administered prior to low-dose intraperitoneal B. pseudomallei 




     1.7(2) CLDC Immunotherapy for Burkholderia Infection 
Our laboratory has carried out studies similar to those conducted with CpG 
oligodeoxynucleotides (discussed in previous section).  We have investigated the 
effectiveness of cationic liposome-DNA complexes (CLDC) to protect mice from 
pneumonic pathogens [99, 208].  CLDC is composed of cationic spherical lipid particles 
complexed with non-coding bacterial plasmid DNA, and have been previously shown to 
be potent activators of non-specific innate immunity [209].    These complexes can be 
delivered via a variety of routes including intravenously, intranasally, or intraperitoneally, 
and they have caused minimal adverse reactions in mice, dogs, and humans [100, 208, 
210-211].  We recently reported that intranasal delivery of CLDC protected 100% of mice 
when administered prior to lethal B. pseudomallei or B. mallei challenge [99].  In this 
particular study, IFN-production induced by CLDC treatment was identified as the key 
cytokine mediating the protection elicited by the immunotherapy [99].           
 
     1.7(3) Prospects of a Melioidosis Vaccine 
  There is currently no approved vaccine for B. pseudomallei.  A variety of vaccine 
formulations have been evaluated in animal melioidosis models to date, including killed 
whole-cell formulations, live-attenuated strains, a variety of Burkholderia protein 
subunits, capsular polysaccharide and lipopolysaccharide antigens, and DNA-based 
vaccines [25].  An overview of these approaches and their efficacy is outlined in Table 
1.3 below.  Even though many of the vaccine formulations tested have offered short-
term protection from acute melioidosis, a big challenge has been the lack of long-term, 
sterilizing protection from chronic disease following vaccination.  Even some of the most 
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promising vaccine candidates fail to protect animals beyond 30-40 days post-infection 
[212], and B. pseudomallei is commonly isolated from the tissues of vaccinated survivors 
at the end of the observation periods [213].   
 Vaccine studies with killed whole-cell formulations have typically used non-
adjuvanted irradiated or heat-killed B. pseudomallei [25, 213-214].  In a study by Barnes 
et al., mice were vaccinated subcutaneously with heat-killed B. pseudomallei and 
challenged intravenously.  The majority of mice vaccinated with heat-killed bacteria 
alone failed to survive beyond 5 days post-intravenous challenge, illustrating the inability 
of killed, non-adjuvanted B. pseudomallei to protect from this challenge route [214].  
Contrastingly, Sarkar-Tyson et al. demonstrated that intraperitoneal vaccination with 
killed B. pseudomallei alone offered protection beyond 40 days from aerosol challenge in 
60% of mice [213].  However, it should be noted that a low aerosol challenge was used 
in this study, as not all unvaccinated mice succumbed to acute disease.  Even greater 
protection was demonstrated by this same group following intraperitoneal challenge, as 
close to 100% of mice were protected for greater than 40 days [213].  However, it was 
noted by the authors that sterilizing immunity is not common in these studies, 
demonstrated by the finding that B. pseudomallei is routinely isolated from the tissues of 
vaccinated survivors [25].  
Live attenuated strains have shown more promise than killed formulations in 
protecting mice from acute melioidosis [26, 28-29, 31-32, 215].  However long-term 
protection from chronic melioidosis is still lacking.  In a study by Haque et al., 100% of 
mice vaccinated intraperitoneally with the live attenuated B. pseudomallei 2D2 strain 
were protected for 25 days following intraperitoneal challenge.  Long-term sterilizing 
immunity was not produced however, as the majority of animals eventually succumbed 
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to chronic disease within 75 days [215].  Since the protection offered by this live 
attenuated strain was incomplete, the effectiveness of a boosting dose was analyzed.  
Boosted mice were found to have lower splenic bacterial burdens (compared to mice 
receiving a single vaccination) on day 1 after intraperitoneal B. pseudomallei challenge, 
but there was no significant difference in splenic burdens at any other time points 
analyzed (days 2, 6, 13 post-challenge) [215].  Additional studies in murine models have 
demonstrated the protective efficacy against lethal B. pseudomallei challenge increases 
when higher immunizing doses containing the live attenuated strain are used for 
vaccination [216].  In addition, the protective effect elicited by the live attenuated B. 
pseudomallei strain CL04 was shown to be greatly diminished when this strain was 
inactivated by gamma irradiation [216].   
A variety of Burkholderia protein subunits have been tested for protective efficacy 
[212, 217-218].  The antigen showing the most promising to date has been LolC [25], an 
outer membrane protein that serves as an adenosine triphosphate-binding cassette 
transporter protein [212].  The majority of mice vaccinated subcutaneously or 
intraperitoneally with adjuvanted LolC were protected from melioidosis for over 30 days 
[212], similar to that seen with live attenuated vaccine formulations.  However, long-term 
sterilizing protection was not offered by LolC or other outer membrane proteins tested to 
date [219].  Both lipopolysaccharide (LPS) and capsular polysaccharides have also been 
investigated as potential subunit vaccine candidates.  Vaccination with either of these 
subunits intraperitoneally was shown to increase the time to death following 





Table 1.3.  Summary of vaccine formulations investigated in murine melioidosis 
models.  (Table continued onto next page). 
Vaccine 
Formulation 







no acute disease 
protection from killed Bp 
alone 
     [214]  
 killed Bp K96243 
killed Bp 576  
i.p. vaccination 
i.p. challenge 
> 80% protection for 20 
days  
     [213]  
 killed Bp K96243 




~ 60% protection for 40 
days 






mutant, Bp 2D2 
i.p. vaccination 
i.p. challenge Bp 
576 
100% protection for 25 
days 
       [215]  
 amino acid 
biosynthesis 
mutant (aroB), Bp 
13B11  
 
(aroC), Bp A2 
i.n. vaccination 









BALB/c mice not protected 








mutant (serC)  
i.p. vaccination 
i.p. challenge, Bp 
576 and K92643 




(purM)                     
(purN) 
          i.p. 
vaccination 
    i.n. challenge 
i.p. vaccination                    
i.n. challenge 
 
Protection beyond 30 days 
 
 
Protection beyond 28 days 
(2/2 mice) 
     [130] 
 
      













Strain/Antigen               Route Outcome Source  





i.p or s.c. 
vaccination 
i.p. challenge Bp 
K96243 
Protection for 
30 days in > 80% 
mice; lack of 
chronic disease 
protection 
     
[212] 
 















i.p. challenge Bp 
D286 
~70% protection 









i.p. challenge Bp 
D286 
~50% protection 








plus Ribi Adjuvant 
System (RAS) 
i.p. vaccination 
i.p. challenge Bp 
NCTC4585 
Increased time 






     1.7(4) Mechanism of Vaccine-Induced Protection  
 The live attenuated strain 2D2 was shown to protect 100% of mice from lethal B. 
pseudomallei challenge for 25 days [215], but failed to protect from long-term 
disseminated disease.  The mechanism of acute disease protection following vaccination 
with this attenuated strain was examined by Haque et al. in 2006 to better understand 
the mechanism behind vaccine-mediated immunity to B. pseudomallei [215].    
Splenocytes were obtained from immunized and control mice, and a significantly greater 
proportion of CD4+ and CD8+ T cells from vaccinated mice were found to produce IFN- 
in response to exposure to dead B. pseudomallei (compared to those cells isolated from 
unvaccinated controls).  The proportion of IFN- producing T cells was greatest among 
the mice that received both a prime and booster vaccination, compared to those 
receiving just a single vaccination [215].  Additional experiments were conducted to 
determine whether the protection elicited by immunization is mediated by CD4+ or CD8+ 
T cells.  Depletion of CD4+ T cells in immunized mice was found to completely abolish 
the protection offered by immunization, whereas CD8+ T cell depletion had no impact on 
protection.  Such findings illustrate that vaccine-induced protection elicited by the live 
attenuated strain 2D2 is mediated by CD4+ T cells [215].   
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RATIONALE FOR RESEARCH AND SPECIFIC AIMS 
 
2.1  Research Overview 
The research project presented in this Dissertation is “The analysis of 
Burkholderia pseudomallei virulence and efficacy of potential therapeutics.”  The first two 
Specific Aims (Chapters 3 and 4) focus on the examination of virulence of a variety of B. 
pseudomallei mutant strains using a murine melioidosis model.  Chapter 3 entails the 
extensive in vivo characterization of two fully attenuated mutant strains with the overall 
purpose of obtaining Select Agent exemption based on their complete attenuation.  The 
identification of potential bacterial factors contributing to morbidity within the host is 
presented in Chapter 4.  The latter two Specific Aims (Chapters 4 and 5) address 
melioidosis from more of a clinical perspective in terms of its treatment and prevention.  
The investigation of a potential enhancement to traditional antibiotic therapy by the co-
administration of immunotherapy is discussed in Chapter 5, and the prevention of 
melioidosis with the development of an effective mucosal vaccine is addressed in 





     2.1(1) Specific Aim 1 (Chapter 3 of Dissertation) 
The basis for Specific Aim 1 is related to a major research challenge with B. 
pseudomallei.  The overall long-term goal of this Aim was to greatly facilitate research on 
this pathogen by the research community.   Basic research on B. pseudomallei is greatly 
hindered due to its Select Agent classification.  All research must take place within 
biosafety level 3 (BSL-3) containment facilities, and studies using B. pseudomallei by 
those institutions lacking such containment laboratories are simply not possible in the 
United States.  For many other bacterial strains on the Select Agent list, including 
Bacillus anthracis, Francisella tularensis and Yersinia pestis, there are already 
attenuated strains available that are excluded from Select Agent regulations 
(www.selectagents.gov/exclusions.html) and suitable for research within BSL-2 settings. 
Many of the attenuated B. pseudomallei mutants constructed to date were created using 
Select Agent non-compliant methods, and have been investigated in terms of protective 
efficacy rather than intensive demonstration of attenuation in immune competent and 
immune deficient animal models [1-4].  Prior to this research, there was no attenuated B. 
pseudomallei strain exempt from Select Agent regulations and approved for research 
outside of the BSL-3 setting.   
 The purpose of Specific Aim 1 was to create two B. pseudomallei attenuated 
mutant strains and fully characterize their attenuation in vivo using both immune 
competent and immune deficient animal models.  Upon successful demonstration of 
attenuation, the strains can be filed for Select Agent exemption.  The attenuated strains 
constructed as part of this research were Bp82, a 1026b purM derivative, and Bp190, a 
K96243 purM derivative.  Both strains lack the capability for adenine and thiamine 
biosynthesis, and were constructed by Kyoung-Hee Choi and Takehiko Mima in the 
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Herbert Schweizer laboratory at Colorado State University.  The attenuated mutant 
strains were tested in a variety of melioidosis models, including BALB/c mice, 129/SvEv 
mice, IFN--/- mice, SCID mice, and Syrian hamsters.  The hypothesis was that both 
strains would be fully avirulent in vivo, and incapable of replication and dissemination 
within a murine melioidosis model.   
 
     2.1(2) Specific Aim 2 (Chapter 4): 
The focus of Specific Aim 2 is the identification and characterization of potential 
B. pseudomallei virulence factors.  Since B. pseudomallei research within the Western 
world was largely lacking until its Select Agent classification [5], much is still unknown 
about this pathogen.  Both iron acquisition and resistance-nodulation-cell division (RND) 
efflux systems have been proposed to play potential roles in virulence [6-7], but the 
impact of these systems during in vivo infection is largely unknown.   B. pseudomallei is 
known to possess the hydroxamate siderophore malleobactin (MbaA) for iron acquisition 
from transferrin and lactoferrin [8-10], and is also thought to produce a second 
siderophore known as pyochelin [8, 11-12].  Homologous siderophores in related 
bacterial species have been shown to be required for full virulence [13-14].  B. 
pseudomallei is also believed to harbor at least 10 efflux pumps including the two 
characterized pumps AmrAB-OprA and BpeAB-OprB [15-16].  The BpeAB-OprB system 
has been proposed to be required for full virulence of B. pseudomallei [7], but this topic 
remains controversial.   
  The purpose of this Aim was to investigate the impact that B. pseudomallei 
siderophores and RND efflux systems have on virulence within a murine melioidosis 
53 
 
model.  This was examined using both a clinical isolate and isogenetic mutants 
constructed within the laboratory.  The two RND efflux systems evaluated within this 
research were the characterized AmrAB-OprA and BpeAB-OprB systems.  The genomic 
region involved with iron transport that was analyzed within these studies was mba, 
containing a 13-gene malleobactin biosynthetic gene cluster [8].  A second iron transport 
factor analyzed within these studies was fptA, encoding the putative pyochelin receptor 
protein [8].  Strains deficient of fptA enabled us to examine the effect of the pyochelin 
siderophore as well as malleobactin on virulence of B. pseudomallei.  The hypothesis 
was that virulence would be diminished in our murine model among the strains harboring 
deletions of efflux and iron acquisition genes, based on the report that homologous 
siderophores in related bacterial species are required for full virulence [13-14].  
 
     2.1(3) Specific Aim 3 (Chapter 5): 
 Specific Aims 3 and 4 focus on the treatment and prevention of melioidosis, with 
great potential relevance for the clinical setting within endemic regions and prophylaxis 
in the event of an intentional biological release.  Even with antibiotic therapy, the overall 
mortality rate during melioidosis is still high, being approximately 50% in Thailand and 
20% in Australia [17-18].  In addition, patient relapse is common after the discontinuation 
of therapy [19-21], illustrating the need for new approaches to improve the effectiveness 
of antimicrobial therapy for B. pseudomallei infection.   
 The purpose of Specific Aim 3 was to determine whether immunotherapy could 
augment the effectiveness of conventional antibiotic therapy for treatment of B. 
pseudomallei.  This was examined in vitro using a macrophage infection model and also 
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in vivo using a murine melioidosis model.  The antibiotic analyzed within these studies 
was ceftazidime, the current recommendation for intensive phase therapy for melioidosis 
treatment [22].  The immunotherapies investigated were cationic liposome-DNA 
complexes (CLDC) and recombinant IFN-.  During the in vivo investigations, the impact 
of this combination therapy was assessed for both the short-term acute and long-term 
chronic stages of melioidosis.  The hypothesis for Specific Aim 3 was that ceftazidime 
therapy would be enhanced with the addition of the immunotherapies.  We predicted this 
combination therapy (immuno-antimicrobial therapy) would increase survival of the mice 
following lethal pneumonic B. pseudomallei challenge, and reduce bacterial loads both in 
vivo and in vitro.  This hypothesis was largely based on our previous findings that CLDC 
is an effective immunotherapeutic against Burkholderia species [23].  
 
     2.1(4) Specific Aim 4 (Chapter 6): 
 The focus of Specific Aim 4 is the development of a mucosal vaccine for B. 
pseudomallei.  There is currently no approved vaccine for human melioidosis, and an 
effective vaccine would likely be effective within both endemic regions of the world and 
among high-risk persons such as the military.  A major current challenge among the 
various vaccine formulations investigated in murine models to date is the lack of long-
term protection from chronic disease.  Even some of the most promising vaccine 
candidates fail to protect animals into the chronic stages of disseminated disease [24].  
In addition, B. pseudomallei is commonly isolated from the tissues of vaccinated 
survivors at the end of the observation periods [25].  These findings indicate a lack of 
sterilizing immunity elicited by the vaccines and illustrate the need for the identification of 
additional vaccine antigens, adjuvants, and effective delivery routes.   
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 The purpose of Specific Aim 4 was to develop an effective mucosal vaccine for 
B. pseudomallei that would provide protection from both short-term acute and long-term 
chronic disease.  Mucosal delivery of antigens (instead of systemic immunization) was 
chosen for these studies, as this route for delivery of antigens has been shown to most 
efficiently produce mucosal immunity [26-28]. The effectiveness of our vaccine 
formulations were tested via intranasal administration and one formulation was also 
tested orally. The challenge route utilized post-vaccination was pneumonic (intranasal) 
due to its biodefense implications.   
The first goal of these studies was to determine whether the cationic liposome-
DNA complexes (CLDC) would serve as an effective mucosal adjuvant.  The vaccine 
formulations tested within these studies included killed bacteria, protein subunits 
conjugated to CLDC, and two live attenuated B. pseudomallei strains.  The hypothesis 
for Specific Aim 4 was that the vaccine formulations delivered intranasally would provide 
both short and long-term protection from melioidosis, based largely on the effective 
mucosal immunity induced by this delivery route [26-28] and the vaccine formulations 
investigated.  In addition, it was hypothesized that the live, attenuated formulations 
would produce the longest term protection, as live vaccines have shown some of the 
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A Burkholderia pseudomallei purM MUTANT IS 
AVIRULENT IN IMMUNOCOMPETENT AND 
IMMUNODEFICIENT ANIMALS:  CANDIDATE STRAIN 
FOR EXCLUSION FROM SELECT AGENT LISTS 
 
 The research presented in this chapter describes the construction and intensive 
demonstration of attenuation of two B. pseudomallei mutant strains.  I acknowledge the 
contribution of Takehiko Mima and Kyoung-Hee Choi for the construction of all bacterial 
strains and genetic analyses described in this chapter. 
    
3.1  Abstract 
Burkholderia pseudomallei causes the disease melioidosis in humans and is 
classified as a category B Select Agent.  Research utilizing this pathogen is highly 
regulated in the United States. and even basic studies must be conducted within 
biosafety level 3 (BSL-3) facilities.  There is currently no attenuated B. pseudomallei 
strain available that is excluded from Select Agent regulations and can be safely handled 
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at BSL-2.  To address this need, we created Bp82 and Bp190, purM derivatives of B. 
pseudomallei strains 1026b and K96243 deficient in adenine and thiamine biosynthesis, 
but replication competent in vitro in rich medium.  A series of animal challenge studies 
was conducted to assure that these strains were fully attenuated.  Whereas the parental 
strains 1026b and K96243 and the complemented mutants Bp410 and Bp454 were 
virulent in BALB/c mice following intranasal inoculation, the purM mutants Bp82 and 
Bp190 were avirulent even when administered at doses 4 logs higher than the parental 
strains.  Animals challenged with high doses of the purM mutants rapidly cleared the 
bacteria from tissues (lung, liver and spleen) and remained free of culturable bacteria for 
the duration of the experiments (up to 60 days post-infection).  Moreover, highly 
susceptible 129/SvEv mice and immune incompetent mice (IFN--/-, SCID) were resistant 
to challenges with the purM mutant Bp82.  This strain was also avirulent in the Syrian 
hamster challenge model.  We conclude that the purM mutant Bp82 is fully attenuated 
and safe for use under BSL-2 laboratory conditions, and thus a candidate strain for 
exclusion from the Select Agent list.   
 
3.2  Introduction 
Humans develop melioidosis following cutaneous or inhalational infection with 
the Gram-negative bacterium B. pseudomallei.  Melioidosis in humans is associated with 
a diverse spectrum of diseases, including acute pneumonia, osteomyelitis, hepatic and 
splenic abscesses, and neurologic disease [1-2].  Septic shock is the most severe 
clinical manifestation of B. pseudomallei infection and is typically associated with 
bacterial dissemination to the lungs, liver, and spleen [2].  Treatment of B. pseudomallei 
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infections is complicated because the organism is intrinsically resistant to many 
antibiotics [3].  Moreover, recurrence of infection is common in patients, even following 
appropriate antimicrobial treatment [4].   
Melioidosis occurs primarily in Southeast Asia and Northern Australia but is 
increasingly found in other tropical and subtropical regions of the world [5], in visitors 
returning from endemic regions [6-7], or in tourists afflicted by natural disasters [8-11].  
However, B. pseudomallei has gained attention in the Western Hemisphere in recent 
years due to its potential for use as a biological weapon [12].  Because of its biodefense 
implications, this pathogen is classified as a category B Select Agent by the U.S. 
Centers for Disease Control and Prevention.  Select Agent listing subjects research 
using B. pseudomallei to strict Federal guidelines that govern its acquisition, possession 
and use [13].  Research with B. pseudomallei in the U.S. can only be conducted by 
cleared personnel in CDC inspected biosafety level 3 (BSL-3) containment laboratories.  
For some bacteria on the Select Agent list, including Bacillus anthracis, Francisella 
tularensis and Yersinia pestis, there are already bona fide attenuated strains available 
(www.selectagents.gov/exclusions.htm) that are excluded from Select Agent listings.  
These attenuated strains can be handled in BSL-2 laboratories which has facilitated 
studies of these bacteria.  However, in the case of B. pseudomallei progress has been 
slow because no approved attenuated strains are available.  We believe that availability 
of such strains would greatly facilitate and accelerate sorely needed basic research with 
this emerging Select Agent and priority pathogen.  Additionally, attenuated strains have 
the potential to be used as live vaccine strains since in many cases pre-dosing of 
animals with the attenuated strains has been shown to afford protection against 
challenges with wild-type bacteria [14-18].  The ultimate goal of the proposed research 
was therefore to derive an attenuated B. pseudomallei strain that would be avirulent in 
61 
 
animal challenge studies, exempt from Select Agent registration, and thus could be 
widely distributed and used in BSL-2 laboratories.   
Diverse B. pseudomallei mutants have been identified that exhibited various 
degrees of attenuation in animal models, including mutants deficient in branched chain 
amino acid biosynthesis [14], aromatic compound synthesis [17], mutants affecting 
capsule biosynthesis [19-21], mutants lacking a type IV pilin [22], and mutants lacking 
components of the type III secretion system [15].  Pilatz et al. [16, 23] conducted a 
transposon mutant screen aimed at identification of B. pseudomallei genes required for 
the intracellular life cycle and in vivo virulence.  Amongst the most highly attenuated 
mutants was a purM mutant.  This mutant, however, was created using a Select Agent 
non-compliant method (transposon mutagenesis with a tetracycline resistance marker), 
was not exhaustively studied in various animal models, and was generated in a strain 
that is not widely used by and available to the research community.  
In the current study, we created purM mutant derivatives of the readily available 
and well-studied B. pseudomallei strains 1026b [24] and K96243 [25].  These mutants 
were constructed by deleting the purM gene, which encodes phosphoribosyl 
formylglycinamide cycloligase.  The product of the reaction catalyzed by this enzyme is 
aminoimidazole ribotide, a precursor for de novo adenine and thiamine biosynthesis.   
Here we report the results of studies conducted to evaluate the in vivo virulence of these 
purM mutants of B. pseudomallei, with particular reference to virulence in immune 





3.3  Materials and Methods 
     3.3(1) Bacterial strains, media, and growth conditions   
B. pseudomallei strain 1026b is a clinical isolate from a case of human 
septicemic melioidosis from Thailand.  This strain is lethal to mice and has been 
extensively studied in the laboratory [24].  Bp82 is a purM derivative of 1026b and 
adenine and thiamine auxotroph.  K96243 is a clinical isolate from a case of fatal human 
melioidosis from Thailand and its sequence was the first for any B. pseudomallei strain 
to be published [25].  Strains Bp410 and Bp454 are Bp82 and Bp190 in which the purM 
alleles have been replaced with wild-type purM sequences from 1026b.  These strains 
are purM+ and adenine and thiamine prototrophs.  Strains were grown to saturation in 
Luria broth (LB) at 37°C with shaking, and then stored at -80°C in 15% glycerol until 
ready to use.  For animal experiments, each strain was thawed just before use and the 
bacteria were diluted to the desired cell numbers using sterile phosphate buffered saline 
(PBS).   For growth curves, each strain was grown overnight at 37°C in LB broth.  The 
overnight culture was diluted 100-fold with either LB broth or M9 medium (22) with 10 
mM glucose and 200 l aliquots of the diluted cultures were transferred to a sterile 96 
well black, clear bottom assay plate (Cat. No. 3603, Corning Incorporated, Corning, NY).  
Growth was recorded using a Synergy HT Multi-Mode Microplate Reader (BioTek 
Instruments, Winooski, VT) using the following settings: temperature 37°C; shake at 
slow speed; read plate every 30 min for up to 48 h at 600 nm.  Where indicated, M9-





     3.3(2) Attenuated mutant strain construction 
A 1,545-bp fragment containing the purM gene and flanking DNA was PCR-
amplified from strain 1026b genomic DNA using Taq DNA polymerase (New England 
Biolabs, Ipswich, MA) and primers 1487 (5’-CACACGTAGAACGTGCGATC) and 1585 
(5’-CTTTCGAGAAGCTTTCGACGG; a newly introduced HindIII site is underlined) 
(purchased from Integrated DNA Technologies, Coralville, IA).  The fragment was ligated 
into the TA cloning vector pCR2.1 (Invitrogen, Carlsbad, CA) resulting in pPS2277.  
Next, a 114-bp NruI fragment was deleted from the purM coding sequence present on 
pPS2277 and replaced with a blunt-ended 776-bp SacI fragment containing a zeocin 
resistance marker from pFZE1 [26].  This step resulted in pPS2336.  A 2,253-bp HindIII 
fragment was purified from pPS2336 and used to transform 1026b utilizing a previously 
described procedure [26-27].  Zeocin resistant transformants were obtained and tested 
for purine auxotrophy by growing selected transformants on M9-glucose minimal 
medium plates [28] with and without 0.6 mM adenine.  One representative colony, Bp80, 
growing only in the presence of adenine was retained for further study.  A zeocin-
susceptible derivative of Bp80 was derived by Flp recombinase-mediated excision of the 
zeocin resistance marker and curing of the Flp source plasmid pFLPe4 using previously 
described methods [26].  The presence of the purM mutation in the resulting strain 
Bp82 was confirmed by PCR amplification of the fragment harboring purM and the FRT 
scar using primers 1505 (5’-GATCTTCCATACCTGCTCGC) and 1508 (5’-
GAATCCTCCGAAATCCGCTC), and sequencing of the resulting 975-bp PCR fragment.  
The K96243 purM derivative Bp190 has previously been described [29]. Repair of the 
purM lesions in Bp82 and Bp190 was achieved by allele replacement with an EcoRI 
fragment containing the 1026b purM gene and a previously described pEXKm5-based 
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sucrose counter-selection method [29]; the resulting adenine and thiamine prototrophs 
derived from Bp82 and Bp190 were named Bp410 and Bp454, respectively.                         
 
     3.3(3) Animals   
Specific pathogen-free female mice between 4 and 6 weeks of age were 
purchased from Jackson Laboratories (Bar Harbor, ME).  Mice used in these studies 
were BALB/c, 129/SvEv, IFN--/- (on the BALB/c background), and SCID (on the BALB/c 
background).  Syrian hamsters 6 weeks of age were purchased from Charles River 
Laboratories (Wilmington, MA). Animals were housed in micro-isolator cages under 
pathogen-free conditions.  All animal studies were approved by the Institutional Animal 
Care and Use Committee at Colorado State University. 
 
 
     3.3(4) Animal infections   
All infections with B. pseudomallei were done using intranasal inoculation.  
Animals were anesthetized with 100 mg/kg ketamine (Fort Dodge Animal Health, 
Overland Park, KS) plus 10 mg/kg xylazine (Ben Venue Labs, Bedford, OH).  The 
desired challenge dose of B. pseudomallei was suspended in PBS and 20 l was 
delivered intranasally, alternating nostrils.  Hamsters were infected in the same manner, 
but the inoculum was delivered in a total volume of 60 l.  For all survival studies, 
animals were monitored for disease symptoms twice daily and were euthanized 
according to pre-determined humane endpoints.   
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     3.3(5) Enumeration of viable B. pseudomallei in organs   
B. pseudomallei was quantified in lung, liver, and spleen tissues at 48 h post-
infection in acute challenge studies and between days 30 and 60 post-infection in long-
term survival studies.  Lungs, spleens, and livers were removed aseptically and 
homogenized in sterile phosphate buffered saline using a stomacher (Teledyne Tekmar, 
Mason, OH).  Viable bacterial counts were determined for each organ by plating serial 
10-fold dilutions of organ homogenates on LB agar.  Plates were incubated at 37°C for 
48 h, then the numbers of colonies on the appropriate plate were scored visually and the 
organ burden of bacteria was expressed as colony forming units (CFU)/organ.  Any 
plates containing organ homogenates that were sterile after 48 h incubation were 
incubated for an additional 2-3 days to ensure sterility. 
 
     3.3(6) Statistical analysis   
Statistical analysis was performed using Prism 5.0 software (GraphPad, La Jolla, 
CA).  Survival times were compared using Kaplan-Meier survival curves and the log-rank 
(Mantel-Cox) test.  Organ bacterial burdens between 2 groups of mice were compared 
using a one sample t-test.  Data were considered to be statistically significant for p 







3.4  Results 
     3.4(1) Construction and properties of B. pseudomallei purM mutants Bp82 
         and Bp190 
A previously described recombinant DNA fragment transformation procedure, 
coupled to Flp-mediated excision of the zeocin resistance gene employed to initially 
mark and select the purM deletion, was used to generate a markerless chromosomal 
purM mutant, Bp82 [26].  This mutant is missing codons 95-132 of purM and is 
expressing a truncated PurM protein of 99 amino acids whose translation terminates at a 
stop codon within the FRT scar (Fig. 3.1A).  As a result, Bp82 does not produce a 
functional PurM enzyme and is an adenine auxotroph (Fig. 3.1D & G).  Bp190 contains 
an in-frame purM deletion without the FRT scar which results in a mutant PurM protein 
that lacks the same 38 amino acids as the protein remnant in Bp82 but terminates with 
the native stop codon (Fig. 3.1B).  However, while its growth is significantly attenuated 
in M9-minimal glucose medium lacking adenine (Fig. 3.1F & H) the K96243 derivative 
Bp190, in contrast to Bp82, is not a strict adenine auxotroph.  The growth rates of 1026b 
and Bp82 as well as K96243 and Bp190 in LB medium are indistinguishable (not 
shown).   Repair of the PurM defects in Bp82 and Bp190 resulted in prototrophs (Bp410 
and Bp454) whose growth rates in M9-minimal glucose medium were indistinguishable 
from that of 1026b or K96243 (Fig. 3.1G & H). 
 Because the product of PurM-catalyzed reaction, aminoimidazole ribotide (AIR), 
is a precursor of thiamine biosynthesis and B. pseudomallei possesses the genes for the 
biosynthesis of thiamine from AIR we assessed whether the purM mutants were also 
thiamine auxotrophs.  For both mutant strains, addition of thiamine alone did not affect 
growth in M9-glucose minimal medium (Fig. 3.1D & F).  While growth of both mutants in 
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the same medium was significantly improved by adenine alone, only addition of adenine 
and thiamine restored growth to levels that were indistinguishable to those observed with 
1026b and K96243 (compare panels D & F with C & E).  The data confirm that both 



















Figure 3.1.  purM mutant alleles and in vitro growth of B. pseudomallei purM mutants 
Bp82 and Bp190 and its purM
+
 derivatives Bp410 and Bp454.   (A) Sequence of the 
FRT scar region present in Bp82.   Lower case letters indicate purM sequences.  Capital 
letters indicate the 86-bp FRT scar sequence with the resident XbaI site and the Flp 
recombination sequences which are boxed.  The residual PurM amino acid sequence is 
shown below the nucleotide sequence.  NruI sites mark the original junction sequences of 
purM and zeocin resistance-encoding cassette from pFZE1 and are the result from fusing a 
NruI half site with a T4 DNA polymerase blunted SacI site.  (B) Sequence of the deletion 
junction present in Bp190.  Deletion of an internal NruI fragment from purM resulted in 
deletion of 38 amino acids from PurM.  The purM open reading frame terminates with the 
stop codon naturally found after valine 351.  (C) to (F) Growth of strains in minimal media.  
The following strains were tested: 1026b and its purM derivative Bp82; K96243 and its 
purM derivative Bp190.  The strains were inoculated into 200 l of M9-glucose medium 
(M9G) with 0.6 mM adenine (M9G+A) or 0.0005% thiamine (M9G+T) or both adenine and 
thiamine (M9G+A+T) and growth at 37
o
C was monitored by reading the optical density (600 
nm) of the cultures at 30 min intervals.  The data points are the mean of three independently 
monitored wells with standard deviations. (G) and (H) Growth of prototype, mutant and 
complemented strains in minimal medium.  The following strains were tested: 1026b and 
its purM derivative Bp82; K96243 and its purM derivative Bp190.  Bp410 and Bp454 which 
are Bp82 and Bp190, respectively, with purM
+
 from 1026b replacing the purM allele. The 
strains were grown in 200 l of M9-glucose minimal medium without supplementation and 
growth at 37
o
C was monitored as described above.   
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     3.4(2) Deletion of purM renders B. pseudomallei non-virulent in BALB/c mice   
B. pseudomallei 1026b is lethal to BALB/c mice following intranasal (i.n.) 
challenge, with an LD50 of approximately 900 CFU [30].  We therefore first determined 
whether the purM deletion would reduce the virulence of strain 1026b in BALB/c mice 
following i.n. challenge.  BALB/c mice (n = 5 per group) were challenged with 5 x LD50 
(approximately 5,000 CFU) of wild-type B. pseudomallei 1026b and survival was 
monitored.  All mice reached end-point and were euthanized within 3 days post-infection 
(Fig. 3.2A).  Next, BALB/c mice (n = 5 per group) were administered high-dose i.n. 
challenge with 1 x 106 and 1 x 108 CFU of purM strain Bp82.  None of the mice 
challenged with Bp82 died.  The animals receiving 1 x 106 CFU did not develop signs of 
infection, while the mice challenged with 1 x 108 CFU had ruffling and mild respiratory 
symptoms lasting for 3-4 days following challenge.  All mice were healthy at the time of 
sacrifice on day 30 post-infection, and the lung, liver, and spleen bacterial burdens for 
both groups challenged with the mutant strain were all below the limit of detection (LOD 
= 100 CFU per organ) (data not shown).  These data indicated that the purM deletion 
resulted in a significant (p < 0.01) reduction in virulence for wild type BALB/c mice.  The 
avirulent phenotype of Bp82 was attributable to deletion of the purM locus since repair of 
this locus with the 1026b purM gene by allelic exchange resulted in a strain (Bp410) 
which regained full virulence (Fig. 3.2A).   
Although the K96243 derivative Bp190 was not a strict adenine and thiamine 
auxotroph, it was avirulent in BALB/c mice when inoculated intranasally at very high 
doses (Fig. 3.2B).  As with Bp82, the avirulent phenotype of Bp190 was attributable to 
deletion of the purM locus since its repair with the 1026b purM gene by allelic exchange 
resulted in a strain (Bp454) which regained full virulence (Fig. 3.2B).  The mice 
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challenged with 1 x 106 CFU Bp190 did not have clinical signs after challenge, and 
appeared healthy during the course of infection. At the time of sacrifice on day 60 post-
infection, the lung, liver, and spleen bacterial burdens for both groups challenged with 
the mutant strain were all below the limit of detection (LOD = 50 CFU per organ) (data 
not shown).  These data indicated that the purM deletion from K96243 also resulted in a 











Figure 3.2.   B. pseudomallei purM mutants Bp82 (A) and Bp190 (B) are 
attenuated in BALB/c mice.  (A) Mice (n = 5 animals per group) were challenged 
intranasally (i.n.) with either 5 x 103 CFU B. pseudomallei 1026b (wild type strain), 1 x 
106 CFU or 1 x 108 CFU purM strain Bp82, or 5 x 103 CFU Bp410 (Bp82 purM lesion 
repaired with purM gene sequences from 1026b).  Animal survival was assessed as 
described in Materials and Methods.  The statistical differences in survival times were 
determined by Kaplan-Meier curves followed by log-rank test (**, p < 0.01 for Bp82 vs. 
1026b, and Bp82 vs. Bp410).   (B) Mice (n = 5 animals per group) were challenged i.n. 
with either 5 x 103 CFU B. pseudomallei K96243 (wild type strain), 1 x 106 CFU purM 
strain Bp190, or 5 x 103 CFU Bp454 (Bp190 purM lesion repaired with purM gene 
sequences from 1026b).  (**, p < 0.01 for Bp190 vs. K92643, and Bp190 vs. Bp454).  





     3.4(3) Genetic deletion of purM enables bacterial clearance of B. pseudomallei 
       following intranasal challenge in immune competent mice   
Experiments were conducted next to assess the degree to which Bp82 was able 
to replicate in BALB/c mice following intranasal (i.n.) challenge. BALB/c mice (n = 3 per 
group) were infected i.n. with 6 x LD50 (approximately 6,000 CFU) of B. pseudomallei 
1026b or Bp82.  At 48 h after infection, the animals were sacrificed and bacterial 
burdens were quantified in the lungs, liver, and spleen.  Wild-type B. pseudomallei 
1026b underwent significant replication within the lungs of infected mice during the 48 h 
post-challenge as evidenced by a greater than a 100-fold increase in bacterial burden.  
Moreover, B. pseudomallei 1026b also disseminated to the liver and spleen following i.n. 
inoculation (Fig. 3.3A).  In contrast, at 48 h following challenge, Bp82 remained below 
the limit of detection for the assay within the lungs, liver, and spleen. 
 To further assess replication and dissemination of Bp82, BALB/c mice were 
subjected to higher i.n. challenge doses.  Thus, one group of mice (n = 3 per group) was 
subjected to i.n. challenge with 1,000 x LD50 (1 x 10
6 CFU) and a second group of mice 
was challenged with 100,000 x LD50 (1 x 10
8 CFU).  Forty-eight hours after infection, the 
mice were euthanized and bacterial burdens were quantified in the lungs, liver, and 
spleen.  In a recently published study, we reported that 40% of the i.n. Burkholderia 
inoculum reaches the lungs within an hour of infection [31].  In mice i.n. challenged with 
1 x 106 CFU Bp82 (assuming 4 x 105 CFU reached the lungs), there was a 3.5-log 
reduction in bacterial burden in the lungs 48 h after challenge, and bacterial counts 
within the liver and spleen were below the limit of detection for the assay (Fig. 3.3B).  In 
mice receiving 1 x 108 CFU Bp82 (assuming 4 x 107 CFU reached the lungs), there was 
greater than a 2.5-log reduction in the bacterial burden within the lungs in the 48 h 
following challenge.  The bacterial burden within the spleen was below the limit of 
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detection.  A single colony grew on the liver plating from one mouse, whereas the 
burdens were below the limit of detection for the other mice (Fig. 3.3C).  These results 
indicate neither efficient pulmonary replication nor dissemination to the liver or spleen in 
wild-type mice following high-dose i.n. challenge with Bp82.   
The replication and dissemination of Bp190 (purM mutant derived from K92643) 
was also assessed.  BALB/c mice (n = 5 per group) were challenged i.n. with 1 x 106 
CFU, and 48 h after infection, the mice were euthanized and bacterial burdens were 
quantified in the lung, liver, and spleen (data not shown).  Assuming 40% of the 
inoculum reached the lungs following challenge (4 x 105 CFU), there was 2-log reduction 
in bacterial burden within the lungs at 48 h following challenge (mean log10 CFU/lung = 
3.4).  The bacterial burden within the spleen was below the limit of detection.  Two of the 
five mice had B. pseudomallei detected within the liver at 48 h (mean log10 CFU/liver for 
all mice = 0.68) (data not shown).  Compared to Bp82, strain Bp190 was not as 
efficiently cleared from the mice within the 48 h time period.  This is consistent with in 
vitro growth data that indicated that Bp190 was not fully attenuated in M9 medium 



















Figure 3.3.  Bacterial burdens in the lungs, liver, and spleen 48 h after intranasal 
challenge with wild-type B. pseudomallei 1026b or purM mutant Bp82.   
(A) BALB/c mice (n = 3 per group) were challenged with 6 x 103 CFU of B. pseudomallei 
1026b or Bp82.  Bacterial burdens were quantified in each organ 48 h after challenge.  
Statistical differences were evaluated using a one sample t-test (**, p < 0.01, *, p < 
0.05).  (B and C) BALB/c mice (n = 3 per group) were challenged with 1 x 106 or 1 x 108 
CFU Bp82 (challenge doses are indicated on the graphs) and bacterial burdens were 
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 3.4(4) B. pseudomallei purM strains Bp82 and Bp190 are avirulent in  
     hypersusceptible mice 
We have previously observed that 129/SvEv mice are extremely susceptible to 
Burkholderia infection (A. Goodyear and S. Dow, unpublished observations).  For 
example, the LD100 dose for both B. pseudomallei and B. mallei following intranasal (i.n.) 
challenge in 129/SvEv mice was found to be less than 100 CFU (data not shown).  
Therefore, we assessed whether Bp82 and Bp190 were lethal when inoculated in these 
hypersusceptible mice.  129/SvEv mice (n = 5 per group) were challenged i.n. with 100 
CFU of wild-type B. pseudomallei 1026b or 1 x 106 CFU of Bp82.  Mice (n = 5 per group) 
were also challenged with 200 CFU B. pseudomallei K92643 or 1 x 106 CFU Bp190.  
The high challenge dose used for Bp82 and Bp190 was more than 10,000 x LD100 for 
wild type B. pseudomallei strains 1026b and K92643 in 129/SvEv mice.  In animals 
challenged i.n. with 100 CFU of B. pseudomallei strain 1026b, the euthanasia endpoint 
was reached by day 5 after infection.  In contrast, challenge with 1 x 106 CFU Bp82 did 
not result in clinical signs or mortality in any of the animals (Fig. 3.4).  Mice challenged 
with 200 CFU strain K92643 reached endpoint on day 2 after infection, whereas 
challenge with 1 x 106 CFU Bp190 did not cause clinical symptoms or mortality in any of 
the mice (Fig. 3.4).   
All mice infected with Bp82 appeared healthy at the time of sacrifice on day 30 
post-challenge.  The bacterial burdens in lung, liver, and spleen for all mice infected with 
Bp82 remained below the limit of detection for the assay (data not shown).  All mice 
infected with Bp190 were sacrificed on day 45 post-challenge, and the bacterial burdens 
in the lung, liver, and spleen were below the limit of detection at this time (data not 
shown).  These data indicate that the purM deletion in both 1026b and K92643 
eliminated virulence of B. pseudomallei, even in hypersusceptible mice. 
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Even though Bp190 was avirulent in both BALB/c and hypersusceptible 
129/SvEv mice, this strain was less attenuated in vitro and not as dissemination deficient 







Figure 3.4.  B. pseudomallei purM strains Bp82 and Bp190 are avirulent in 
129/SvEv mice.  Mice (n = 5 animals per group) were challenged intranasally (i.n.) with 
either 100 CFU B. pseudomallei 1026b or 1 x 106 CFU Bp82.  Mice (n = 5 animals per 
group) were also challenged with either 200 CFU B. pseudomallei K92643 or 1 x 106 
CFU Bp190.  Statistical differences in survival times were determined by Kaplan-Meier 





     3.4(5) B. pseudomallei purM strain Bp82 is avirulent in immune deficient mice   
Previous studies have clearly demonstrated that interferon-gamma (IFN-) is vital 
for host defense against B. pseudomallei [32] and B. mallei infection [33].  To further 
investigate the degree to which Bp82 was attenuated, IFN--/- mice (n = 3-4 mice per 
group) were challenged intranasally (i.n.) with a low dose (approximately 500 CFU) of 
wild-type B. pseudomallei 1026b or a high dose (1 x 106 CFU) of Bp82.  While we did not 
experimentally determine the LD50 dose for B. pseudomallei in IFN-knockout mice, we 
estimate that the LD50 was in the range of 10 to 100 CFU.  Therefore, the 10
6 CFU 
challenge dose with purM B. pseudomallei Bp82 would represent approximately 
100,000 times the estimated LD50 dose, and therefore similar to the difference in doses 
given the BALB/c mice.  We observed that all mice challenged with B. pseudomallei 
1026b developed severe disease and were euthanized on day 2 following challenge 
(Fig. 3.5A).  In contrast, none of the IFN--/- mice challenged with a high-dose of Bp82 
developed clinical signs or succumbed to infection.  The lung, liver, and spleen bacterial 
burdens for IFN--/- mice infected with Bp82 were below the limit of detection at day 30 
post-infection (data not shown).  
The attenuation of B. pseudomallei purM strain Bp82 was also evaluated in 
severe combined immune deficiency (SCID) mice.  SCID mice are nearly devoid of B 
and T lymphocytes, thereby largely abolishing adaptive immune responses, while 
leaving innate immunity intact.  SCID mice (n = 5 mice per group) were challenged with 
1 x 104 CFU of B. pseudomallei 1026b or with 1 x 106 CFU of Bp82.  The SCID mice 
challenged with wild type B. pseudomallei succumbed to infection within 5 days of 
challenge, which was a significantly increased time to death compared to the IFN--/- 
mice (p=0.003) and wild type BALB/c mice (p=0.004) following challenge with 1026b.  All 
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of the SCID mice challenged with Bp82 remained healthy throughout infection and 
survived (Fig. 3.5B).  Bacterial burdens at day 30 post-infection were below the limit of 
detection for mice challenged with Bp82 (data not shown). 
 
 
Figure 3.5.  B. pseudomallei purM mutant Bp82 is avirulent in immune deficient 
mice.  (A) IFN--/- mice (n = 3-4 mice per group) were challenged intranasally with either 
500 CFU of B. pseudomallei 1026b or 1 x 106 CFU of purM strain Bp82.  (B) SCID 
mice (n = 5 mice per group) were challenged i.n. with either 1 x 104 CFU of B. 
pseudomallei 1026b or 1 x 106 CFU of Bp82.  Statistical differences in survival times 
were determined by Kaplan-Meier curves followed by log-rank test (**, p < 0.01, *, p < 
0.05 for Bp82 vs. 1026b).  
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     3.4(6) B. pseudomallei purM strain Bp82 is attenuated in Syrian hamsters   
Syrian hamsters have previously been shown to be exquisitely susceptible to B. 
pseudomallei infection [34].  Therefore, we subjected Syrian hamsters to intranasal (i.n.) 
challenge with wild type and mutant B. pseudomallei.  Syrian hamsters (n = 5 animals) 
were challenged i.n. with a low dose of wild type B. pseudomallei 1026b (approximately 
400 CFU) or with a high dose (1 x 106 CFU) of Bp82 (Fig. 3.6).  Animals challenged with 
B. pseudomallei 1026b developed acute illness and all were euthanized by day 4 post-
challenge.  In contrast, there were no signs of disease in the animals challenged with 
Bp82.  All hamsters infected with Bp82 remained healthy for 30 days post-infection, and 
bacterial burdens within the lung, liver, and spleen were all below the limit of detection at 










Figure 3.6.  B. pseudomallei purM strain Bp82 is avirulent in Syrian hamsters.  
Hamsters (n = 5 animals per group) were challenged intranasally with 400 CFU of B. 
pseudomallei 1026b or 1 x 106 CFU of purM mutant Bp82.  Statistical differences in 
survival times were determined by Kaplan-Meier curves followed by log-rank test (**, p < 











3.5  Discussion  
Despite the medical importance of melioidosis, studying B. pseudomallei remains 
cumbersome, especially in Western countries where the awareness of melioidosis as a 
potential bioweapon has led to implementation of stringent security and containment 
requirements.  Nowhere is this more evident than in the United States.  The strict 
regulations governing the acquisition, possession and use of B. pseudomallei in the U.S. 
hinder even basic studies on the physiology, genetics, antimicrobial resistance, etc., of 
this important yet understudied pathogen and make mutant sharing an arduous 
endeavor because of the permit requirements.   Therefore, there is a growing need for 
safe, attenuated mutants of B. pseudomallei that can be utilized under BSL-2 
containment conditions.   
 As mentioned before, several B. pseudomallei mutants have been identified that 
exhibited various degrees of attenuation in cell culture or animal models.  These mutants 
were created mostly for purposes of live vaccine studies.  Attenuated mutants fall into 
roughly two categories, those that do not express virulence factors, e.g. capsule [19-21], 
mutants lacking a type IV pilin [22], and mutants lacking components of the type III 
secretion system [15], and those that exhibit metabolic defects, e.g. branched chain 
amino acid biosynthesis [14], aromatic compound synthesis [17], and purine 
biosynthesis [16, 23].   Most of these mutants, however, were either not created using 
Select Agent compliant methods, nor well characterized at the molecular level or 
thoroughly evaluated in various animal models to meet the criteria required for an 
organism to be considered for exclusion from the Select Agent list.   
 In this study we created attenuated mutants, characterized them at the molecular 
level, and thoroughly evaluated them in various animal models with the goal of defining a 
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strain that would meet the criteria for exclusion from the Select Agent list.  We used 
Select Agent compliant methods to isolate and characterize defined purM mutants.  
This target was chosen for mainly for two reasons.  First, transposon-induced B. 
pseudomallei purM mutants were shown to be severely replication-deficient in cell 
culture and attenuated in a murine melioidosis model [16, 23].  Second, the purine 
biosynthetic pathway is a validated target for attenuated mutant construction in bacteria.  
It has been successfully targeted in attempts to isolate attenuated mutants of  
Francisella tularensis [18], Brucella abortus [35], Shigella flexneri [36], Actinobacillus 
pleuropneumoniae [37], and Mycobacterium tuberculosis [38].  In this study we 
constructed Bp82 and Bp190, purM derivatives of strains 1026b and K96243, 
respectively.  1026b and K9623 were originally isolated from human melioidosis patients 
in Thailand.  While 1026b is amenable to genetic manipulation and has been widely 
used for research in North America, K96243 is the sequenced prototype strain.   
In vitro growth experiments demonstrated that Bp82 was an obligate auxotroph 
and required both adenine and thiamine for normal growth in M9-glucose minimal 
medium.  In contrast, the growth of Bp190 was only partially attenuated in the same 
medium and normal growth again required addition of both adenine and thiamine.  At 
present we do not understand the reason(s) for why Bp190 is not an obligate adenine 
auxotroph.  A possible explanation may be that in contrast to the truncated 99 amino 
acid PurM protein present in Bp82, the Bp190 PurM contains an internal in-frame 38 
amino acid deletion.  This 313 amino acid PurM protein may retain some enzymatic 
activity sufficient to sustain partial growth in minimal media in the absence of adenine 
and thiamine supplementation. For both mutants we did not observe any suppressors of 
adenine and thiamine auxotrophy in vitro.    
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Both purM mutants constructed in this study contain an internal deletion which 
is unlikely to be repaired by natural means.  The growth rates of 1026b and K96243 and 
its purM derivatives Bp82 and Bp190 in rich medium were indistinguishable indicating 
that their fitness under these conditions is very similar.  These data indicate that purM 
mutants a valid surrogates for many basic biological and applied studies, e.g. 
deciphering antibiotic resistance mechanisms or drug discovery research. 
Using intranasal inoculation, the purM mutants were fully avirulent in acute 
BALB/c infection models even at high (up to 106 CFU) challenge doses.  For full 
demonstration of safety and lack of virulence in vivo, it is often necessary to conduct 
challenge studies in strains of animals that are extremely susceptible to bacterial 
infection and in immune deficient animals.  The results of the present study show that 
the B. pseudomallei purM mutants Bp82 and Bp190 were fully attenuated in 
hypersusceptible 129/SvEv mice, and Bp82 was also avirulent in the Syrian hamster 
model.  In addition, the mutant strains failed to efficiently replicate in vivo or disseminate 
following intranasal challenge with high doses.   It should also be noted that animals in 
these studies were infected via the inhalational challenge route, which is the most lethal 
route of infection and by which healthy laboratory workers would most likely be infected 
[39].  Moreover, the B. pseudomallei purM strain Bp82 failed to cause mortality in 
immune-deficient mice, including IFN--/- mice and SCID mice.  Thus, by very stringent 
animal challenge criteria the B. pseudomallei the purM strains created here are fully 
attenuated.  This attenuation was solely due to the purM defect since repair of the Bp82 
and Bp190 purM allele with wild-type sequences resulted in adenine and thiamine 
prototrophy and restored virulence.    
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 In summary, the extensive in vitro characterization and stringent animal 
challenge studies show that both B. pseudomallei purM derivatives constructed and 
tested in this study are in principal viable candidates for exclusion from Select Agent 
lists.  However, given the overall evidence we consider the 1026b B. pseudomallei 
purM mutant Bp82 the superior attenuated strain candidate.   It is fully attenuated in 
vitro when grown in adenine and thiamine deficient growth medium.  In addition, it is 
avirulent in vivo, even following high-dose challenge in extremely susceptible wild-type 
and immune-deficient animals.  Moreover, the mutant does not replicate in vivo and also 
does not establish chronic infections.  Thus, we conclude that the B. pseudomallei 
purM mutant Bp82 is to date the most viable candidate strain for exclusion from Select 
Agent lists and with good laboratory practice safe for use under BSL-2 conditions.  
Federal regulations permit such exclusions from the list of select biological agents in 
cases where it has been established that an attenuated strain of a select biological agent 
does not pose a severe threat to public health and safety, animal health, or animal 
products.  Unlike B. mallei where variants exist that are severely attenuated for virulence 
in their natural host and thus likely candidates for exclusion from the select agent list 
[40], clinically attenuated B. pseudomallei strains that grow normally in laboratory media 
have yet to be discovered.  Until such strains are discovered, genetically engineered and 
well-characterized strains such as the one described here are the only candidates for 
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Burkholderia pseudomallei RND EFFLUX AND THE 
MALLEOBACTIN/PYOCHELIN SIDEROPHORES ARE 
DISPENSABLE FOR VIRULENCE 
 
 The studies described in this chapter focus on the impact that resistance-
nodulation-cell division (RND) efflux systems and two major siderophores have on 
virulence and lethality of B. pseudomallei.  I acknowledge the contributions of Lily 
Trunck, Takehiko Mima, and Brian Kvitko for the construction and genetic 
characterization of all the bacterial mutant strains described herein.    
 
4.1  Abstract 
 Burkholderia pseudomallei is the causative agent of the fatal human disease 
melioidosis, and this pathogen is endemic to various tropical regions of the world.  B. 
pseudomallei is currently classified as a category B Select Agent due to its potential use 
as a biological weapon.  Even though this pathogen is associated with high morbidity 
and mortality, the specific bacterial factors contributing to virulence have not yet been 
completely elucidated.  The purpose of these studies was to investigate the impact that 
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both siderophores and resistance-nodulation-cell division (RND) efflux systems have on 
the virulence of B. pseudomallei in vivo.  This was examined using a B. pseudomallei 
clinical isolate (strain 708a) naturally devoid of both the AmrAB-OprA efflux system and 
gene cluster for malleobactin synthesis, and by the construction of various isogenetic 
derivatives.  The B. pseudomallei efflux systems analyzed within these studies include 
the two characterized RND systems, AmrAB-OprA and BpeAB-OprB.   The genetic 
deletion of one or both of these efflux pumps did not reduce lethality in our murine 
model, indicating these systems are dispensable for virulence and in vivo replication of 
B. pseudomallei.  We also created mutant strains devoid of one or both of the major 
known B. pseudomallei siderophores including malleobactin and pyochelin.  These iron 
transport systems were also found to be completely non-essential for virulence within 
our pneumonic melioidosis model.  Contrary to what has been observed with other 
related bacterial species, these results indicate that both of the characterized RND 
systems and major known siderophores are not critical for virulence and lethality of this 
pathogen.  B. pseudomallei appears to possess great redundancy of certain bacterial 
factors, and capable of utilizing iron transport systems other than malleobactin and 
pyochelin during iron-limiting conditions within the host.    
   
 4.2  Introduction 
 Burkholderia pseudomallei is the causative agent of the disease melioidosis.  
The genome of this pathogen is over 7Mbp contained within two chromosomes, and is 
one of the largest bacterial genomes characterized [1-2].  Since research on this 
pathogen was largely lacking in the Western world until its classification as a category B 
Select Agent, the precise bacterial factors contributing to virulence of B. pseudomallei 
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are not completely understood [3].  A number of B. pseudomallei virulence factors have 
been identified to date, which include the capsule, lipopolysaccharide, flagella, pili, 
quorum sensing, a type three secretion system, and morphotype switching [4-15].  
However, additional bacterial factors have yet to be characterized.  Our laboratory 
acquired a clinical B. pseudomallei isolate obtained from a human melioidosis patient 
with a large natural deletion of greater than 100kb of genetic material, including both 
resistance-nodulation-cell division (RND) efflux and iron acquisition genes [16].  Since 
siderophores and RND efflux systems have been proposed to have potential roles in 
virulence [17-18], the purpose of this research was to investigate the impact of these 
systems in vivo using a murine melioidosis model.  This was examined using both the 
clinical isolate harboring the natural deletion, and also by the construction and 
characterization of various isogenetic mutants.  
Siderophore production is imperative for iron acquisition by bacteria and has 
been considered a potential B. pseudomallei virulence factor [17].  B. pseudomallei 
contains a large biosynthetic cluster (mbaA, mbaF, mbaJ, mbaI, fmtA) encoding the 
hydroxamate siderophore, malleobactin (MbaA), that is known to be expressed during 
iron-deficient conditions [15, 19].  Malleobactin is homologous to the pyoverdine 
siderophore produced by the closely related bacterial species Pseudomonas aeruginosa 
[20], and is capable of releasing iron from transferrin, lactoferrin, and to a lesser extent 
from erythrocytes [21].  Malleobactin deficient B. pseudomallei mutants have been 
previously shown to be unable to grow under iron-limiting conditions in vitro [19].  In 
addition, homologous iron acquisition genes in both of the related species P. aeruginosa 
and B. cepacia are essential for full virulence in many experimental models [22-23].   
However, the impact of malleobactin on B. pseudomallei virulence is largely unknown to 
date.  Based on homologous sequences to P. aeruginosa, B. pseudomallei is also 
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thought to produce a second siderophore known as pyochelin [19, 24-25].  Pyochelin is 
encoded by the putative gene BPSS0587, and the putative pyochelin receptor protein 
FptA is encoded by the fptA open reading frame [19, 26].  In P. aeruginosa, a 
homologous receptor is used for iron delivery to the bacterial cell when complexed with 
the pyochelin siderophore [24].  The impact pyochelin has on B. pseudomallei virulence 
is also unknown to date.   
  Genome sequencing of B. pseudomallei strains indicates the presence of at 
least 10 RND efflux pumps [1, 27].  Two of these systems that have been characterized 
in B. pseudomallei are AmrAB-OprA and BpeAB-OprB [18, 28].  AmrAB-OprA confers 
resistance to both aminoglycosides and macrolides, and BpeAB-OprB contributes to 
macrolide and fluoroquinolone resistance [28-29].  It was reported by Chan et al. in 2005 
that invasion of human lung epithelial cells and macrophages by B. pseudomallei was 
significantly reduced in the absence of the BpeAB-OprB efflux system [18].  This 
reduced invasion was proposed to be the result of impaired quorum sensing by the 
strain lacking BpeAB-OprB, as virulence was restored upon the addition of homoserine 
lactone molecules [18].  Within this same study, BpeAB-OprB was also required for 
siderophore and phospholipase C production, and for biofilm formation by B. 
pseudomallei, indicating a potential relation between this efflux pump and virulence of 
strain KHW [18].  Contrasting data was more recently reported by Mima et al. with the 
finding that BpeAB-OprB is not required for quorum sensing or siderophore production in 
B. pseudomallei strain 1026b [29].  The true purpose for efflux systems in bacteria is 
largely unknown [27, 30] and aside from antibiotic resistance, their role in the host during 
in vivo infection has yet to be elucidated, providing a foundation for the studies 
presented herein.   
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The impact that RND efflux and two different iron acquisition systems have on 
virulence was examined in these studies using a clinical isolate obtained from a human 
melioidosis patient encompassing a large natural deletion [16] and by the construction of 
isogenetic derivatives.  The virulence of these strains was characterized in vivo using a 
murine melioidosis model.  The two RND efflux systems evaluated within this research 
were the characterized B. pseudomallei AmrAB-OprA and BpeAB-OprB systems.  The 
genomic region involved with iron transport that was analyzed was mba, a 13-gene 
malleobactin biosynthetic gene cluster and its extracytoplasmic sigma factor MbaS [19].  
A second iron transport factor analyzed was FptA, encoding the putative pyochelin 
receptor protein [19].  Strains deficient of fptA enabled us to examine the effect of the 
pyochelin siderophore on virulence of B. pseudomallei.  In summary, our results indicate 
that neither the efflux systems nor the iron acquisition genes analyzed within these 
studies are required for full virulence and lethality of B. pseudomallei in a pneumonic 
murine model of melioidosis.   
 
4.3  Materials and Methods 
     4.3(1) Bacterial strains, media and growth conditions   
All strains used in these studies are listed in Table 4.1.  The wild type strain from 
which all efflux pump deletion mutants were derived is B. pseudomallei 1026b.  The 
efflux pump mutants created from this strain include Bp50, Bp227, Bp340, and Bp400 
(Table 4.1).  Strain 1026b is a clinical isolate from a case of human septicemic 
melioidosis in Thailand.  This strain is lethal to mice and has been extensively studied in 
the laboratory [8].  The strain from which all siderophore mutants were derived is B. 
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pseudomallei 1710b.  Strain 1710b is also lethal to mice and is a clinical isolate from the 
blood of a melioidosis patient from Thailand [31].  The iron acquisition mutants derived 
from this strain include Bp327, Bp338, Bp416 (Table 4.1).  B. pseudomallei 708a is a 
clinical isolate containing a  natural deletion of genomic material of more than 100kb, 
including both amrAB-oprA and iron acquisition genes [16].  Refer to Table 4.1 for a list 
of all deletions within this particular strain.   
All strains were grown to saturation in Luria broth (LB) at 37°C with shaking, and 
then stored at -80°C in 15% glycerol until ready to use.  For animal experiments, each 
strain was thawed just before use and the bacteria were diluted to the desired 
concentration using sterile phosphate buffered saline (PBS, Sigma-Aldrich, St. Louis, 


















Table 4.1.  Bacterial strains utilized in these studies. 
B. pseudomallei                                    Relevant Properties/                                               Reference 
                                       Deleted Genes and Putative Gene Functions 
Wild type strains: 
          1026b                                         clinical isolate                                                                        [8]                    
          1710b                                         clinical isolate                                                                       [31] 
          708a                                      clinical isolate; natural deletion of >100kb:                                [16] 
                                                 1.  amrAB-oprA) (efflux pump)  
                                                 2.  (BPSL1801-BPSL1800-BPSL1799 (putative fimbrial protein)                       
                                                 3.  mba (malleobactin siderophore synthesis gene cluster) 
                                                 4.  cob (putative vitamin B12 biosynthetic pathway) 
                                                 5.  arcD and arcABC (arginine deiminase pathway)  
                                                 6.  (BPSL1732-1731)  
                                                     (putative chemotaxis citrate transducer/chemotaxis protein) 
 
Efflux mutants: 
         Bp50                            1026b with amrAB-oprA) (efflux pump)                                          [16] 
         Bp227                          1026b with (bpeAB-oprB) (efflux pump)                                  This study 
         Bp340                          1026b with (amrAB-oprA) (efflux pump)                                  This study 
         Bp400                          1026b with (amrAB-oprA)(bpeAB-oprB)                                  This study 
                                                    (two characterized efflux pumps) 
  
Iron acquisition mutants: 
         Bp327                       1710b with mba  (malleobactin siderophore synthesis)            This study 
         Bp338                       1710b with (mba)(amrAB-oprA)                                                This study 
                                                     (malleobactin siderophore synthesis, efflux pump) 
         Bp416                       1710b with (mba)(amrAB-oprA)(fptA)                                       This study 
                          (malleobactin siderophore synthesis, efflux pump, pyochelin receptor) 
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     4.3(2) Mutant construction and deletion determination of strain 708a   
All of the deletion mutant constructs listed in Table 4.1 were provided by the 
Herbert Schweizer laboratory (Colorado State University, Fort Collins, CO).  Mutant 
strains constructed specifically for these studies were all created using Select Agent 
compliant methods.  Next Gen sequencing, PCR and qRT-PCR were used to determine 
the deletion region of B. pseudomallei strain 708a.       
 
     4.3(3) Animals and pulmonary challenge model   
Female BALB/c mice were used for these studies (Jackson Laboratories, Bar 
Harbor, ME).  All mice were 6-12 weeks of age at the time of infection and were housed 
under pathogen free conditions.  All animal studies were approved by the Institutional 
Animal Care and Use Committee at Colorado State University. 
All animal infections with B. pseudomallei were performed using intranasal (i.n.) 
inoculation.  Animals were anesthetized with 100 mg/kg ketamine (Fort Dodge Animal 
Health, Overland Park, KS) plus 10 mg/kg xylazine (Ben Venue Labs, Bedford, OH).  
The desired challenge dose of B. pseudomallei was suspended in PBS and 20 l was 
delivered i.n. alternating nostrils.  The challenge dose was confirmed by retrospective 
plating on LB agar.  For all survival studies, animals were monitored for disease 
symptoms twice daily and were euthanized according to pre-determined humane 
endpoints.  All procedures were performed in a biosafety level 3 (BSL-3) facility, in 




     4.3(4) Statistical analyses   
Data were analyzed using Prism 5.0 software (Graph Pad, San Diego, CA).  
Survival times were analyzed by Kaplan-Meier analysis, followed by the log-rank test.  
For comparisons of survival times of more than one group in an experiment, the 
Bonferroni corrected threshold was applied to correct for multiple comparisons. 
 
4.4  Results 
     4.4(1) B. pseudomallei 708a caused clinical disease in a human melioidosis  
       patient despite the presence of a large deletion in chromosome 1   
B. pseudomallei strain 708a is a virulent clinical isolate from a 32 year old male 
melioidosis patient in Thailand [32].  This patient had no risk factors for melioidosis, and 
presented with 21 days of fever and abdominal pain for 14 days.  There was a splenic 
abscess present, and a splenectomy was required to control infection.  Following 
ceftazidime and doxycycline treatment, the patient survived [16].  This clinical data 
indicates the ability of strain 708a to result in severe illness in the human melioidosis 
patient from whom it was isolated. Genotypic analyses later determined that strain 708a 
contains a large deletion of more than 100kb of genetic material within chromosome 1 
[16].  The deletion region and notable genes involved are shown in Fig. 4.1.  Despite the 
large deletion, this strain was virulent in this particular patient and capable of causing 





Figure courtesy of Trunck, Propst et al., 2009 [16]. 
Figure 4.1.  Natural deletion in chromosome 1 of the B. pseudomallei strain 708a 
clinical isolate.  The large deletion region in strain 708a is shown and the notable 
deleted genes are listed below: 
                      1.  amrAB-oprA) (efflux pump)  
                    2.  (BPSL1801-BPSL1800-BPSL1799 (putative fimbrial protein)                       
                    3.  mba (malleobactin siderophore synthesis) 
                    4.  cob (putative vitamin B12 biosynthetic pathway)                                            
                    5.  arcD and arcABC (arginine deiminase pathway)  
                    6.  (BPSL1732-1731) (putative chemotaxis citrate transducer/chemotaxis 
                          protein) 
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     4.4(2) B. pseudomallei strain 708a is fully virulent in a murine inhalational 
       challenge model  
Our laboratory has previously shown that B. pseudomallei 1026b is lethal to 
BALB/c mice following intranasal (i.n.) challenge, with an LD50 of approximately 900 CFU 
[33].  For these studies, BALB/c mice (n = 5 per group) were challenged with 5 x LD50 
(approximately 5,000 CFU) of wild type B. pseudomallei 1026b and survival was 
monitored.  All mice reached end-point and were euthanized within 3 days post-infection 
(Fig. 4.2).  We then wanted to determine whether the B. pseudomallei strain 708a 
containing the large genomic deletion had similar lethality in our pneumonic murine 
model.  BALB/c mice (n = 4 per group) were challenged with 5 x 103 CFU strain 708a 
and survival was monitored.  All mice reached end-point within 3 days post-infection, 
similar to that seen with B. pseudomallei 1026b (Fig. 4.2), indicating that strain 708a is 
fully virulent in our murine melioidosis model despite its large natural genomic deletion.   
 Mice (n = 5 per group) were also challenged with 5 x 103 CFU Bp50, an 
isogenetic (amrAB-oprA) 1026b derivative of strain 708a.  Unlike that seen with B. 
pseudomallei 708a, this challenge with Bp50 was not lethal to any of the mice, and all 
survived acute infection (Fig. 4.2).  We found that a 10-fold higher intranasal challenge 
dose was required for the strain to be lethal in 100% of the mice and produce a similar 
time to death as that seen with B. pseudomallei strains 708a and 1026b.  Mice (n = 5 per 
group) challenged with 5 x 104 CFU Bp50 reached acute disease end-point by day 4 
post-infection (Fig. 4.2). 
 Our finding that the amrAB-oprA deletion did not compromise virulence of B. 
pseudomallei 708a, but did appear to reduce the virulence of the 1026b isogenetic 
derivative Bp50 was an unexpected result.  For this reason, a second amrAB-oprA 
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construct was created, which is strain Bp340.  In vivo testing with this construct and 






















Figure 4.2.  B. pseudomallei strain 708a is fully virulent in an acute murine 
melioidosis infection model.  BALB/c mice (n = 4-5 mice per group) were infected 
intranasally with 5 x 103 CFU of 1026b, 5 x 103 CFU of strain 708a, and 5 x 103 or 5 x 
104 CFU of isogenetic (amrAB-oprA) strain 1026b derivative, Bp50.  Statistical 
differences in survival times were determined by Kaplan-Meier curves followed by log-
rank test.  The Bonferroni corrected threshold was applied and comparisons with p < 
0.017 were considered significant. **, p < 0.01 for strain 1026b vs. Bp50 (5 x 103 CFU 
challenge dose) and 708a vs. Bp 50 (5 x 103 CFU challenge dose).  Data shown above 








     4.4(3) The efflux systems AmrAB-OprA and BpeAB-OprB do not contribute to  
       B. pseudomallei virulence in vivo  
Despite the natural deletion of amrAB-oprA in B. pseudomallei strain 708a, this 
clinical isolate was fully virulent in our pneumonic melioidosis model (Fig. 4.2).  Bp340, a 
second isogenetic (amrAB-oprA) 1026b derivative was created and tested for lethality 
following inhalational challenge.  When BALB/c mice were challenged with 1 x 103 CFU 
Bp340, all succumbed to end-point by day 2 post-infection (Fig. 4.3).  Since the LD50 for 
wild type 1026b is approximately 900 CFU [33], Bp340 appears to be at least as virulent, 
and perhaps even more lethal than the parental 1026b strain with an intact amrAB-oprA 
operon.  This finding indicates that AmrAB-OprA is dispensable for B. pseudomallei 
lethality in our murine model. 
 The impact of another characterized efflux system, BpeAB-OprB, was also tested 
in our studies.  Even though this efflux pump is intact within strain 708a, we wanted to 
determine its impact on virulence in vivo since it has been proposed to impact both the 
invasive potential and cellular toxicity of B. pseudomallei [18].  When BALB/c mice were 
challenged with 2 x 103 CFU Bp227, a (bpeAB-oprB) 1026b derivative, all mice 
reached end-point by day 2 post-challenge (Fig. 4.3), indicating this efflux system  is 
also dispensable for strain 1026b virulence.  A construct lacking both characterized 
efflux systems (Bp400) was also tested in our murine model.  1 x 104 CFU Bp400, a 
(amrAB-oprA)(bpeAB-oprB) 1026b derivative, was lethal to 100% of mice challenged 
(Fig. 4.3).  Combined, these results indicate that neither AmrAB-OprA nor BpeAB-OprB 







Figure 4.3.  Neither AmrAB-OprA nor BpeAB-OprB is required for full virulence of 
B. pseudomallei 1026b in a pneumonic murine melioidosis model.  BALB/c mice (n 
= 5 per group) were infected intranasally with 1x103 CFU (amrAB-oprA) Bp340, 2x103 
CFU (bpeAB-oprB) Bp227, or 1x104 CFU (amrAB-oprA)(bpeAB-oprB) Bp400 and 
survival was monitored.  All strains were lethal to 100% of the mice challenged.   










     4.4(4) Malleobactin and pyochelin siderophores do not serve as virulence 
      determinants in B. pseudomallei   
B. pseudomallei 708a was virulent in our animal studies despite the deletion of 
the 13-gene malleobactin biosynthetic gene cluster, mba (Fig. 4.2).  We further 
characterized the impact of this siderophore by the construction of isogenetic deletion 
mutants lacking mba.  These mutant strains were derived from the clinical isolate B. 
pseudomallei 1710b, as we believe this strain background is most similar to the clinical 
isolate 708a.  Wild type B. pseudomallei 1710b was less lethal in our murine model than 
strain 1026b, as when BALB/c mice (n = 9 mice) were challenged intranasally with 2 x 
103 CFU strain 1710b, there were acute disease survivors (Fig. 4.4).  (Survivors would 
not be expected following a similar challenge dose with strain 1026b).  
In order to determine the impact that iron acquisition genes had within this strain 
background, Bp327, Bp338, and Bp416 were all tested for virulence in our murine 
melioidosis model (n = 9-10 mice per group).  Bp327 is a (mba) 1710b derivative 
containing a 31 kb malleobactin biosynthetic gene cluster deletion of the same extent as 
B. pseudomallei 708a.  BALB/c mice were challenged intranasally with 2 x 103 CFU 
Bp327 and all reached acute disease end-point by day 3 (Fig. 4.4).  Since the natural 
deletion mutant, B. pseudomallei 708a, is also lacking the AmrAB-OprA efflux pump (in 
addition to the malleobactin biosynthetic gene cluster and other genes), the isogenetic 
(mba)(amrAB-oprA) 1710 derivative Bp338 was also tested for lethality.  Of the three 
1710b derived mutants, Bp338 is most homologous in terms of genetic deletions to 
strain 708a. This strain was also lethal to 100% of the mice infected, as all animals 
reached acute disease end-point by day 3.5 post-challenge (Fig. 4.4).   
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The final deletion mutant tested in vivo was Bp416.  This is a (amrAB-
oprA)(mba)(fptA) 1710b derivative that has a deletion of the putative pyochelin receptor 
protein, FptA, in addition to the efflux system and malleobactin biosynthetic gene cluster.  
Even though fptA is intact in B. pseudomallei strain 708a, Bp416 provided insight as to 
whether pyochelin, a second known B. pseudomallei siderophore, is imperative for iron 
acquisition within the host.  All BALB/c mice challenged 1 x 103 CFU Bp416 reached 
end-point by day 2.5 post-infection.  This strain is incapable of utilizing the two major 
siderophores (malleobactin and pyochelin) and is also lacking AmrAB-OprA, and still 
produced the shortest time to death among all four strains tested (Fig. 4.4).  Also 
notable is that this particular group of animals received the lowest challenge dose of all 
four isolates.  This challenge dose (used for Bp416) is near the LD50 intranasal challenge 
dose for wild type strain 1026b [34] and was 50% reduced compared to the sub-lethal 
challenge dose used for wild type 1710b, and still produced the shortest time death.  
Combined, these results indicate that neither the malleobactin nor pyochelin 
siderophore is required for virulence following pneumonic challenge in a murine 
melioidosis model.  If anything, deletion of these genes actually appeared to increase 
the virulence of the three deletion mutants, as they were all lethal to 100% of mice 
challenged, whereas wild type parental strain 1710b was not (Fig. 4.4).  All three 
mutants had increased lethality and decreased time to death compared to wild type B. 









Figure 4.4.  Deletion of amrAB-oprA, mba, and fptA does not reduce lethality of B. 
pseudomallei following inhalational challenge. BALB/c mice (n = 9-10 per group) 
were infected intranasally with 2 x 103 CFU wild type B. pseudomallei 1710b, (mba) 
1710b derivative Bp327, (mba)(amrAB-oprA) 1710b derivative Bp338, or 
(mba)(amrAB-oprA)(fptA) 1710b derivative Bp416.  Statistical differences in survival 
times were determined by Kaplan-Meier curves followed by log-rank test.  The 
Bonferroni corrected threshold was applied and comparisons with p < 0.017 were 
considered significant.  (p < 0.001 for Bp327 vs. 1710b; p < 0.01 for Bp338 vs. 1710b; p 







4.5  Discussion 
The bacterial factors that enable B. pseudomallei to cause disease have yet to 
be fully elucidated, and there is a gap in knowledge regarding its virulence determinants 
compared to other well-studied Gram-negative pathogens [17].  These studies were 
conducted to assess whether two characterized resistance-nodulation-cell division 
(RND) efflux pumps and known B. pseudomallei siderophores are imperative for in vivo 
infection within a pneumonic murine melioidosis model.  We have demonstrated in these 
studies that both of the efflux systems analyzed, including AmrAB-OprA and BpeAB-
OprB, are dispensable for B. pseudomallei lethality in vivo.  In addition, neither 
malleobactin nor pyochelin is required for B. pseudomallei virulence during pneumonic 
infection, indicating the likely utilization of additional uncharacterized iron transport 
systems.  These findings were based on the study of a clinical isolate naturally devoid of 
>100kb of genetic material (including both iron acquisition and efflux genes), and by the 
construction of a variety of isogenetic mutants.   
The finding that neither AmrAB-OprA nor BpeAB-OprB is required for B. 
pseudomallei virulence in our murine melioidosis model is contrasting to previous 
research.  It was reported by Chan et al. that B. pseudomallei invasion of both human 
lung epithelial cells and macrophages in vitro was significantly reduced in the absence of 
BpeAB-OprB [18].  However, when mice were challenged in our studies with the strains 
devoid of BpeAB-OprB and/or AmrAB-OprA, all were fully virulent.  These isolates 
caused marked respiratory distress and were lethal to 100% of mice challenged, similar 
to that observed with wild type B. pseudomallei containing intact efflux systems.  In fact, 
in the survival studies with the single efflux pump deletion mutants Bp340 and Bp227, 
the time to death (by day 2.0) appeared to be even slightly reduced compared to the 
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predicted time of death among mice infected with a similar challenge dose with the 
parental 1026b strain.  The LD50 for strain 1026b is 900 CFU [34], and mice challenged 
with a 1-2 x 103 CFU (a relatively low lethal intranasal dose) would be expected to 
survive until approximately day 3 (data not shown).  Our clinical observations of mice 
infected with the different efflux pump deficient strains (Bp340, Bp227, and Bp400) are 
likely indicative of no impaired invasion of murine pulmonary epithelial cells or reduction 
of virulence in the absence of BpeAB-OprB or AmrAB-OprA, contrasting to that reported 
by Chan et al. with strain KHW.  These findings coincide with the previous reports of 
BpeAB-OprB being dispensable for virulence in B. pseudomallei strain 1026b [29].  
Potential differences between strains 1026b and KHW merit further characterization in 
vivo.  Challenge studies with efflux deficient mutants constructed from the KHW 
background are needed to determine differences in virulence determinants among 
different B. pseudomallei strains.  In addition, whether the remaining uncharacterized 
RND efflux systems impact virulence of B. pseudomallei is also unknown at this time.  
Upon their future genetic characterization, this will need to be investigated in vivo using 
melioidosis models. 
 Siderophore production has been considered a likely B. pseudomallei virulence 
factor [17] and was also investigated within these studies.  In the related species 
Burkholderia cepacia, the siderophore ornibactin is required for full virulence in a 
pulmonary rat agar bead infection model [22].  A mutant B. cepacia strain lacking 
ornibactin biosynthesis had a 4-log reduction within the lungs on days 7 and 28 post-
infection, and produced reduced pulmonary pathology compared to a wild type strain 
[22].  In addition, the pyoverdine siderophore is required for infection and virulence of 
Pseudomonas aeruginosa, and is believed to contribute to iron acquisition by this 
pathogen in vivo  [23].  Pyoverdine biosynthesis was shown to be upregulated when P. 
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aeruginosa is grown in sputum in vitro [35], and both pyoverdine and pyochelin were 
shown to contribute to P. aeruginosa persistence in the blood of a mouse infection 
model [36].   However, in the studies described herein, the deletion of either the 
malleobactin biosynthesis gene cluster or pyochelin receptor, subsequently preventing 
the usage of these major siderophores by this pathogen, failed to reduce the virulence of 
B. pseudomallei.   
The clinical isolate 708a containing a natural deletion of the 13-gene 
malleobactin biosynthesis cluster (mba) was fully virulent in our murine model.  This 
clinical isolate was known to cause severe splenic disease (resulting in a splenectomy) 
from the patient from whom it was isolated [16].  In addition, intranasal challenge with 
the isogenetic Bp416 mutant containing deletions of both mba and the pyochelin 
receptor fptA, which abolished both malleobactin and pyochelin usage by this strain, 
produced the shortest time to death of all the isogenetic mutants, even following a 
relatively low challenge dose.  Mice infected with Bp416 received a challenge inoculum 
that was 50% reduced compared to that used for the wild type 1710b background strain, 
and yet still had the shortest time to death.  In contrast to previous findings with the 
related bacterial species B. cepacia and P. pseudomonas [22-23], both malleobactin and 
pyochelin appear to be dispensable for B. pseudomallei replication in vivo and virulence.  
These results indicate that unlike what is observed with the related bacterial pathogens, 
B. pseudomallei is likely capable of using additional iron transport systems for iron 
acquisition in vivo, perhaps even alternating between pathways dependent on 
availability.  One possibility is a heme-hemin receptor and transporter proteins, encoded 
by the genes BPSS0244 and BPSS0243 [26].  As observed with other B. pseudomallei 
siderophores, these genes have been shown to be induced under iron-limiting conditions 
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and are hypothesized to play a potential role in iron acquisition [19, 26].   Additional 
studies are needed upon further characterization of these genes. 
These studies have provided additional insight into virulence determinants of B. 
pseudomallei.  The contrasting data observed between B. pseudomallei strains KHW 
and 1026b in regards to the efflux system BpeAB-OprB is indicative of potential genetic 
diversity among different B. pseudomallei isolates.  This observation illustrates that 
potential virulence factors merit characterization using a variety of B. pseudomallei strain 
backgrounds.  The finding that both pyochelin and malleobactin are dispensable for B. 
pseudomallei virulence in our murine melioidosis model further illustrates the plasticity 
and likely redundancy of certain bacterial factors like iron transport.   
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IMMUNOTHERAPY MARKEDLY INCREASES THE 
EFFECTIVENESS OF ANTIMICROBIAL THERAPY FOR 
TREATMENT OF Burkholderia pseudomallei INFECTION 
 
 The studies presented in this chapter focus on a significant enhancement to 
traditional antibiotic therapy by the co-administration of immunotherapies for treatment of 
B. pseudomallei infection.  I acknowledge the tremendous contribution of Ryan Troyer 
for conducting the in vitro experiments described in this chapter. 
 
5.1  Abstract 
Burkholderia pseudomallei is a soil bacterium endemic to southeast Asia and 
northern Australia that can cause both acutely lethal pneumonia as well as chronic 
systemic infections in humans.  Effective treatment of infection with B. pseudomallei 
requires rapid diagnosis and prolonged treatment with high doses of antimicrobials, and 
even with appropriate antibiotic therapy, patient relapse is common.  Thus, new 
approaches to treat B. pseudomallei infection are needed.  In the present study, we 
asked whether active immunotherapy with IFN-, a key cytokine regulating intracellular 
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replication of B. pseudomallei, could increase the effectiveness of conventional 
antimicrobial therapy for B. pseudomallei infection.  Macrophage infection assays and in 
vivo pulmonary challenge models were used to assess the inhibitory effects of combined 
treatment with IFN- and ceftazidime on B. pseudomallei infection.  We found that 
treatment with even very low doses of IFN- and ceftazidime elicited strong synergistic 
inhibition of B. pseudomallei growth within infected macrophages.  In vivo, active 
immunotherapy markedly potentiated the effectiveness of low-dose ceftazidime therapy 
for treatment of infected mice in a pulmonary challenge model of B. pseudomallei.  
Combined treatment was associated with a significant reduction in bacterial burden and 
significant lessening of bacterial dissemination.  We concluded therefore that 
immunotherapy with either endogenous or exogenous IFN- could significantly increase 
the effectiveness of conventional antimicrobial therapy for treatment of acute B. 
pseudomallei infection.   
 
5.2  Introduction 
Burkholderia pseudomallei is a soil bacterium endemic in southeast Asia and 
northern Australia [1], and other tropical and subtropical regions of the world [2].  This 
pathogen causes several thousand human cases of melioidosis every year [3-6].  
Without prompt antimicrobial therapy, infection with B. pseudomallei is often fatal, as 
illustrated by high mortality rates for untreated cases [5].  Even after initial appropriate 
therapy, many patients are still susceptible to relapse or re-infection with B. 
pseudomallei [3, 7-8].  Because B. pseudomallei infection is difficult to eradicate, 
prolonged antimicrobial therapy (months) is often prescribed for infected persons [9].  B. 
pseudomallei also displays high levels of intrinsic resistance to many commonly used 
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antibiotics.  Though B. pseudomallei is not endemic in North America, there is still 
considerable concern for this organism by the Centers for Disease Control and 
Prevention because of its high potential for use as a biological weapon.  B. pseudomallei 
is currently classified as a category B Select Agent.  There is also currently no vaccine 
available for preventing infection with Burkholderia.   
 For these reasons, new approaches to improve the effectiveness of antimicrobial 
therapy for B. pseudomallei infection are urgently needed.  Previous studies have shown 
that non-specific activation of innate immunity by systemic (intraperitoneal) 
administration of CpG oligonucleotides prior to infection could provide protection against 
systemic challenge with B. pseudomallei [10].  We recently reported that mucosally 
delivered cationic liposome-DNA complex (CLDC) immunotherapy was particularly 
effective in protecting mice from inhalational challenge with both B. mallei and B. 
pseudomallei [11].  In that study, IFN- was identified as the key cytokine mediating the 
protection afforded by CLDC immunotherapy. 
 In the studies described herein we investigated whether active immunotherapy 
could be combined with conventional antimicrobial therapy to increase the effectiveness 
of B. pseudomallei treatment.  Such an approach was evaluated previously, using the 
cytokine granulocyte-colony stimulating factor (G-CSF) in combination with ceftazidime, 
based on previous studies showing that neutrophils were key effector cells for controlling 
B. pseudomallei infection [12-14].  However, subsequent studies in mouse infection 
models revealed that G-CSF was not effective when combined with ceftazidime for 
treatment of B. pseudomallei infection [15]. 
 In several other infection models, IFN- has been combined with antimicrobial 
agents to increase the effectiveness of treatment.  For example, the combination of IFN-
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 with the antibiotics gentamicin and vancomycin enhanced the clearance of 
Enterococcus faecalis in an in vitro neutrophil infection model [16].  However, in a mouse 
model of E. faecalis infection, only low doses IFN-  increased the effectiveness of 
antimicrobial therapy, while high IFN- doses were ineffective or deleterious [17].  In a 
Francisella novicida infection model, intranasal administration of recombinant IL-12 (rIL-
12) (which induced IFN- production) increased the effectiveness of antimicrobial 
therapy [18].  Similarly, treatment of Mycobacterium avium infected mice with rIL-12 was 
found to increase the effectiveness of antimicrobial therapy in clearing bacterial infection 
[19].  
 Thus, there was reason to believe that immunotherapy, particularly with an 
immunotherapeutic capable of stimulating potent release of IFN- might be effective 
when combined with antimicrobial therapy for treatment of B. pseudomallei infection.  
Currently, first-line antimicrobials used for treatment of acute B. pseudomallei infection 
include ceftazidime, amoxicillin-clavulanic acid, carbapenems (meropenem or 
imipenem), and trimethoprim-sulfamethoxazole [5, 9].  Of these, ceftazidime is the 
current recommendation for intensive phase therapy, and has been evaluated the most 
extensively in mouse infection models and was therefore selected for the studies 
reported here [9, 15, 20-21].  For stimulation of IFN- release in vivo, cationic liposome-
DNA complexes (CLDC) were used, as our prior studies have shown that CLDC are 
potent inducers of IFN- release [22-23].   
 Therefore, we designed experiments to investigate the interactions between IFN-
 immunotherapy and ceftazidime for control of intracellular infection with B. 
pseudomallei.  Our results suggest that IFN- may be uniquely effective as an 
immunotherapeutic for increasing the susceptibility of intracellular Burkholderia to killing 
116 
 
by certain classes of antimicrobials.  Thus, there is reason to believe that immuno-
antimicrobial therapy is a promising new approach to improving the effectiveness of 
current antimicrobial drugs for treatment of B. pseudomallei infection.    
 
5.3  Materials and Methods 
     5.3(1) Bacteria   
B. pseudomallei strain 1026b was used for these studies [24].  This strain was 
inoculated in Luria broth (LB) and grown at 37°C with shaking for 16 h, and then stored 
at -80°C in 15% glycerol.  Each vial was thawed just before use and the bacteria were 
diluted to the desired concentration using sterile phosphate buffered saline (PBS, 
Sigma-Aldrich, St. Louis, MO).  The LD50 dose of B. pseudomallei in BALB/c mice by the 
intranasal route was determined by the Reed-Muench method to be 900 CFU [11].  The 
challenge dose used for the in vivo studies was 8 x LD50 (approximately 7,500 CFU).  
 
     5.3(2) Mice   
Female BALB/c mice were used for these studies (Jackson Laboratories, Bar 
Harbor, ME).  All mice were 6-12 weeks of age at the time of infection and were housed 
under pathogen free conditions.  All animal studies were approved by the Institutional 
Animal Care and Use Committee at Colorado State University. 
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     5.3(3) Preparation and administration of cationic liposome-DNA complexes 
        (CLDC)   
CLDC were prepared as previously described [11, 22]. Briefly, sterile complexes 
of cationic liposomes were prepared using equimolar amounts of DOTIM 
(octadecanoyloxy {ethyl-2-heptadecenyl-3-hydroxyethyl} imidazolinium chloride) and 
cholesterol.  Non-coding ultra-low endotoxin plasmid DNA was then added to liposomes 
at a final concentration of 0.1 mg/ml to form CLDC.  Preformed CLDC were diluted in 
Tris-buffered 5% dextrose water (pH 7.4) and administered to mice intraperitoneally (i.p.) 
in a total volume of 200 µl.  CLDC treatment was administered once i.p., 6 h after 
infection. 
 
     5.3(4) Recombinant IFN-   
Recombinant murine interferon- (IFN-) was purchased from PeproTech (Rocky 
Hill, NJ) and reconstituted in PBS with 0.1% bovine serum albumin.  Aliquots were 
frozen at -80°C until use.  For in vitro studies, rIFN- was added at the indicated 
concentrations after bacterial infection and elimination of extracellular bacteria with 
kanamycin.  For in vivo treatment, rIFN- was diluted in PBS with 0.1% bovine serum 
albumin and administered i.p. at 6 h and 18 h after infection in a total volume of 200 µl. 
 
     5.3(5) Ceftazidime   
Ceftazidime was purchased from Sigma-Aldrich (St. Louis, MO) and diluted in 
PBS with 0.1% bovine serum albumin.  Aliquots of the desired concentration were frozen 
at -20°C until use.  The concentration of ceftazidime used for in vivo mouse treatments 
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was 25 mg/kg body weight, administered 6 h after infection and continued every 12 
hours for a total of six treatments (administered at 6, 18, 30, 42, 54 and 66 h after 
infection).   
 
5.3(6) In vitro macrophage infection assay to assess in vitro interaction 
   between cytokines and ceftazidime   
The mouse alveolar macrophage cell line AMJ.2 (American Type Tissue 
Collection, Manassas, VA) was used to investigate the ability of CLDC elicited cytokines 
to enhance the activity of antimicrobial drugs.  AMJ.2 cells were cultured in complete 
medium, which consisted of MEM medium (Invitrogen, Carlsbad, CA) containing 10% 
FBS (Gemini Bio-Products, West Sacramento, CA), 2 mM L-glutamine (Invitrogen), 1x 
non-essential amino acids (Invitrogen), and 0.075% sodium bicarbonate (EMD Science, 
Gibbstown, NJ), without antibiotics added.  B. pseudomallei was added to 2 x 105 AMJ 
cells per well of a 24-well plate at an MOI of 5 CFU per cell in 500 µl antibiotic-free 
medium.  Plates were centrifuged at 2400xg for 2 min and then incubated for 1 h in at 
37C and 5% CO2.  Extracellular bacteria were then removed by washing the 
macrophages three times with 2 ml PBS, followed by treatment with medium plus 350 
µg/ml kanamycin (Sigma-Aldrich) for 1 h.  After incubation with kanamycin, the 
macrophages were washed three times with PBS.   
 Ceftazidime, CLDC supernatants or rIFN-, alone or in combination, were then 
added to the cultures and the macrophages were cultured for an additional 24 h.  The 
treatment medium was then removed and cells were washed three times with 2 ml 
sterile PBS, then lysed with 1 ml sterile dH2O in order to quantify intracellular bacteria.  
Serial dilutions of lysates were plated on LB agar plates and plates were incubated at 
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37C for 48 h prior to counting colonies.  In several experiments, bacteria present in the 
last PBS wash were plated and counted, then subtracted from the cell lysate counts to 
control for any extracellular bacteria not removed by thorough washing.  In all treatment 
groups the amount of bacteria present in the last PBS wash was negligible compared to 
the amount of bacteria present in cell lysates.  Thus, lysate counts reflected the number 
of intracellular bacteria.  
 The ability of cytokines elicited by CLDC immunotherapy to inhibit intracellular 
growth of B. pseudomallei was assessed by adding diluted supernatants prepared from 
overnight cultures of spleen cells from mice treated with CLDC, as described previously 
[11].  The concentration of IFN- in the CLDC supernatants used in these studies was 
found to be 1813 pg/ml by cytokine bead array (BD Biosciences, San Jose, CA), while 
the concentration of TNF-α was 160 pg/ml.  Control supernatants were prepared from 
spleens of untreated mice.  Neutralizing antibodies were used to determine whether IFN-
 or TNF- was responsible for generating antibacterial activity in the in vitro 
macrophage infection assay.  For this experiment, supernatants from CLDC-stimulated 
spleen cells were treated with 10 µg/ml anti-IFN- antibody (Clone R4.6A2; eBioscience, 
San Diego, CA) or with 10 µg/ml of anti-TNF- antibody (Clone TN3-19.12; eBioscience) 
for 30 minutes prior to the addition of the supernatants to cells.  Isotype antibodies for 
anti-IFN- (clone eBRG1) and anti-TNF- (clone eBio299Arm) were used as controls 
(eBioscience).  Infected AMJ cells were incubated with supernatants for 24 h, and 





     5.3(7) Pulmonary challenge model   
All infections with B. pseudomallei were performed using intranasal (i.n.) 
inoculation.  Animals were anesthetized with 100 mg/kg ketamine (Fort Dodge Animal 
Health, Overland Park, KS) plus 10 mg/kg xylazine (Ben Venue Labs, Bedford, OH).  
The desired challenge dose of B. pseudomallei was suspended in PBS and 20 l was 
delivered i.n. alternating nostrils.  The challenge dose was confirmed by retrospective 
plating on LB agar.  For all survival studies, animals were monitored for disease 
symptoms twice daily and were euthanized according to pre-determined humane 
endpoints.  All procedures were performed in a biosafety level 3 (BSL-3) facility, in 
accordance with approved BSL-3 and Select Agent protocols.   
 
     5.3(8) Determination of bacterial burden in vivo   
Numbers of viable B. pseudomallei were quantified in lung, liver, and spleen 
tissues at 48 h after infection.  Lungs, livers and spleens were removed aseptically and 
homogenized in 5 ml sterile phosphate buffered saline and homogenized using a 
Stomacher 80 Biomaster (Seward, Bohemia, NY).  Viable bacterial counts were 
determined for each organ by plating serial 10-fold dilutions of organ homogenates on 
LB agar.  Plates were incubated at 37°C for 48 h, and the numbers of colonies on the 
appropriate plate were scored visually.  The organ burden of bacteria was expressed as 
colony forming units (CFU)/organ.  The limit of detection for determination of bacterial 





     5.3(9) Statistical analyses   
Data were analyzed using Prism 5.0 software (Graph Pad, San Diego, CA).  
Survival times were analyzed by Kaplan-Meier analysis, followed by the log-rank test.  
For comparisons of survival times of more than one group in an experiment, the 
Bonferroni corrected threshold was applied to correct for multiple comparisons.  Other 
analyses were performed using Mann Whitney test (two group comparisons) or one-way 
ANOVA followed by a Tukey’s multiple mean’s comparison test (comparison of more 
than two groups).  Possible synergistic interactions between antimicrobials and 
cytokines as detected using in vitro assays were assessed using two-way ANOVA, as 
described previously [25].  Differences were considered statistically significant for p < 
0.05. 
 
5.4  Results 
     5.4(1) CLDC-elicited cytokines synergize with ceftazidime to inhibit intracellular 
        replication of B. pseudomallei in macrophages in vitro 
 An in vitro macrophage infection assay was used to determine whether 
immunotherapy could increase the effectiveness of ceftazidime therapy for inhibiting 
intracellular replication of B. pseudomallei, since macrophages represent a major target 
cell for B. pseudomallei infection in vivo [26-29].  Supernatants generated from spleens 
of mice treated in vivo with CLDC were used as a source of CLDC-stimulated cytokines.   
 Dose titration studies demonstrated that treatment with 10 µg/ml ceftazidime did 
not significantly inhibit B. pseudomallei replication in infected macrophages.  This 
concentration of ceftazidime is well within the range of clinically achievable 
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concentrations of ceftazidime in vivo [30].  Similar titrations were performed for CLDC 
supernatants and we found that a 1:5 dilution was effective in partially inhibiting B. 
pseudomallei replication in infected macrophages.   
 Subtherapeutic concentrations of ceftazidime and CLDC supernatants were then 
combined to treat infected macrophages.  Marked, synergistic inhibition of intracellular 
replication of B. pseudomallei was observed when cells were treated with the two agents 
in combination (Fig. 5.1).  For example, combined treatment reduced intracellular B. 
pseudomallei concentrations by almost 2 log10, from 1.9 x 10
6 CFU to 2.0 x 104 CFU.  
This effect was not observed when supernatants from non-stimulated spleen cells were 
used with ceftazidime.  Synergistic inhibition of B. pseudomallei was observed at CLDC 
supernatant dilutions up to 1:20 when combined with 10 µg/ml ceftazidime (Fig. 5.1).  
Thus, cytokines elicited by CLDC immunotherapy were capable of synergistically 
inhibiting intracellular B. pseudomallei replication when combined with a low dose of 











Figure 5.1.  CLDC supernatants synergize with ceftazidime to inhibit intracellular 
replication of B. pseudomallei.  AMJ.2 macrophages were infected in triplicate wells 
with B. pseudomallei strain 1026b for 1 h, and then treated with ceftazidime and/or 
CLDC spleen supernatants, alone or in combination, for 24 hours, as described in 
Materials and Methods.  Concentrations of intracellular bacteria were quantified by serial 
dilution plating of macrophage lysates.  The effects of CLDC supernatants at the 
dilutions indicated, alone or combined with 10 µg/ml of ceftazidime, on intracellular 
replication of B. pseudomallei were assessed.  Mean bacterial concentrations in each 
treatment group were plotted and bars represent means ± SD.  Synergistic interactions 
were assessed statistically by two-way ANOVA (***, p < 0.001).  These data are 








     5.4(2) IFN- is responsible for synergistic inhibition of B. pseudomallei 
        replication  
Experiments were conducted next to identify cytokines present in CLDC 
supernatants that mediated the synergistic interaction with ceftazidime.  Previous studies 
had identified interferon- (IFN-) as the most likely candidate cytokine [11, 22, 31], so 
the in vitro infection assay was repeated using CLDC supernatants that had been pre-
treated with a neutralizing antibody to IFN-, as described in Materials and Methods.  
The effects of neutralizing tumor necrosis factor- (TNF-) activity were also evaluated.  
Neutralization of IFN- activity in CLDC supernatants eliminated nearly all of the 
synergistic antibacterial activity, thus identifying IFN- as the cytokine primarily 
responsible for the interaction with ceftazidime (Fig. 5.2).  Neutralization of TNF- 
activity had essentially no effect on the interaction of CLDC supernatants with 












Figure 5.2.  Synergistic inhibitory activity of CLDC stimulated supernatants is 
mediated by IFN-.  Macrophages were infected in triplicate wells in vitro with B. 
pseudomallei for 1 h, then treated for 24 h with CLDC-stimulated spleen supernatants 
(1:5 dilution) alone or combined with ceftazidime at 10 µg/ml.  CLDC supernatants were 
untreated, or treated with IFN- neutralizing antibody or isotype control antibody for 30 
min before adding to infected macrophages.  Intracellular bacterial numbers were 
determined 24 h after infection and mean bacterial numbers (± SD) were plotted.  
Synergistic interactions were assessed statistically by two-way ANOVA (***, p < 0.001).  







     5.4(3) Synergistic inhibition of B. pseudomallei replication when IFN- is 
        combined with ceftazidime  
The preceding experiments identified IFN- as the primary cytokine mediating 
CLDC and ceftazidime synergistic activity.  Therefore, we next determined whether 
recombinant murine IFN-(rIFN-) could reproduce the effects of CLDC supernatants in 
the in vitro infection assay.  Infected macrophages were treated with ceftazidime (10 
µg/ml) and a range of rIFN- concentrations from 1000 to 0.1 U/ml and the effects on 
intracellular B. pseudomallei infection were assessed (Fig. 5.3).  We observed that the 
combination of rIFN- and ceftazidime elicited strong synergistic inhibition of B. 
pseudomallei replication, reducing bacterial counts from 1.9 x 106 CFU/ml in untreated 
cultures to 5.7 x 103 CFU/ml in cultures treated with 1000 U/ml rIFN- and ceftazidime.  
Concentrations of rIFN- as low as 1 U/ml elicited synergistic inhibition of B. 
pseudomallei intracellular growth (Fig.5.3).  Titration of ceftazidime in combination with 
100 U/ml rIFN- demonstrated that ceftazidime concentrations as low as 1 µg/ml could 












Figure 5.3.  Recombinant IFN- and ceftazidime reciprocally increase inhibition of 
intracellular replication of B. pseudomallei in vitro.  Macrophages were infected in 
triplicate wells in vitro with B. pseudomallei for 1 h, and then treated with rIFN- and 
ceftazidime for 24 h, and intracellular bacterial numbers were determined.                           
(A) Decreasing concentrations of rIFN- were added to infected macrophages treated 
with a 10 µg/ml of ceftazidime and the effects on intracellular B. pseudomallei replication 
were assessed.  For each treatment, the mean bacterial numbers were plotted and bars 
represent group means ± SD.  (B) Decreasing concentrations of ceftazidime were added 
to macrophages treated with a fixed concentration of rIFN- (100 U/ml) and the effects 
on intracellular B. pseudomallei replication were assessed.  Synergistic interactions were 
assessed statistically by two-way ANOVA (***, p < 0.001).  These data are 
representative of two independent experiments. 
128 
 
     5.4(4) Combined treatment with IFN- and ceftazidime rapidly suppresses 
       intracellular replication and induces killing of B. pseudomallei in infected 
       macrophages   
Experiments were conducted next to characterize the B. pseudomallei inhibition 
kinetics following combined immuno-antibiotic treatment in vitro.  Infected macrophages 
were treated with ceftazidime (10 µg/ml) and rIFN- (100 U/ml).  The effects on 
intracellular B. pseudomallei infection were assessed at the time of treatment initiation 
and at 6, 12 and 24 h after treatment (Fig. 5.4).  Following B. pseudomallei infection, 
bacterial counts were approximately 2 x 104 CFU/ml.  In untreated cultures and cultures 
treated with ceftazidime alone or IFN- alone, intracellular B. pseudomallei counts rose 
continuously over time to >1 x 106 CFU/ml at 24 h post-infection.  However, in cultures 
treated with both ceftazidime and IFN-, bacterial counts initially increased during the 
first 6 h of treatment, then subsequently decreased by 12 h and decreased further by 24 
h to approximately 4 x 103 CFU/ml.  Thus, at 12 h macrophages treated with ceftazidime 
and IFN- had significantly lower bacterial counts than macrophages treated with 
ceftazidime or IFN- alone.  In addition, the progressive decrease in intracellular 
bacterial counts in ceftazidime plus IFN- treated cultures demonstrated that combined 










Figure 5.4.  Time course of intracellular B. pseudomallei replication and killing 
following treatment with IFN- and ceftazidime.  Macrophages were infected in 
triplicate wells in vitro with B. pseudomallei for 1 h, and then treated with rIFN- (100 
U/ml) or ceftazidime (10 µg/ml) or both for the indicated time periods, and intracellular 
bacterial numbers were determined.  Mean bacterial concentrations (± SD) were 
compared over time in the individual treatment groups using repeated measures ANOVA 
with the Bonferroni post-tests (***, p < 0.001, ceftazidime + IFN- combined group versus 









5.4(5) In vivo treatment with CLDC and ceftazidime generates significant 
   protection from lethal pneumonic B. pseudomallei challenge   
A murine model of acute pulmonary B. pseudomallei infection was used to 
determine whether the combination of immunotherapy plus ceftazidime treatment was 
also effective in vivo.  Mice were infected intranasally (i.n.) with 8 x LD50 B. pseudomallei 
1026b, and treated 6 h after challenge with ceftazidime administered intraperitoneally 
(i.p.).  This treatment was repeated every 12 h for a total of 6 treatments.  The dose of 
ceftazidime that consistently protected 20% or fewer acutely infected mice (when 
administered as single agent without immunotherapy) was 25 mg/kg.  For the in vivo 
studies, a single dose of cationic liposome-DNA complexes (CLDC) was administered 
i.p. 6 hours after infection, as previous studies have found that the immune stimulatory 
effects of CLDC are prolonged [11, 23].  A dose of 20 l CLDC administered i.p. was 
found to protect 20% or fewer B. pseudomallei infected mice (when injected as a single 
treatment without ceftazidime).  Therefore, these sub-therapeutic doses of ceftazidime 
and CLDC were selected for the combination therapy studies. 
 For the combination therapy studies, mice were challenged i.n. with B. 
pseudomallei, and 6 h later treated with CLDC alone, ceftazidime alone, or both agents 
in combination.  We observed that 90% of mice treated with the combination of CLDC 
and ceftazidime survived acute pulmonary challenge with B. pseudomallei (Fig. 5.5A).  
In contrast, only 10% of mice treated with ceftazidime or CLDC alone survived until day 
20 post-challenge.  Therefore, we concluded that combined treatment with a potent IFN-
 inducing immunotherapeutic (i.e., CLDC) significantly enhanced the efficacy of low-
dose ceftazidime treatment for acute B. pseudomallei infection.   
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 We also assessed the effects of the brief course of combined low-dose therapy 
on long-term survival following high-dose B. pseudomallei pulmonary challenge.  
Notably, five of the nine mice in the combination treated group that survived the initial 20 
days after challenge (Fig. 5.5A) survived for an additional 40 days (Fig. 5.5B).  When 
these animals were euthanized at the end of the observation period and their organs 
cultured, four of the five mice were found to be free of culturable B. pseudomallei. In 
contrast, the one surviving CLDC- treated mouse was euthanized on day 55 due to B. 
pseudomallei splenic infection, and the single ceftazidime-treated mouse euthanized at 
the end of the observation period had B. pseudomallei detected within the lungs.  Thus, 
a brief 3-day course of treatment with combined low-dose immuno-antimicrobial therapy 
produced long-term cures in 40% of the treated animals.  Therefore, it is reasonable to 
expect that longer treatment with full-dose therapy should be capable of generating even 












Figure 5.5.  Low-dose ceftazidime (ceftaz.) plus CLDC immunotherapy effectively protects 
mice from acute and chronic infection with B. pseudomallei.  (A) BALB/c mice (n = 10 mice 
per group) were challenged intranasally with 7.5 x 10
3
 CFU B. pseudomallei.   Six hours later 
mice were treated intraperitoneally with 25 mg/kg ceftazidime, 20 µl CLDC, or both agents in 
combination.  The ceftazidime treatments were continued every 12 h for a total of six treatments, 
and the CLDC was administered once.  Short-term (20-day) survival times were assessed.  (B) 
Mice (n = 10 per group) that initially survived the 20-day short-term period were followed for an 
additional 40 days to assess the effects of treatment on long-term chronic infection.   Statistical 
differences in survival times were determined by Kaplan-Meier curves, followed by log-rank test.  
The Bonferroni corrected threshold was applied for comparison of multiple survival curves, such 
that a p value of < 0.02 was considered significant for these analyses.  (***, p < 0.001 for 
combination therapy vs. CLDC treatment, and for combination therapy vs. ceftazidime treatment).  
Data are representative of two combined experiments. 
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     5.4(6) Combined immunotherapy and antimicrobial therapy suppresses B. 
       pseudomallei replication and dissemination in vivo   
The effects of combined CLDC and ceftazidime treatment on bacterial burdens in 
infected mice were assessed.  Mice were sacrificed 48 h after pulmonary B. 
pseudomallei challenge, and bacterial burdens in lung, spleen, and liver tissues were 
quantified.  Mice treated with ceftazidime and CLDC in combination had a significant 
decrease in bacterial burden in the lungs, spleen and liver compared to mice treated with 
either ceftazidime or CLDC alone, or compared to untreated mice (Fig. 5.6).  These 
results indicated that combined therapy effectively suppressed bacterial replication in the 














Figure 5.6.  Combined treatment with CLDC and ceftazidime significantly decreases 
bacterial burden.  BALB/c mice (n = 5 mice per group) were challenged intranasally with 8 x 10
3
 
CFU B. pseudomallei.  Six hours later mice were treated intraperitoneally with 25 mg/kg 
ceftazidime, 20 µl CLDC, or both agents in combination.  The ceftazidime treatments were 
continued every 12 h for a total of six treatments, and the CLDC was administered once.  At 48 h 
after challenge, the mice were sacrificed and bacterial burdens were quantified in the lungs (a), 
spleen (b), and liver (c).  Organ bacterial burdens were compared statistically, using one-way 
ANOVA and Tukey multiple means comparison test.  (***, p < 0.001;  **, p < 0.01).  Significant 
reductions (p < 0.01) in bacterial counts of single-agent treated animals were also observed, but 
are not noted. 
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     5.4(7) Treatment of mice with rIFN- significantly increases the effectiveness of 
       ceftazidime therapy   
Next, we investigated whether recombinant IFN- (rIFN-) could be substituted 
for CLDC and combined with low-dose ceftazidime treatment to generate increased in 
vivo protection from B. pseudomallei challenge.  In dose titration studies in vivo, high 
doses of rIFN- (> 1 x 104 U rIFN- per mouse) administered intraperitoneally (i.p.) at 6 
and 18 h after infection significantly protected mice from lethal inhalational challenge 
with B. pseudomallei (data not shown).  However, lower doses of rIFN- (< 5 x 103 U) did 
not protect mice from lethal B. pseudomallei challenge (data not shown).  Thus, a sub-
therapeutic dose of 3 x 103 U IFN- per mouse, administered at 6 and 18 hours after 
infection, was selected for subsequent combination treatment studies.  This dose 
consistently protected 20% or fewer mice when administered without ceftazidime (data 
not shown).   
 Seventy percent of mice treated with the combination of low-dose rIFN- and low-
dose ceftazidime survived for 20 days following inhalational challenge inhalational with 
B. pseudomallei (Fig. 5.7A).  In contrast, only 10% of mice treated with rIFN- alone 
survived the challenge and none of the mice treated with low-dose ceftazidime alone 
survived until day 20 post-infection.  Therefore, we concluded that treatment with rIFN- 
could also be used to significantly enhance the effectiveness of low-dose ceftazidime 
treatment. 
 We also examined the effects of rIFN- and ceftazidime combination treatment 
on long-term chronic infection with B. pseudomallei.  When mice that survived the initial 
20-day period following challenge were observed for 40 more days, six of the seven 
surviving animals treated with combination therapy eventually succumbed to chronic 
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infection (Fig. 5.7B).  In addition, when the single surviving combination-treated mouse 
was euthanized at day 65 post-challenge, B. pseudomallei was present within the 
spleen.  The long-term survival times of the combination-treated mice were significantly 
(p < 0.001) increased compared to the group of mice treated with only ceftazidime, but 
were not significantly different when compared to the rIFN- treated animals.  However, 
the trend apparent in these results was that the combination of rIFN- immunotherapy 
combined with ceftazidime antimicrobial therapy was more potent than either therapy 
alone.  It was also apparent from these results that combined short-term treatment with 
rIFN- and ceftazidime was not as potent as treated with CLDC plus ceftazidime, 











Figure 5.7.  Treatment with low-dose ceftazidime plus rIFN- protects mice from acute but 
not chronic B. pseudomallei infection.  (A) BALB/c mice (n = 10 per group) were challenged 
intranasally with 7.5 x 10
3
 CFU B. pseudomallei.  Six hours later mice were treated 
intraperitoneally with 25 mg/kg ceftazidime, 3 x 10
3
 U rIFN-, or with both agents in combination.  
The ceftazidime treatments were continued every 12 h for a total of six treatments.  Treatment 
with rIFN- was administered twice, at 6 and 18 h post-infection.  Short-term (20-day) survival 
was assessed.  (B) Mice (n = 10 per group) that initially survived the 20-day short-term period 
were followed for an additional 40 days to assess the effects of the combination treatment on 
chronic infection.  Statistical differences in survival times were determined by Kaplan-Meier 
curves followed by log-rank test.  The Bonferroni corrected threshold was applied for comparison 
of multiple survival curves and a p value of < 0.02 was considered significant for these analyses.  
(***, p < 0.001 for combination therapy vs. rIFN- treatment, and for combination therapy vs. 
ceftazidime treatment).  Data are representative of two combined experiments.  
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5.5  Discussion 
There is a clear need for new approaches to increase the effectiveness of 
antimicrobial therapy for B. pseudomallei infection, given the inherent antimicrobial 
resistance of B. pseudomallei and high probability of patient relapse even after 
prolonged, appropriate antibiotic therapy [3, 7-8]  In the current study we demonstrated 
that treatment with recombinant IFN-, or a cationic liposome-DNA complex (CLDC)  
immunotherapeutic that efficiently induces IFN- production in vivo, significantly 
increased the effectiveness of conventional antimicrobial therapy for B. pseudomallei 
infection.  These findings are important because they suggest a general strategy for 
improving the effectiveness of antimicrobial therapy for melioidosis.  Immunotherapy has 
been shown previously to increase the effectiveness of antimicrobial therapy in mouse 
models of Mycobacterium avium, Enterococcus faecalis, and Francisella novicida 
infection [17-19].  The effectiveness of combined therapy has also been demonstrated in 
a Cryptococcus infection model [32-33].  However, to our knowledge this is the first 
report that demonstrates marked enhancement of antimicrobial therapy by 
immunotherapy for treatment of B. pseudomallei infection using an acute lethal 
challenge model.   
 Previous studies suggested that treatment with recombinant granulocyte-colony 
stimulating factor (rG-CSF) might be used to augment the effectiveness of antimicrobial 
therapy for treatment of B. pseudomallei infection [13].  These studies were based on 
the protective role of neutrophils in B. pseudomallei infection [14].  However, studies 
failed to confirm an in vivo role for treatment with rG-CSF for augmenting the 
effectiveness of ceftazidime for treatment of B. pseudomallei infection [15].  Our studies 
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indicated that immuno-antimicrobial therapy can be used effectively for treatment of B. 
pseudomallei infection, but that IFN- would be the preferred cytokine for this application.   
These studies also suggest that combined immuno-antimicrobial therapy may be 
particularly effective for eliminating the chronic stage of B. pseudomallei infection.  The 
brief 3-day course of treatment with combination therapy resulted in long-term chronic 
disease protection.  This extended protection has the potential to be even augmented 
further with a longer duration of treatment.  In addition, in these studies low-doses of 
ceftazidime and immunotherapy were used for the purpose of determining whether 
conventional antimicrobial therapy was markedly enhanced with immunotherapy.  
However, full-dose therapy should be capable of generating even greater protection from 
chronic B. pseudomallei infection.   
The direct implications of these findings to human melioidosis patients have been 
addressed by clinicians within endemic melioidosis regions upon the publication of these 
results.  Mortality from B. pseudomallei is especially high in septic patients even with 
appropriate antimicrobial therapy.  In a 10-year prospective study conducted in northern 
Australia, 86% of melioidosis patients with septic shock died despite the administration 
of ceftazidime or carbapenems [34].  The septic melioidosis patient definitely constitutes 
one of the biggest clinical challenges with melioidosis.  With the purpose of more 
accurately representing the human septic patient in our murine model and determining 
whether the combination therapy would improve clinical outcome, we conducted 
preliminary studies with slightly altered parameters to our model.  Under the new 
parameters, mice were challenged intranasally with 5 x 104 CFU B. pseudomallei 
(approximately 1-log higher than used in our initial model) and treatment regimens were 
not initiated until 24 h post-challenge (18 h later than the previous model) to most 
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accurately mimic the clinical situation of advanced septic disease prior to therapeutic 
intervention.  In addition, we tested a more clinically relevant, high-dose of ceftazidime in 
this revised model of 600 mg/kg (twice daily), and animals were treated with CLDC for 
an extended period of time (three total treatments instead of a single dose).  Under 
these revised parameters to our in vivo model we saw no enhancement to ceftazidime 
therapy by the CLDC immunotherapy.  The high B. pseudomallei challenge dose 
(greater than 50x LD50) required to overcome the 600mg/kg dose of ceftazidime when 
administered as a single agent caused the mice to reach very advanced pneumonic 
disease by the time therapy was administered (24 h post-challenge).  Even with the 
combination therapy, B. pseudomallei could not be effectively controlled under these 
parameters.  We believe the enhancement to ceftazidime therapy with immunotherapy is 
most effectively illustrated using the initial model described in Materials and Methods, 
and believe immuno-antimicrobial therapy still has great potential for reducing patient 
relapse.  
 At present, the mechanism(s) by which IFN- interacts with ceftazidime to 
suppress intracellular replication of B. pseudomallei remains undetermined.  Possible 
mechanisms include the induction of reactive nitrogen or reactive oxygen species by 
IFN-, which then subsequently increase the susceptibility of B. pseudomallei to killing by 
ceftazidime.  However, preliminary experiments suggest that this is not the case.  It is 
also possible that IFN-treatment could increase the permeability of macrophages to 
ceftazidime, but again preliminary experiments suggest that this is not the mechanism.  
Therefore, at present the mechanisms by which IFN- and certain antibiotics interact to 
generate synergistic killing of intracellular Burkholderia remain unknown.  The CXC 
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chemokines (CXCL9 and CXCL10) induced by IFN- and known to possess 
antimicrobial activity are currently under investigation by our laboratory [35]. 
 In summary, we report a strong synergistic interaction between IFN- and 
ceftazidime that suppresses B. pseudomallei in both acute and chronic infection models.  
The effect was demonstrated using an in vitro macrophage infection model and 
confirmed in vivo using a lethal bacterial challenge model.  These experiments also 
suggest that immunotherapy capable of eliciting a more sustained release of IFN- may 
be more effective than short-term treatment with rIFN-.  The combined immuno-
antimicrobial treatment approach may be especially useful for reducing the duration of 
antimicrobial treatment and reducing the chance for patient relapse following antibiotic 
therapy.  
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THE DEVELOPMENT OF AN EFFECTIVE MUCOSAL 
VACCINE FOR Burkholderia pseudomallei 
 
 The studies described in this chapter investigate the protective efficacy of 
different mucosal vaccine formulations for melioidosis.  I acknowledge Angela Duffy for 
assistance with the heat-killed/CLDC studies, Mark Estes for providing the Burkholderia 
protein antigens, the Herbert Schweizer laboratory for providing Bp82, the Tung Hoang 
laboratory for providing Bp422, and Andrew Goodyear for assisting with the oral 
vaccination studies and monitoring of the mice. 
 
6.1  Abstract 
 Burkholderia pseudomallei causes the disease melioidosis and currently there is 
no approved vaccine for human use.  A variety of vaccine candidates have been tested 
in animal melioidosis models, but those investigated to date have consistently failed to 
protect long-term from chronic melioidosis.  The purpose of this research was to develop 
a mucosal vaccine for B. pseudomallei providing protection from both acute and chronic 
melioidosis, and to identify an effective mucosal adjuvant.  A variety of vaccine 
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formulations were tested in these studies including killed bacteria, purified protein 
Burkholderia subunits, and two live attenuated strains.  All vaccine candidates were 
administered intranasally and one of the attenuated mutants was also tested for efficacy 
following oral delivery.  A cationic liposome-DNA complex (CLDC) adjuvant was found to 
significantly enhance protection from lethal pneumonic challenge.  We found that 
adjuvanted killed bacteria and protein subunits significantly protected mice compared to 
non-adjuvanted antigens.  Vaccination with either the adjuvanted killed bacteria or the 
two attenuated B. pseudomallei strains protected 100% of mice from acute pneumonic 
melioidosis, whereas the recombinant protein antigens, BimA, BopA, and LolC, offered 
less effective short-term protection.  The best long-term protection from chronic 
melioidosis was elicited following intranasal vaccination with Bp82, a fully attenuated 
purM 1026b mutant that is exempt from Select Agent regulations.  Mice vaccinated with 
Bp82 were protected for 100 days following lethal pneumonic challenge.  This 
attenuated strain was also administered orally to the animals, and significantly increased 
their time to death following pneumonic challenge.  Bp82 has great potential as a live 
vaccine strain for high-risk persons. 
 
6.2  Introduction 
 Burkholderia pseudomallei is a human pathogen endemic to Southeast Asia, 
Northern Australia, and other tropical regions of the world [1].  There is also concern for 
this pathogen in the Western Hemisphere due to its potential for use as a biological 
weapon [2].  This pathogen causes the disease melioidosis and there is currently no 
approved vaccine available.  An approved vaccine would be advantageous in protecting 
those at risk within endemic regions and could also lessen the desire to weaponize this 
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pathogen for intentional release [3].  The overall purpose of these studies was to 
develop an effective mucosal vaccine for B. pseudomallei providing both short and long-
term protection from melioidosis. 
 Vaccine research for melioidosis has been complicated by a variety of factors.  
Producing long-term protective immunity has proven to be one of the biggest challenges 
[4].  Since B. pseudomallei is a facultative intracellular pathogen, it is likely that both 
effective cell-mediated and humoral immune responses will be critical for long-term 
protection [5].  Humans have been shown to produce bacterial-specific antibodies 
following melioidosis [6-7].  However, recurrent B. pseudomallei infection within just one 
year of primary disease is commonly seen in melioidosis patients [8], illustrating the 
likelihood that antibody presence does not confer sterilizing immunity.  Most vaccine 
research has been conducted in murine models and many vaccine candidates tested 
have produced short-term protection from acute melioidosis, but do not often confer long 
lasting protection from disseminated disease beyond 30-40 days [4, 9].  In addition, B. 
pseudomallei is commonly isolated from the tissues of vaccinated survivors at time of 
sacrifice, further indicative of a lack of sterilizing immunity [10]. 
 A variety of Burkholderia vaccine approaches have been investigated in murine 
melioidosis models.  Killed whole-cell formulations (composed of heat-killed or irradiated 
bacteria) have been tested for efficacy, but have not consistently produced long-term 
protection [10-12].  One of the more promising studies involved intraperitoneal 
vaccination with killed B. pseudomallei that offered protection beyond 40 days from 
aerosol challenge in the majority of mice [10].  It must be noted, however, that a low-
dose aerosol challenge dose was used in this study as not all unvaccinated mice 
succumbed to acute disease.  Live attenuated strains have shown more promise in 
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providing protection than killed formulations [13-18].  This was demonstrated by the 
finding that the protective effect elicited by the live attenuated B. pseudomallei strain 
CL04 was greatly diminished when this strain was inactivated by irradiation [19].  
Attenuated mutant B. pseudomallei strains previously investigated have included 
auxotrophic strains deficient in amino acid synthesis [13, 15], purine biosynthesis [16], 
type III secretion [18], and strains defective in other biosynthetic pathways [20].  The 
attenuated strains tested have been most often administered intraperitoneally.  Long-
term protection is still an issue, as mice vaccinated intraperitoneally with a live 
attenuated B. pseudomallei strain 2D2 eventually succumbed to chronic disease within 
75 days [17].  
Outer membrane and type III secretion protein subunits have been examined as 
vaccine candidates [21-23].  The protein subunit that is considered one of the most 
promising is the lipoprotein-releasing system transmembrane protein, LolC [4].  LolC 
serves as an adenosine triphosphate-binding cassette transporter protein [22].  The 
greatest protection was observed when mice were vaccinated intraperitoneally with this 
subunit along with adjuvant immunostimulating complex (ISCOMS) and CpG 
oligodeoxynucleotide.  Vaccinated mice did not begin succumbing to chronic disease 
infection until 30-50 days post intraperitoneal challenge with B. pseudomallei [22]. 
Previous B. pseudomallei vaccine research has most often used the 
intraperitoneal route for vaccination and subsequent challenge.  Our purpose, however, 
was to develop a mucosal vaccine since mucosal delivery of antigens has been shown 
to most efficiently produce mucosal immunity [24-26].  The protective efficacy of all 
vaccine candidates within our research was tested using intranasal vaccination, and one 
of our attenuated strains was also delivered orally.  Since the inhalational challenge 
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route is considered the most lethal route of B. pseudomallei infection [27] and also the 
route considered most likely during a potential biological attack, all B. pseudomallei 
challenges following vaccination were conducted intranasally.  In this series of studies, 
we have explored a variety of vaccine candidates, including killed whole cell B. 
pseudomallei, live attenuated strains, and a series of protein subunits. 
In addition to identifying vaccine candidates, we also explored the effectiveness 
of using a cationic liposome-DNA complex (CLDC)-based adjuvant in conjugation with B. 
pseudomallei antigens.  We have previously demonstrated the effectiveness of CLDC 
when used as immunotherapy to enhance antibiotic therapy [28] and as a highly 
effective pre-exposure prophylaxis against lethal bacterial pathogens [29-30].  Similar 
lipid-based vaccine formulations have shown protection against other bacterial 
pathogens including Mycobacterium tuberculosis and Vibrio cholerae when administered 
intranasally to mice [31-33]. 
In summary, we have identified a promising CLDC mucosal vaccine adjuvant that 
greatly enhances mucosal protection when combined with heat-killed B. pseudomallei 
and purified Burkholderia protein subunits.  The most effective vaccine candidate 
identified by our studies that offered protection from both acute and long-term chronic 
melioidosis for 100 days was the live attenuated strain Bp82, a fully attenuated 1026b 
purM derivative.  Because of its exemption from Select Agent regulations and previous 
demonstration of complete attenuation [34], this strain could serve as a potential vaccine 





6.3  Materials and Methods 
     6.3(1) Bacterial strains, media and growth conditions   
B. pseudomallei strain 1026b is a clinical isolate from a case of human 
septicemic melioidosis from Thailand.  This strain is lethal to mice and has been 
extensively studied in the laboratory [35].  B. pseudomallei 1026b was the strain used for 
vaccination with heat-killed bacteria.   Strain 1026b was also the virulent challenge strain 
used to test the protective efficacy of all vaccine formulations investigated within these 
studies.   
Bp82 is a purM derivative of 1026b, and adenine and thiamine auxotroph.  This 
strain is completely attenuated in mice and hamsters [34], and was tested as a potential 
vaccine strain for protection against subsequent intranasal challenge with the fully 
virulent B. pseudomallei strain 1026b.  A second attenuated strain that was investigated 
as a potential vaccine strain within these studies was Bp422 (kindly provided by Tung 
Hoang, University of Hawaii at Manoa, HI).  Bp422 is a asd derivative of 1026b, 
harboring a mutation within the aspartate-beta-semialdehyde dehydrogenase (asd) 
gene.  This strain is a diaminopimelate (DAP) auxotroph in rich media, and a DAP, 
lysine, methionine, and threonine auxotroph in minimal media [36].  Due to the inability 
to synthesize DAP, Bp422 is unable to crosslink D-alanine in neighboring peptidoglycan 
strains during cell wall synthesis, resulting in cell death unless growth media is 
supplemented with DAP [37]. 
Strains 1026b and Bp82 were grown to saturation in Luria broth (LB) at 37°C with 
shaking, and then stored at -80°C in 15% glycerol until ready to use.  For quantification, 
strains 1026b and Bp82 were plated on LB agar.  Bp422 was grown to saturation in LB 
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supplemented with 200 g/ml DAP, and then stored at -80°C in 15% glycerol until ready 
to use.  For quantification, Bp422 was grown on LB agar plus 200 g/ml DAP.  For 
animal experiments, strains 1026b and Bp422 were thawed just before use and the 
bacteria were diluted to the desired cell numbers using sterile phosphate buffered saline 
(PBS).   Bp82 was grown fresh prior to each intranasal vaccination.  This strain was 
inoculated fresh into LB, grown to saturation, and diluted to the desired cell numbers 
using sterile phosphate buffered saline.    
 
     6.3(2) Mice   
Female BALB/c mice were used for these studies (Jackson Laboratories, Bar 
Harbor, ME).  Mice were between approximately 6-16 weeks of age at the time of 
experimentation and were housed under pathogen free conditions.  All animal studies 
were approved by the Institutional Animal Care and Use Committee at Colorado State 
University. 
 
     6.3(3) Preparation of cationic liposome-DNA complex (CLDC) for adjuvant use 
       within mucosal vaccines 
Liposomes were prepared by combining cationic liposome DOTIM 
octadecenoyloxy (ethyl-2-heptadecenyl-3-hydroxyethyl) imidazolinium chloride and 
cholesterol in equimolar concentrations as described previously [38].  Non-coding 
plasmid DNA (0.2 mg/ml, Juvaris Biotherapeutics) was diluted in sterile Tris-buffered 5% 
dextrose water.  The cationic liposomes were then added with gentle pipetting at a 
concentration of 100 l of liposomes per 1 ml of solution, resulting in the spontaneous 
151 
 
formation of CLDC.  To formulate the CLDC-adjuvanted vaccines, the protein subunits or 
heat killed B. pseudomallei were added to the CLDC.  Vaccines were delivered to mice 
within 30 min of preparation. 
 
     6.3(4) Vaccination with heat-killed B. pseudomallei and CLDC 
B. pseudomallei 1026b was heat-killed for intranasal vaccination of mice.  The 
bacteria were washed, resuspended in PBS, and then heated to 80˚C for 1 h using a 
heat block.  Complete bacterial killing was confirmed by plating on LB agar.  To 
determine whether CLDC has potential as a mucosal vaccine adjuvant for protection 
against lethal B. pseudomallei challenge, BALB/c mice were vaccinated intranasally with 
CLDC adjuvant alone, 1 x 105 heat-killed B. pseudomallei organisms alone, heat-killed 
bacteria mixed with 10 μl CLDC, or left unvaccinated. 
For all vaccinations, mice were anesthetized by intraperitoneal injection with 100 
mg/kg ketamine (Fort Dodge Animal Health, Overland Park, KS) plus 10 mg/kg xylazine 
(Ben Venue Labs, Bedford, OH).  All mice were vaccinated intranasally, alternating 
nostrils, with a total volume of 20 l of the appropriate vaccine, and were boosted in the 
same manner 10 d later.   Fourteen days after the boost, mice were subjected to lethal 
intranasal challenge with 7,500 CFU live B. pseudomallei 1026b (8 x LD50).  Mice were 
monitored for disease symptoms twice daily and were euthanized according to pre-
determined humane endpoints. 
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     6.3(5) Vaccination with protein subunits 
 The recombinant protein subunits evaluated as potential vaccine candidates 
within these studies included BimA, BopA, and LolC (all antigens kindly provided by 
Mark Estes, University of Texas Medical Branch, Galveston, TX).  BimA is an 
autotransporter protein and BopA is a type III secretion system protein, both isolated 
from B. mallei.  LolC is an ABC transporter protein from B. pseudomallei.   These three 
protein subunits were tested as part of collaborative research with M. Estes to determine 
their cross-protection potential against both B. pseudomallei and B. mallei.  The adjuvant 
tested within the protein subunit vaccines was CLDC.   
BALB/c mice (n = 5-15 mice per group) were vaccinated intranasally with BopA 
protein alone (no adjuvant), BimA mixed with CLDC, BopA mixed with CLDC, LolC 
mixed with CLDC, or left unvaccinated.  For all vaccinations, mice were anesthetized by 
intraperitoneal injection with 100 mg/kg ketamine (Fort Dodge Animal Health, Overland 
Park, KS) plus 10 mg/kg xylazine (Ben Venue Labs, Bedford, OH).  All mice were 
vaccinated intranasally with 2 g of purified recombinant protein in a total volume of 20 
l.  Mice were boosted 1-2 times in the same manner 10-14 d later.   Fourteen days after 
the final boost, mice were subjected to lethal intranasal challenge with approximately 3 x 
103 CFU live B. pseudomallei 1026b (3 x LD50).  Mice were monitored for disease 
symptoms twice daily and were euthanized according to pre-determined humane 
endpoints.  
 
     6.3(6) Vaccination with live attenuated B. pseudomallei strains 
 Bp82, a purM 1026b derivative, and Bp422, a asd 1026b derivative, were the 
two attenuated strains tested for protective efficacy against lethal B. pseudomallei 
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challenge.  Bp82 has been shown to be completely attenuated in mice [34], and mice 
were vaccinated with this strain using both intranasal and oral delivery.  For intranasal 
vaccination, BALB/c mice (n = 5 mice per group) were vaccinated with 1 x 106 CFU 
Bp82 (freshly grown in LB at stationary phase).  All mice were anesthetized for 
intranasal vaccination by intraperitoneal injection with 100 mg/kg ketamine (Fort Dodge 
Animal Health, Overland Park, KS) plus 10 mg/kg xylazine (Ben Venue Labs, Bedford, 
OH).  All mice were vaccinated with Bp82 in a total volume of 20 l and boosted in the 
same manner 14 d later.   For oral vaccination with Bp82, BALB/c mice (n = 10 mice per 
group) were gavaged with inoculums ranging from 1 x 107 to 1 x 109 CFU Bp82 using a 
stainless steel gavage needle, and boosted 14 d later.  Fourteen days after the 
intranasal or oral boosts, all mice were subjected to lethal intranasal challenge with 
approximately 5 x 103 CFU live B. pseudomallei 1026b (5 x LD50).  Mice were monitored 
for disease symptoms twice daily and were euthanized according to pre-determined 
humane endpoints. 
 Since Bp422 had not been previously tested in vivo for attenuation, BALB/c mice 
(n = 5 mice per group) were challenged intranasally with 1 x 107 CFU Bp422 and 
monitored for 80 d.  And the end of this observation period, their lungs, livers, and 
spleens were plated for sterility to assess chronic colonization by this attenuated strain.  
Bp422 was also tested for vaccine efficacy against lethal B. pseudomallei challenge.  
BALB/c mice (n = 10 mice per group) were vaccinated intranasally with 1 x 107 CFU 
Bp82 and boosted in the same manner 3 weeks later.  Two weeks following the boost 
mice were challenged intranasally with 4 x 103 CFU (4 x LD50) B. pseudomallei 1026b.  
Mice were monitored for disease symptoms twice daily and were euthanized according 




     6.3(7) Statistical analyses  
Data were analyzed using Prism 5.0 software (Graph Pad, San Diego, CA).  
Survival times were analyzed by Kaplan-Meier analysis, followed by the log-rank test.  
For comparisons of survival times of more than one group in an experiment, the 
Bonferroni corrected threshold was applied to correct for multiple comparisons. 
 
6.4  Results 
     6.4(1) Mucosal vaccination with heat killed bacteria plus CLDC adjuvant 
      generates effective long-term protection against lethal pulmonary 
      B. pseudomallei challenge 
 Experiments were conducted to identify an effective mucosal vaccine adjuvant 
for protection from B. pseudomallei.  This adjuvant would be later tested for protective 
efficacy in conjugation with the Burkholderia protein subunits.  The adjuvant examined 
by these studies was cationic liposome-DNA complexes (CLDC) that we have previously 
shown to offer prophylactic protection from lethal bacterial challenge and enhancement 
to antibiotic therapy [28, 30].  BALB/c mice were vaccinated and boosted intranasally 
with the CLDC adjuvant alone, heat-killed Burkholderia pseudomallei, or heat-killed 
bacteria mixed with CLDC.  All mice were then subjected to lethal intranasal challenge 
and survival times were determined.  All non-vaccinated control mice reached end-point 
prior to day 3 after challenge, and mice vaccinated with the CLDC adjuvant alone 
succumbed to end-point by day 4.  In contrast, 4 of the 9 mice vaccinated with heat-
killed bacteria alone survived for more than 40 d (Fig. 6.1).  However, it is important to 
note that all of the surviving mice vaccinated with heat-killed B. pseudomallei only 
eventually succumbed to chronic disease by day 60 post-challenge (data not shown).  In 
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contrast, 100% of mice vaccinated with heat-killed bacteria plus CLDC survived bacterial 
challenge for more than 40 d (Fig. 6.1), and 5 of these 9 mice survived beyond day 60 
post-challenge (data not shown), indicating the ability of CLDC to enhance the protective 
effect elicited by the heat-killed bacteria.  These results indicate the effectiveness of a 
CLDC-adjuvanted vaccine at offering protection from both acute and chronic melioidosis, 














Figure 6.1.  Mucosal immunization with heat-killed (HK) bacteria and CLDC 
adjuvant generates effective protection from both acute and chronic B. 
pseudomallei (Bp) infection.  BALB/c mice (n = 4-5 mice per non-vaccinated control 
and CLDC alone groups, and 9 mice per heat-killed B. pseudomallei alone and heat-
killed B. pseudomallei + CLDC groups) were primed intranasally with the adjuvant alone, 
1 x 105 CFU heat-killed B. pseudomallei 1026b suspended in D5W buffer, or with heat-
killed bacteria complexed to the CLDC adjuvant.  Mice were boosted in the same 
manner 10 d later.  All animals were then challenged intranasally with 7500 CFU live B. 
pseudomallei 1026b (8 x LD50) 14 d following the boost and survival was monitored.  
Statistical differences in survival times were determined by Kaplan-Meier curves 
followed by log-rank test.  The Bonferroni corrected threshold was applied and 
comparisons with p < 0.013 were considered significant.  (*p = 0.01 for mice vaccinated 
with heat-killed bacteria alone vs. mice vaccinated with heat-killed bacteria adjuvanted 
with CLDC), indicating the significant effect elicited by the CLDC adjuvant on protection.  







     6.4(2) Mucosal vaccination with CLDC adjuvanted Burkholderia protein 
      subunits elicits protection from acute pneumonic melioidosis 
 Once CLDC was identified as an effective mucosal adjuvant for protection from 
both acute and chronic melioidosis (Fig. 6.1), this adjuvant was tested in conjugation 
with a variety of Burkholderia protein subunits.  BimA and BopA, both B. mallei proteins, 
and the B. pseudomallei protein, LolC, were all tested within these studies.  BALB/c mice 
were vaccinated with BimA, BopA, or LolC, all in conjugation with the CLDC adjuvant.  
To assess the impact of the CLDC adjuvant in conjugation with the individual protein 
subunits, another group of mice were vaccinated with the BopA subunit alone.  Control 
mice remained unvaccinated.  Mice were primed and boosted 1-2 times, and challenged 
with live B. pseudomallei 1026b two weeks after the final boost.  Our data indicated 
short-term protection elicited by the three adjuvanted protein antigens lasting for 20 d in 
40-60% of the mice (Fig. 6.2).  However, this protection waned over time, as the majority 
of the mice succumbed to disseminated chronic melioidosis by day 60 post-infection.  
When mice were vaccinated with the BopA subunit alone, there was no protective effect 
initiated and these mice succumbed to acute disease similar to that observed in non-
vaccinated controls.  These results indicate the necessity of the CLDC adjuvant within 






Figure 6.2.  Mucosal vaccination with Burkholderia protein subunits in 
conjugation with CLDC elicits short-term protection from pneumonic B. 
pseudomallei. BALB/c mice (n = 5 mice) were vaccinated with the BopA subunit alone, 
and other groups (n = 15 mice per group) were vaccinated with BimA, BopA, or LolC, all 
in conjugation with the CLDC adjuvant.  Control mice (n = 14 mice) were left 
unvaccinated.  Vaccinated mice were primed and boosted 1-2 times, and challenged 
with  3 x 103 CFU live B. pseudomallei 1026b (3 x LD50) two weeks after the final boost.  
Survival was monitored for 60 d post-challenge, and mice were euthanized according to 
pre-determined humane end-points.  Approximately 40-60% of the mice were protected 
until day 20 from lethal B. pseudomallei challenge.  All antigens tested conferred 
increased survival and time to death compared to non-vaccinated control animals (***, p 
< 0.0001 for BimA, BopA, and LolC vaccinated groups vs. non-vaccinated controls).  









     6.4(3) Intranasal vaccination with Bp422, a B. pseudomallei 1026b asd 
      derivative, offers protection from acute B. pseudomallei infection  
Two different attenuated mutant B. pseudomallei strains were tested in these 
studies as potential live vaccine strains.  Bp422, a asd 1026b derivative, was tested for 
both attenuation and as a live vaccine strain in our murine melioidosis model.  This strain 
is a diaminopimelate (DAP) auxotroph and unable to crosslink D-alanine in neighboring 
peptidoglycan during cell wall synthesis [36-37].  To ensure in vivo attenuation of this 
strain, BALB/c mice were challenged intranasally with 1 x 107 CFU Bp422 (10,000x LD50 
for wild type 1026b) and monitored for survival.  Despite the observation of ruffling and 
mild respiratory symptoms in the initial days following challenge (most-likely due to the 
high burden of LPS), this Bp422 was completely non-lethal to the mice (Fig. 6.3).  At 75 
d post-infection, the lungs, livers, and spleens were all plated from infected animals to 
rule out long-term colonization by this mutant.  All organs were sterile at this time, 
indicative of complete bacterial clearance and no persistent colonization by Bp422 (data 
not shown). 
Bp422 was also tested for vaccine efficacy against lethal B. pseudomallei 
challenge.  BALB/c mice were vaccinated intranasally with 1 x 107 CFU Bp82 and 
boosted 3 weeks later.  Two weeks after the boost mice were challenged intranasally 
with 4 x 103 CFU (4 x LD50) B. pseudomallei 1026b and survival was monitored.  Non-
vaccinated control mice succumbed to acute disease end-point by day 3 post-infection, 
whereas 100% of mice vaccinated with Bp422 were protected from the lethal challenge 
for 16 d (Fig. 6.4).  However, Bp422 vaccination failed to protect from long-term chronic 
melioidosis, as all mice eventually succumbed to disseminated infection end-point by 60 





Figure 6.3.  Bp422, a asd 1026b derivative, is completely avirulent to mice.  
BALB/c mice (n = 5 mice per group) were challenged intranasally with 1 x 107 CFU Bp82 
and survival was monitored.  For purpose of comparison, survival from mice challenged 
with 5 x 103 CFU wild type 1026b is shown.   (**, p = 0.0016 for mice challenged with 
Bp422 mutant vs. wild type 1026b strain).  And the end of this observation period, their 
lungs, livers, and spleens were plated for sterility, and no B. pseudomallei bacteria were 













Figure 6.4.  Vaccination Bp422, a asd 1026b derivative, elicits protection from 
acute pneumonic melioidosis.  BALB/c mice (n = 10 mice per group) were vaccinated 
intranasally with 1 x 107 CFU Bp422, an attenuated asd 1026b derivative, and boosted 
in the same manner 3 weeks later.  Control mice remained unvaccinated.  Two weeks 
following the boost, mice were challenged intranasally with 4 x 103 CFU (4 x LD50) B. 
pseudomallei 1026b.  Mice were monitored for disease symptoms twice daily and were 
euthanized according to pre-determined humane endpoints.  (***, p < 0.0001 for 
vaccinated mice vs. non-vaccinated controls).  Data shown are representative of 2 
combined independent experiments.   
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     6.4(4) Intranasal vaccination with Bp82, a fully attenuated B. pseudomallei  
     1026b purM derivative, offers protection from lethal B. pseudomallei disease 
      for 100 days 
 A second attenuated mutant tested for protective efficacy against pneumonic B. 
pseudomallei challenge was Bp82, a purM 1026b derivative.  Complete attenuation in 
both immune competent and immune deficient has been previously demonstrated within 
our previous studies [34], and Bp82 has since been excluded from Select Agent 
regulations.  Two different routes of vaccination were investigated, including both 
intranasal and oral delivery.  For intranasal vaccination, BALB/c mice were vaccinated 
with 1 x 106 CFU freshly growing Bp82 and boosted two weeks later.  Fourteen d 
following boost, mice were challenged intranasally with 5 x 103 CFU B. pseudomallei 
1026b (5 x LD50) and survival was monitored (Fig. 6.5).  All of the mice were protected 
from acute pneumonic melioidosis, as 100% survived for 37 d following lethal pneumonic 
challenge.  Three of the 5 animals went on to survive beyond 100 d, illustrating the 
ability of Bp82 to protect long-term from disseminated B. pseudomallei infection.  (Two of 
these animals succumbed to chronic disease post-100 d).   
It is also worthy to note that during this long-term observation period lasting 
greater than three months, the mice vaccinated with Bp82 had less chronic disease 
symptoms than all other vaccinated survivors within these studies.  It was observed that 
mice vaccinated intranasally with this attenuated mutant had markedly less ruffling, 
squinty eyes, weight loss, and splenic lesion formation compared to the animals 
vaccinated with other formulations tested in these studies (heat-killed, protein subunit, 
and Bp422 vaccinated mice).  Also worthy of mention is that the Bp82 vaccinated 
survivors unexpectedly experienced a cage flood within the first 20 d post-challenge in 
which this stress induced on the animals could have potentially negatively impacted 




Figure 6.5.  Intranasal vaccination with Bp82, a fully attenuated B. pseudomallei 
1026b purM derivative, offers protection from both acute and long-term chronic 
melioidosis.  BALB/c mice (n = 5 mice per group) were vaccinated intranasally with 1 x 
106 CFU Bp82 and boosted in the same manner 2 weeks later.  Control mice remained 
unvaccinated.  Two weeks following the boost, mice were challenged intranasally with 5 
x 103 CFU (5 x LD50) B. pseudomallei 1026b.  Mice were monitored for disease 
symptoms twice daily and were euthanized according to pre-determined humane 
endpoints.  (**, p = 0.003 for vaccinated mice vs. non-vaccinated controls).         
   








     6.4(5) Oral vaccination with an attenuated strain increases survival time 
      following lethal intranasal B. pseudomallei challenge 
 The pneumonic delivery of attenuated bacterial strains to humans has not been 
widely approved.  However, oral delivery of avirulent strains is often considered more 
acceptable, and live attenuated strains have been approved for human use to date, 
including the Salmonella vaccine strain Ty21a and other attenuated Salmonella strains 
[39-40].  In addition, an oral inactivated whole-cell Pseudomonas aeruginosa vaccine 
has been tested in a phase 1 clinical trial with the overall the purpose of reducing 
pulmonary P. aeruginosa colonization [41].  Based on the similarity between P. 
aeruginosa and B. pseudomallei, and the overall acceptance of the oral vaccine route, 
we wanted to determine whether oral vaccination with Bp82, a purM fully attenuated 
strain, would protect mice from pneumonic B. pseudomallei challenge.  Since Bp82 is 
exempt from all Select Agent regulations and is fully attenuated [34], it has potential as a 
possible human vaccine strain.  For oral vaccination, BALB/c mice were gavaged with 
inoculums ranging from 1 x 107 CFU to 1 x 109 CFU, as we found that protection was not 
affected by the vaccine dose (data not shown).  Mice were boosted orally two weeks 
later, and challenged intranasally with 5 x 103 CFU B. pseudomallei 1026b (5 x LD50) two 
weeks following the boost.  For the majority of the mice, survival was increased by 1 d 
(Fig. 6.6).  However, 20% of the vaccinated mice were completely protected from 
melioidosis for more than 30 d following pneumonic challenge.  When comparing the 
orally vaccinated mice to non-vaccinated controls, there was a significant increase in 





Figure 6.6.  Oral vaccination with Bp82, a fully attenuated live B. pseudomallei 
strain, increases survival time following pneumonic challenge.  BALB/c mice were 
orally vaccinated by intragastric gavage with 1 x 107 CFU to 1 x 109 CFU Bp82, a purM 
1026b derivative, and boosted orally two weeks later.  Two weeks following boost, mice 
were challenged intranasally with 5 x 103 CFU B. pseudomallei 1026b (5 x LD50) and 
survival was monitored.  Mice were monitored for disease symptoms twice daily and 
were euthanized according to pre-determined humane endpoints.  Control mice 
remained unvaccinated.  (**, p = 0.003 for vaccinated mice vs. non-vaccinated controls).  
Data shown are representative of 2 combined independent experiments.   
   








6.5  Discussion 
Melioidosis is a highly fatal disease and there is currently no approved vaccine 
for human use [42-43].  The primary purpose of this research was to develop an 
effective mucosal vaccine for B. pseudomallei.  We examined the protective efficacy of a 
variety of B. pseudomallei vaccine formulations, including killed whole bacteria, purified 
protein subunits, and two live attenuated strains.  We examined the protection elicited by 
the different vaccine formulations from both acute pneumonic infection and also 
disseminated chronic melioidosis over several months.  Previous melioidosis vaccine 
research has most often used the intraperitoneal vaccination route; however mucosal 
delivery of antigens has been shown to most efficiently produce mucosal immunity [24-
26].  Therefore, the protective efficacy of all vaccine formulations tested within our 
studies was examined following intranasal vaccination and one live attenuated strain 
was delivered orally.  All challenges following vaccination were conducted intranasally, 
as the inhalational challenge route is considered the most lethal route of B. pseudomallei 
infection [27] and the route considered most likely during an intentional biological 
release.   
The first goal of this research was to identify an effective mucosal vaccine 
adjuvant for use with purified Burkholderia protein subunits.  Antigens adjuvanted by 
lipid-based adjuvants have previously been shown to elicit protection when administered 
mucosally against bacterial pathogens [31-33], and we have previously investigated 
cationic-liposome-DNA complexes (CLDC) as a Burkholderia pre-exposure prophylaxis 
[29] and as an enhancement to antimicrobial therapy [28].  Based on its proinflammatory 
properties, we chose to investigate the adjuvant potential of CLDC when delivered 
mucosally.  The CLDC adjuvant was first tested in conjugation with heat-killed B. 
pseudomallei, and this vaccine formulation protected 100% of mice from lethal 
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pneumonic challenge for 40 d.  Less than half of mice vaccinated with heat-killed 
bacteria alone were protected, illustrating the ability of the CLDC adjuvant to elicit 
protective mucosal immunity from both acute and chronic melioidosis.  In previous 
vaccine studies using killed B. pseudomallei, mice were often vaccinated with non-
adjuvanted bacteria [10].  However, our findings indicate the ability of an effective 
adjuvant to enhance protection with whole-cell killed bacterial formulations, and provide 
a probable rationale why complete protection has not been commonly reported in the 
literature with killed bacteria alone [4, 10, 12] 
CLDC was also tested in conjugation with BimA and BopA, two recombinant 
protein B. mallei antigens, and the B. pseudomallei protein subunit, LolC.  Since subunit 
vaccines are more often approved for human use than killed or attenuated live strains 
[4], these experiments provide insight into potential clinically relevant vaccines.  
Intranasal vaccination with each subunit adjuvanted by CLDC moderately protected mice 
from acute pneumonic disease, but failed to offer long-term protection from chronic 
melioidosis.  LolC has been considered a promising vaccine candidate within the 
literature to date [4], however intranasal vaccination of mice within our studies protected 
only half of the animals from acute disease and this protection waned over time.  In a 
study by Harland et al., intraperitoneal vaccination with adjuvanted LolC protected 100% 
of mice for greater than 20 d following intraperitoneal B. pseudomallei challenge [22].  
We believe the enhanced protection observed in that study is due to the intraperitoneal 
route being far less virulent in murine melioidosis models than the pneumonic challenge 
route used in our studies [44].  Of all the vaccine formulations tested within our studies, 
the recombinant protein subunit vaccines were the least effective against acute 
pneumonic melioidosis, indicating the likelihood that an effective mucosal vaccine may 
need to encompass multiple antigens.      
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Live attenuated B. pseudomallei vaccines are considered the most effective of 
the melioidosis vaccine formulations investigated in mouse melioidosis models to date, 
as they consistently protect the majority of vaccinated mice from acute disease [4, 13-
18].  However, as seen in other vaccine formulations, sterilizing immunity has also been 
lacking in the studies and has only been reported in a C57BL/6 model [13], which some 
consider to be a mouse strain more resistant to Burkholderia infection [45].  Our vaccine 
studies using live attenuated strains were largely consistent with findings in the literature.  
Intranasal vaccination with either of the attenuated strains tested protected 100% of 
mice from acute disease for at least 20 d post-infection with lethal B. pseudomallei 
1026b.  However, it should be noted that vaccination with Bp422, a live attenuated 
1026b asd derivative, was far less effective at protecting mice from long-term chronic 
disease than vaccination with heat-killed B. pseudomallei complexed with CLDC.  Mice 
vaccinated with CLDC adjuvanted heat-killed bacteria were protected beyond 40 days 
post-infection, whereas mice vaccinated with Bp422 began to succumb to chronic 
melioidosis end-point shortly after 20 d.   
A second live attenuated mutant tested in our studies for protective efficacy was 
Bp82, a fully attenuated purM 1026b derivative [34].  Even though both Bp82 and 
Bp422 were constructed from the same strain background (1026b), Bp82 was shown to 
produce superior protection, indicating protection is dependent on the type of attenuated 
strain used.  Intranasal vaccination with this strain demonstrated protection from not only 
acute pneumonic melioidosis, but long-term protection in 60% of the animals lasting 
beyond 100 d.  To our knowledge, this is approaching the longest survival time recorded 
in the literature to date, especially following the highly lethal intranasal challenge route in 
BALB/c mice.  This study definitely needs to be repeated, and long-term protection likely 
could be enhanced even further by adjuvanting Bp82 with CLDC or by boosting animals 
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during the chronic disease stage.  Based on the protective efficacy of this attenuated 
strain and its exemption from Select Agent regulations, we believe this strain could serve 
as a likely vaccine option for high-risk persons, similar to the Francisella tularensis live 
vaccine strains (LVS) approved for use in exposed laboratory workers and military 
personnel [46-47].   
Since pneumonic delivery of an attenuated B. pseudomallei strain is unlikely for 
human approval, we also investigated the protective efficacy elicited by oral delivery of 
Bp82.  Oral delivery of attenuated Salmonella strains and an inactivated whole-cell 
Pseudomonas strain has been previously approved for human use [39-41], indicating the 
acceptance of this delivery route.  It is also worthy to note that oral vaccination has been 
shown to elicit protection from pneumonic challenge in a variety of infection models, 
including P. aeruginosa and F. tularensis [48-50].  Previous findings have shown that 
intestinal vaccination induces IgA antibody production within the lower airways and 
protects against pulmonary bacterial infection [48-49].  Therefore, we investigated 
whether oral vaccination with Bp82 would protect mice from lethal B. pseudomallei 
pneumonic challenge.  Even though oral vaccination significantly increased the time to 
death following lethal intranasal challenge, only 20% of vaccinated mice were protected 
beyond 4 d post-infection.  This is far less protection than that observed by KuoLee et al. 
following oral vaccination with LVS and pneumonic F. tularensis challenge [50].  
However, the protection could potentially be enhanced by orally boosting the mice with 
Bp82 in the period after lethal B. pseudomallei challenge.  Protection may also be 
enhanced by adjuvanting Bp82 with CLDC, as we have recently discovered that CLDC 
adjuvanted vaccines are effective when administered orally [51]. 
In summary, these studies have identified CLDC as effective mucosal vaccine 
adjuvant and based on efficacy and safety, this adjuvant has great potential for human 
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use [52-53].  Adjuvanting additional promising Burkholderia antigens would be beneficial 
for future investigations.  Even though approval of live attenuated strains for human use 
is less likely than fully inactive vaccine formulations [4], vaccination with attenuated B. 
pseudomallei strains have shown the most promise in terms of protective efficacy in our 
studies.  Intranasal vaccination with the fully attenuated purM 1026b strain effectively 
protected mice from acute and chronic melioidosis for a more than three months, and 
has great promise as a potential melioidosis vaccine candidate.  
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7.1  Significance of Work  
The research projects described in this Dissertation has made contributions to 
both the Burkholderia pseudomallei research community and the clinical side of 
melioidosis in terms of its prevention and treatment.  A fully attenuated B. pseudomallei 
strain was extensively characterized in vivo and granted exemption of Select Agent 
regulations, greatly facilitating B. pseudomallei studies for the first time at biosafety level 
2 (BSL-2) instead of BSL-3 containment.  Virulence determinants were also investigated 
in vivo providing additional insight into the bacterial factors required for successful 
persistence in vivo.  Clinically relevant findings include the identification of 
immunotherapies that efficiently enhance traditional antimicrobial therapy for the 
treatment of melioidosis, and the discovery of novel vaccine formulations and antigen 






7.2  Specific Aims 1 and 2  
B. pseudomallei is endemic to Southeast Asia and Northern Australia, and 
causes the fatal disease melioidosis in humans [1].  There are currently many 
challenges associated with this pathogen.  One particular challenge is the Federal 
regulations that greatly hinder research with B. pseudomallei.  Select Agent listing of this 
pathogen subjects research to strict Federal guidelines that govern its acquisition, 
possession and use.  Research with B. pseudomallei in the United States can only be 
conducted by cleared personnel in inspected BSL-3 containment laboratories [2], greatly 
preventing research on this pathogen by institutions not possessing such facilities.  The 
purpose of Specific Aim 1 (Chapter 3) was to develop a fully attenuated B. 
pseudomallei strain that could be granted exemption of Select Agent regulations and 
safely handled in the BSL-2 setting.  This Specific Aim addressed the challenge of the 
strict regulations restricting research on this pathogen, as the availability of such 
attenuated strains would both facilitate and accelerate sorely needed basic research with 
this priority pathogen. 
 The two attenuated strains constructed were Bp82 and Bp190, purM derivatives 
of B. pseudomallei strains 1026b and K96243.  Both strains are deficient in adenine and 
thiamine biosynthesis, but replication competent in vitro in rich medium.  Both mutants 
were completely avirulent in mice following inhalational challenge with doses ranging 
from 3 to 5-logs greater than the established LD50 for wild type B. pseudomallei [3].  
Bp82 was the mutant characterized most extensively in vivo, and this strain failed to 
replicate within the lungs or disseminate to the liver and spleen following inhalational 
challenge in mice.  Both Bp82 and Bp190 were completely non-lethal to a strain of mice 
known to be hypersusceptible to B. pseudomallei, and Bp82 was also shown to be 
176 
 
completely avirulent to immune deficient mice and even Syrian hamsters.  Upon this 
demonstration of complete attenuation in both immune competent and immune deficient 
animal models, Bp82 has been granted exemption of Select Agent regulations and is 
now approved for research within the BSL-2 setting.  This is the most characterized 
attenuated strain of B. pseudomallei created to date, and is also the first B. pseudomallei 
strain approved for research outside of BSL-3 containment.  The other attenuated B. 
pseudomallei strains constructed previously have not been as extensively characterized 
in vivo using immune deficient and hypersusceptible species, nor granted Select Agent 
exemption [4-7].  The availability of Bp82 to the research community greatly facilitates 
basic research on this pathogen. 
 B. pseudomallei was a bacterial pathogen largely unheard of in the Western 
world until its classification as a category B Select Agent [8].  Basic research on this 
pathogen has largely been lacking until recent years in the United States, and as a 
result, much is still unknown about B. pseudomallei.  Many bacterial factors potentially 
contributing to virulence within the host have yet to be fully elucidated, thus providing a 
basis for Specific Aim 2 (Chapter 4).  The purpose of this Aim was to determine 
whether siderophores and resistance-nodulation-cell division (RND) efflux systems 
impact virulence within a murine melioidosis model.  This was analyzed using a clinical 
B. pseudomallei isolate (strain 708a) naturally devoid of both the malleobactin 
siderophore and AmrAB-OprA efflux pump, and by the construction of a variety of 
deletion mutants. 
 B. pseudomallei 708a is a clinical melioidosis isolate that contains a natural 
deletion of more than 130kb of genetic material, including genes for malleobactin 
siderophore synthesis (encoded by the mba gene cluster) and a characterized efflux 
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system (amrAB-oprA) [9].   Despite such deletions, this strain caused clinical disease in 
the patient from which it was isolated and was also lethal in our murine melioidosis 
model, similar to that observed with the wild type strains 1026b and K96243.  Upon the 
characterization of B. pseudomallei mutants lacking RND efflux systems, it was further 
determined that neither the AmrAB-OprA nor BpeAB-OprB system is required for full 
virulence following pneumonic challenge in a murine melioidosis model.  Removal of one 
or both of these characterized systems failed to reduce the lethality of the mutant strains.  
In addition, deletion of the malleobacin siderophore (mba) and pyochelin receptor (fptA) 
failed to reduce lethality within our murine model, indicating that both the malleobactin 
and pyochelin siderophores are dispensable during B. pseudomallei in vivo infection.  In 
fact, simultaneous removal of the genes mba, fptA, and the efflux system, amrAB-oprA, 
actually appeared to increase lethality of strain Bp416 in our murine model.  These 
findings are contrasting to previous finding in the literature proposing the BpeAB-OprB 
efflux systems and siderophores are required for the virulence of B. pseudomallei or 
related bacterial species [10-13].  Our results indicate that B. pseudomallei is capable of 
utilizing additional iron transport pathways other than pyochelin and malleobactin during 
melioidosis that need to be characterized by future research, and the potential for great 
genetic diversity between different strain backgrounds.   
 
7.3  Specific Aims 3 and 4 
 There are many challenges in the clinical setting with the melioidosis, in terms of 
both treatment of the disease and its prevention in endemic regions or for high-risk 
persons.  The current antibiotic regimen recommended for treatment of melioidosis is 
months in duration [2], and even with antibiotic therapy, relapse still occurs in 
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approximately 13-23% of patients [14-15].  This relapse is most often the result of 
reactivation of the original infecting strain of B. pseudomallei [15-16].  New approaches 
are needed to improve the effectiveness of antimicrobial therapy for B. pseudomallei 
infection, providing the rationale for Specific Aim 3 (Chapter 5).  Its purpose was to 
determine whether immunotherapy could enhance the effectiveness of ceftazidime 
treatment.  This was analyzed using both an in vitro macrophage infection model and a 
murine melioidosis model.   
 The first immunotherapy investigated within these studies was cationic liposome-
DNA complexes (CLDC) which we have previously shown to be protective against 
Burkholderia and Francisella species [3, 17].  When combined with ceftazidime, CLDC 
synergistically increased intracellular bacterial killing by alveolar macrophages in vitro 
and produced multi-log reductions in B. pseudomallei counts.  This finding was found to 
translate effectively to our in vivo murine melioidosis model as well, as nearly 100% of 
mice were protected from acute melioidosis when CLDC was combined with a low, 
subtherapeutic dose of ceftazidime.  In addition, the brief 3-day course of treatment with 
combination therapy resulted in effective long-term chronic disease protection in our 
animals.  Since recombinant IFN- (rIFN-) has been used in the clinical setting [18] and 
we demonstrated the protective effect from the combination therapy is dependent on 
IFN- [3], we also examined its effectiveness in combination with ceftazidime for treating 
melioidosis.  The majority of mice were still protected from acute disease, but the rIFN- 
was not as effective as the CLDC in the prevention of disseminated, chronic melioidosis.  
Combined, these results indicate that ceftazidime effectiveness may be augmented in 
the clinical setting and disease relapse reduced when combined with an immunotherapy 
such as CLDC.   Based on the efficacy of CLDC to produce a sustained IFN- release 
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over time and its safety in a variety of models, this immunotherapy has potential for use 
in the human melioidosis setting [19-21].    
In addition to the challenges associated with melioidosis treatment, another 
obstacle lies in the prevention of this disease.  Due to the high mortality rates with 
melioidosis, prevention strategies are vital and could be extremely effective, especially 
within endemic regions of the world [22].  There is currently no approved vaccine for 
human use and the diphasic nature of melioidosis, often characterized by an acute 
pneumonic/septic stage followed by chronic disseminated disease, has proven to be a 
challenge in many of the vaccine candidates investigated in animal models to date.  
There has commonly been a lack of long-term, sterilizing protection following vaccination 
in many of the murine vaccination studies conducted [23-24].  The intraperitoneal route 
has been most community utilized in previous studies for antigen delivery.  However, 
since mucosal delivery of antigens has been shown to most efficiently produce mucosal 
immunity [25-27], the purpose of Specific Aim 4 (Chapter 6) was to develop a mucosal 
vaccine for B. pseudomallei.  Within this Aim, CLDC was investigated as a potential 
mucosal vaccine adjuvant, and a variety of vaccine formulations were tested for 
protective efficacy including heat-killed bacteria, protein subunits, and two attenuated B. 
pseudomallei strains. 
 When delivered intranasally with heat-killed B. pseudomallei, CLDC proved to be 
an effective vaccine adjuvant, as all of the mice were protected from melioidosis beyond 
40 d after lethal intranasal challenge.  Non-adjuvanted killed bacteria alone protected 
less than half of the mice from acute disease and all eventually succumbed to long-term 
chronic melioidosis, illustrating the protective effect initiated by the CLDC adjuvant.  
CLDC complexed to a variety of Burkholderia protein subunits offered partial protection 
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from acute disease, but was far less protective than the adjuvanted killed bacteria.  The 
longest term protection from lethal challenge, with more than half of the mice surviving 
beyond 100 d, was afforded by the attenuated B. pseudomallei purM strain, Bp82.  
However, this highly effective protection appears to be unique to Bp82, as when Bp422, 
a asd attenuated mutant, was tested for protective efficacy, protection began to wane 
just beyond 20 d following lethal B. pseudomallei challenge. 
 Since Bp82 has been demonstrated to be fully attenuated and well-characterized 
in vivo [28], and also been granted Select Agent exemption, this fully attenuated mutant 
holds great potential for use as a vaccine strain.  One of the biggest challenges with 
many murine vaccine studies is the lack of long-term protection, however Bp82 
demonstrated the longest sterilizing immunity of all of the vaccine formulations tested 
within these studies and of those reported recently in the literature [24].  This strain has 
great potential as a vaccine option for high-risk persons, similar to the Francisella 
tularensis live vaccine strains (LVS) approved for use in exposed laboratory workers and 
military personnel [29-30].  In fact, Bp82 is even less virulent than LVS when delivered 
intranasally to mice [17] and is one of the most attenuated B. pseudomallei strains 
characterized to date [4-7, 28].  This strain also showed partial protection from lethal 
pneumonic B. pseudomallei challenge following oral delivery, illustrating the diversity in 







7.4  References    
1. Currie, B.J., D.A. Dance, and A.C. Cheng, The global distribution of Burkholderia 
pseudomallei and melioidosis: an update. Trans R Soc Trop Med Hyg, 2008. 102 Suppl 1: 
p. S1-4. 
2. Peacock, S.J., et al., Management of accidental laboratory exposure to Burkholderia 
pseudomallei and B. mallei. Emerg Infect Dis, 2008. 14(7): p. e2. 
3. Goodyear, A., et al., Protection from pneumonic infection with burkholderia species by 
inhalational immunotherapy. Infect Immun, 2009. 77(4): p. 1579-88. 
4. Atkins, T., et al., Characterisation of an acapsular mutant of Burkholderia pseudomallei 
identified by signature tagged mutagenesis. J Med Microbiol, 2002. 51(7): p. 539-47. 
5. Atkins, T., et al., A mutant of Burkholderia pseudomallei, auxotrophic in the branched 
chain amino acid biosynthetic pathway, is attenuated and protective in a murine model 
of melioidosis. Infect Immun, 2002. 70(9): p. 5290-4. 
6. Breitbach, K., J. Kohler, and I. Steinmetz, Induction of protective immunity against 
Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life 
cycle. Trans R Soc Trop Med Hyg, 2008. 102 Suppl 1: p. S89-94. 
7. Stevens, M.P., et al., Attenuated virulence and protective efficacy of a Burkholderia 
pseudomallei bsa type III secretion mutant in murine models of melioidosis. 
Microbiology, 2004. 150(Pt 8): p. 2669-76. 
8. Aldhous, P., Tropical medicine: melioidosis? Never heard of it. Nature, 2005. 434(7034): 
p. 692-3. 
9. Trunck, L.A., et al., Molecular basis of rare aminoglycoside susceptibility and 
pathogenesis of Burkholderia pseudomallei clinical isolates from Thailand. PLoS Negl 
Trop Dis, 2009. 3(9): p. e519. 
10. Chan, Y.Y., et al., Control of quorum sensing by a Burkholderia pseudomallei multidrug 
efflux pump. J Bacteriol, 2007. 189(11): p. 4320-4. 
11. Chan, Y.Y. and K.L. Chua, The Burkholderia pseudomallei BpeAB-OprB efflux pump: 
expression and impact on quorum sensing and virulence. J Bacteriol, 2005. 187(14): p. 
4707-19. 
12. Sokol, P.A., et al., Role of ornibactin biosynthesis in the virulence of Burkholderia 
cepacia: characterization of pvdA, the gene encoding L-ornithine N(5)-oxygenase. Infect 
Immun, 1999. 67(9): p. 4443-55. 
13. Visca, P., F. Imperi, and I.L. Lamont, Pyoverdine siderophores: from biogenesis to 
biosignificance. Trends Microbiol, 2007. 15(1): p. 22-30. 
14. Chaowagul, W., et al., Relapse in melioidosis: incidence and risk factors. J Infect Dis, 
1993. 168(5): p. 1181-5. 
15. Currie, B.J., et al., Melioidosis: acute and chronic disease, relapse and re-activation. 
Trans R Soc Trop Med Hyg, 2000. 94(3): p. 301-4. 
16. Maharjan, B., et al., Recurrent melioidosis in patients in northeast Thailand is frequently 
due to reinfection rather than relapse. J Clin Microbiol, 2005. 43(12): p. 6032-4. 
17. Troyer, R.M., et al., Mucosal immunotherapy for protection from pneumonic infection 
with Francisella tularensis. Vaccine, 2009. 27(33): p. 4424-33. 
18. Condos, R., et al., Recombinant gamma interferon stimulates signal transduction and 
gene expression in alveolar macrophages in vitro and in tuberculosis patients. Infect 
Immun, 2003. 71(4): p. 2058-64. 
182 
 
19. Dow, S., et al., Phase I Study of Liposome-DNA Complexes Encoding the Interleukin-2 
Gene in Dogs with Osteosarcoma Lung Metastases. Human Gene Therapy, 2005. 16(8): 
p. 937-946. 
20. Dow, S.W., et al., Lipid-DNA Complexes Induce Potent Activation of Innate Immune 
Responses and Antitumor Activity When Administered Intravenously. Journal of 
Immunology, 1999. 163(3): p. 1552-1561. 
21. Dow, S., Liposome-nucleic acid immunotherapeutics. Expert Opin Drug Deliv, 2008. 5(1): 
p. 11-24. 
22. Peacock, S.J., Melioidosis. Current Opinion in Infectious Diseases, 2006. 19(5): p. 421-
428. 
23. Nelson, M., et al., Evaluation of lipopolysaccharide and capsular polysaccharide as 
subunit vaccines against experimental melioidosis. J Med Microbiol, 2004. 53(Pt 12): p. 
1177-82. 
24. Sarkar-Tyson, M. and R.W. Titball, Progress toward development of vaccines against 
melioidosis: A review. Clin Ther, 2010. 32(8): p. 1437-45. 
25. Belyakov, I.M. and J.D. Ahlers, What role does the route of immunization play in the 
generation of protective immunity against mucosal pathogens? J Immunol, 2009. 
183(11): p. 6883-92. 
26. Lamm, M.E., Interaction of antigens and antibodies at mucosal surfaces. Annu Rev 
Microbiol, 1997. 51: p. 311-40. 
27. Neutra, M.R. and P.A. Kozlowski, Mucosal vaccines: the promise and the challenge. Nat 
Rev Immunol, 2006. 6(2): p. 148-58. 
28. Propst, K.L., et al., A Burkholderia pseudomallei deltapurM mutant is avirulent in 
immunocompetent and immunodeficient animals: candidate strain for exclusion from 
select-agent lists. Infect Immun, 2010. 78(7): p. 3136-43. 
29. Burke, D.S., Immunization against tularemia: analysis of the effectiveness of live 
Francisella tularensis vaccine in prevention of laboratory-acquired tularemia. J Infect Dis, 
1977. 135(1): p. 55-60. 
30. Isherwood, K.E., et al., Vaccination strategies for Francisella tularensis. Adv Drug Deliv 
Rev, 2005. 57(9): p. 1403-14. 
 
 
